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Abstract 
Pouria Akhbari 
Analysis of Cellular Transcriptomic Changes Induced by Merkel Cell 
Polyomavirus miRNA 
Keywords: Virus, Cancer, miRNA 
Merkel cell carcinoma (MCC) is a highly aggressive skin cancer with rising 
global incidence. Merkel cell polyomavirus (MCV) was discovered in 2008 in 
80% of MCC samples and since then a causal link between MCV and the 
majority of MCC cases has been established. microRNAs (miRNA, miR) are 
a family of small non-coding RNAs which play a key role in post-
transcriptional regulation of gene expression and are considered significant 
players in disease and development in many species. Whilst the focus of 
MCV research has thus far been on the oncogenic MCV early proteins, large 
tumour (LT) and small tumour (sT) antigens, there is a knowledge gap 
regarding MCV miRNA and its functional significance in MCV pathogenesis. 
Given the emerging importance of viral miRNAs in virus-host interaction and 
pathogenesis, the aim of this doctoral research project was to investigate 
alterations in host cell transcripts induced by MCV miRNA and determine any 
functional significance these might have on virus-host cell interaction. RNA 
sequencing (RNA-Seq) in the presence and absence of MCV miRNA 
uncovered a multitude of downregulated cellular transcripts. Gene ontology 
analysis revealed that MCV miRNA targets transcripts associated with 
multiple cellular processes, however, regulation of immune response was 
overrepresented in our datasets. Validation of RNA-Seq data using MCV 
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miRNA mimics and a synthetic, fully replicative MCV genome (MCVSyn) 
confirmed RNA-Seq data at mRNA and protein expression level for several 
targets, including the cytokine stimulating gene, SP100, and the neutrophil 
stimulator chemokine, CXCL8. Moreover, dual luciferase assays revealed 
that SP100 and MAPK10 (a member of mitogen-activated protein kinases 
(MAPK) family which is involved in regulation of CXCL8 expression) are 
directly and specifically targeted and downregulated by MCV miRNA. The 
MCV miRNA-dependent dysregulation of CXCL8 secretion is associated with 
impaired neutrophil migration, suggesting that the virus miRNA may be 
implicated in evasion of the host immune response. 
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1. Introduction 
1.1. Background 
Merkel cell polyomavirus (MCV or MCPyV) was identified in 2008 in 80% of 
Merkel cell carcinoma (MCC) samples via digital transcriptome subtraction 
(DTS) (Feng et al. 2008). MCC is a rare but aggressive skin cancer that 
typically occurs in immunocompromised individuals. However, the rising 
incidence of MCC especially in the ageing population (Hodgson 2005) and 
implication of MCV in the majority of MCC cases has prompted extensive 
research on the life cycle and virus-host interaction of MCV as well as 
mechanisms leading to MCV infection and MCC tumourigenesis. Thus far, 
the central role of LT and sT antigens of MCV in cell transformation, 
maintenance of cancerous state and metastasis has been described 
(Houben et al. 2010; Shuda et al. 2015). MCV T antigens also play an 
important role in virus immune evasion by targeting host innate immune 
ligands TLR9 (Toll like receptor 9) and nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) essential modulator (NEMO) (Griffiths 
et al. 2013; Shahzad et al. 2013). These immune evasion and oncogenesis 
properties have been described in other polyomaviruses and herpesviruses. 
Murine polyomavirus (MuPyV) and bandicoot papillomatosis carcinomatosis 
virus (BPCV) have been directly implicated in the aetiology of cancer 
(Stewart et al. 1958; Woolford et al. 2007). BK and JC polyomaviruses 
establish persistent infection in their host by targeting UL16 binding protein 3 
(ULBP3) via an identical virus-encoded miRNA (Bauman and Mandelboim 
2011; Bauman et al. 2011) and Epstein-Barr Virus (EBV) and Kaposi’s 
sarcoma-associated herpesvirus (KSHV) manipulate host immune response  
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in order to establish latent/persistent infection (Li et al. 2016; Piedade and 
Azevedo-Pereira 2016; Sun et al. 2016). Despite significant differences in 
terms of genome size and complexity (~5kb versus >120kb), polyomaviruses 
and herpesviruses share several common features including, a double-
stranded DNA (dsDNA) genome, the ability to code for miRNAs and the 
capacity to establish latent and persistent infection in their host (Arvin et al. 
2007; Cann 2012). Of particular relevance to this thesis is the emerging role 
of viral miRNAs in immune evasion and carcinogenesis, as described in 
tumorigenic herpesviruses, such as KSHV and EBV (Pfeffer and Voinnet 
2006; Boss et al. 2011; Suffert et al. 2011; Kincaid and Sullivan 2012). In 
addition, as mentioned above, BK and JC polyomaviruses encode an 
identical miRNA that is implicated in virus persistence and immune evasion 
(Bauman et al. 2011). Reduced susceptibility of wild type (WT) simian virus 
40 (SV40) polyomavirus to cytotoxic T-cells compared to miRNA-mutant virus 
suggests a role for SV40 miRNA in host immune evasion (Sullivan et al. 
2005). Similarly, a miRNA-deficient MCV loses its ability to establish long 
term infection (Theiss et al. 2015). Whilst these observations are indicative of 
a role for SV40 and MCV miRNAs in host immune evasion it is yet to be 
determined whether the miRNA exerts such effect solely by downregulating 
its cognate target, the virus LT antigen or, like BK and JC viruses, via direct 
targeting of transcripts encoding components of the host cell immune system. 
The aim of this thesis was to determine if MCV miRNA (MCV-miR-M1) 
modulates the expression of cellular transcripts and the functional impact of 
any observed alteration on MCV and host cell interactions.  
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1.2. Merkel Cells 
Merkel cells (MCs) are 10-15µm oval shape cells, located in basal layer 
(stratum basale) of the epidermis, the hair follicle external sheath (Lucarz and 
Brand 2007), ectoderm-derived mucosa (Halata et al. 2003) and may also be 
found in the dermis (Mahrle and Orfanos 1974; Moll et al. 1986) (Figure 1.1). 
Merkel cells are defined as slowly adapting type 1 (SA1) mechanoreceptors 
and are involved in sense of touch, predominantly found in areas of skin with 
acute sensory perception such as finger tips, and form mechanoreceptors in 
synaptic contact with discoid axon terminals while simultaneously binding to 
keratinocytes via desmosomes (Ross and Wojciech 2010). It has been 
shown that elimination of MCs via atonal homolog 1 (Atoh1) knockout results 
in loss of light touch sense in the mice skin (Maricich et al. 2009). A model 
has been proposed in which activation of mechanosensitive receptors leads 
to MC depolarisation followed by opening of voltage-gated calcium channels 
and calcium-induced Ca++ release in MCs. This results in release of thus far 
unidentified neurotransmitters which in turn triggers action potential in SA1 
afferent nerves (Nakatani et al. 2015).  
MCs are most prevalent in the palm of hands, the feet and plantar surface of 
the toes (Hartschuh and Grube 1979). They are also more abundant in sun-
exposed skin compared to covered skin (Lucarz and Brand 2007). 
Morphologically, MCs are characterised by their oval shape with protrusions, 
a large lobulated nucleus and dense core granules near their junction with 
nerve terminals (Figure 1.2) (Halata et al. 2003). Hair follicle MCs generally 
lack nerve association and it is suggested that they may contribute to hair 
development by paracrine activity (Lucarz and Brand 2007), however, it is 
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postulated that unlike nerve terminal-associated MCs, hair follicle MCs are 
considered immature (undifferentiated) cells because of the absence of nerve 
connection (Uchigasaki et al. 2004). In addition, Merkel cell-like cells are 
located in the skin with suggested neuroendocrine but not mechanoreceptor 
functions (Halata et al. 2003; Lucarz and Brand 2007). These cells usually 
reside in the same area as MCs, however, they can be distinguished by a 
pale oval nucleus, non-lobulated nucleus, skin surface-facing dense-core 
granules, lack of contact with nerve endings and lack of cytoplasmic 
processes (Figure 1.3). Halata et al. conclude that, based on the available 
data, it is not certain whether MC-like cells and MCs are from different origins 
with different functions or they both stem from the same origin but adopt 
different forms and functions (Halata et al. 2003). Unless stained by specific 
markers, MCs are difficult to identify and hardly recognisable via light 
microscopy. In electron microscopy, MCs characteristically appear as cells 
bearing 80-140nm dense-core granules near the cells nerve terminal junction 
site, with nuclear lobules and microvilli protruding into neighbouring cells 
(Figure 1.4).  
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Figure 1.1. Location of Merkel cells in the skin. Taken from National Cancer 
Institute (General Information About Merkel Cell Carcinoma 2016). 
 
Figure 1.2. Merkel cells in the skin of the eyelid. A Merkel cell (M) 
surrounded by nerve terminals (T) and glial cells (S) and in contact with an 
epidermal keratinocyte (K) (A and B); cytoplasmic protrusions of Merkel cells 
are marked by asterisks (B). Taken from (Halata et al. 2003).  
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Figure 1.3. Merkel cell-like cells (N) with oval shape and non-lobulated 
nucleus and without cytoplasmic protrusions or contact with nerve endings. 
Dense-core granules are mainly located towards the skin surface (Right, 
larger magnification). K, keratinocyte; F, fibroblast. Taken from (Halata et al. 
2003).  
 
MCs also form desmosomes (intercellular junctions responsible for providing 
adhesion between cells (Garrod and Chidgey 2008))  with surrounding 
keratinocytes and might similarly bear small numbers of melanosomes 
(Lucarz and Brand 2007). With regards to their cytoskeleton, MCs express 
epithelial type cytokeratin (CK) filaments such as CK8, CK18, CK19 and 
CK20. Similarly, both MCs and MCCs express neuroendocrine markers such 
as synaptophysin and chromogranin A, while NF-H, a heavy chain 
neurofilament has also been reported in adult human scalp MCs (Moll et al. 
2005).  A variety of markers have been used to identify MCs. In light 
microscopy, CK20 is the most specific marker for cutaneous MCs (Boot et al. 
1992; Moll et al. 1995). Specificity and sensitivity of CK20 has also been 
used for diagnosis of MCC and differential diagnosis of MCC with other 
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neoplasms such as melanoma (Scott and Helm 1999). Uranaffin reaction 
(UR) is a specific staining for neurosecretory (NS) granules of the 
neuroendocrine system (Beiras et al. 1986) and electron microscopy-based 
detection of uranaffin has been used for identification of MCs (Munde et al. 
2013). Other neuropeptides such as Calcitonin gene-related peptide or 
CGRP (Garcia-Caballero et al. 1989) and vasoactive intestinal polypeptide or 
VIP (Alvarez et al. 1988) have been detected in dense-core granules of MCs.  
 
Figure 1.4. Schematic presentation of the ultrastructure of a 
mechanoreceptor Merkel cell. MCs contain dense-core granules (G) located 
near the nerve junction (NJ) site, melanosomes (me) and a lobulated nucleus 
(N). P, cytoplasmic protrusions (or microvilli); m, mitochondria; go, Golgi  
apparatus; D, desmosome; A, axon; BL, basal lamina; HD, hemidesmosome; 
if, intermediate filaments; K, keratinocyte. Taken from (Lucarz and Brand 
2007).  
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The developmental origin of MCs has been a matter of controversy and both 
the neural crest and epidermis have been proposed as the origin of MCs. 
The neural crest hypothesis is supported by the observation that avian MCs 
migrate, along with melanocytes and glial cells, from neural crest (Grim and 
Halata 2000), however, it is noteworthy that Grandry cells, the avian 
equivalent of MCs, reside in the dermis rather than epidermis (Lucarz and 
Brand 2007). The evidence for neural crest origin of mammalian MCs comes 
from the observation that whisker pad MCs express β-galactosidase under 
the control of Wnt1 promoter in R26R double transgenic mice. Given that 
Wnt1 is specifically and transiently expressed in neural crest and some cells 
of the embryonic central nervous system (CNS), the authors conclude that β-
galactosidase-positive MCs are of neural crest descent (Szeder et al. 2003). 
However, most recent studies provide strong evidence for the epidermal 
origin of mammalian MCs. It has been shown that MCs express the 
transcription factor Atoh1 and require its expression for their formation (Ben-
Arie et al. 2000; Maricich et al. 2009). Using conditional ablation of Atoh1 
from the skin or neural crest, Morrison et al. showed that MCs are absent in 
the skin of epidermal but not the neural crest mouse lineage (Morrison et al. 
2009). Atoh1-dependent differentiation of MCs from epidermal progenitor 
cells was independently confirmed via another in vivo mouse study (Van 
Keymeulen et al. 2009), further strengthening the epidermal origin 
hypothesis.  Van Keymeulen et al. showed that Atoh1 conditional ablation 
renders MCs undetectable via both ultrastructural investigation and 
immunoreactivity of markers such as CK18, CK20 and Rab3c in newborn 
and adult mice (Van Keymeulen et al. 2009). Finally, most recently it has 
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been shown that Atoh1 is directly activated by SRY (sex determining region 
Y)-box 2 (Sox2) transcription factor, whilst Sox2 itself is repressed by the 
polycomb repressive complex (PRC) histone-lysine N-methyltransferases 
Enhancer of zeste homolog 1 (Ezh1) and Ezh2 in epidermal stem cells 
(Bardot et al. 2013). Bardot et al. described a Sox2 binding site in the Atoh1 
enhancer and demonstrated a significant upregulation in Atoh1 mRNA 
following overexpression of Sox2 in cultured epidermal progenitor cells. 
Ezh1/Ezh2 ablation resulted in Sox2 upregulation and MC differentiation 
whilst Sox2 ablation led to the loss of MCs in the epidermis of all tested body 
regions in the mice, suggesting that Sox2 is repressed by Ezh1 and Ezh2 
preventing it from driving differentiation of epidermal progenitor cells to MCs 
(Bardot et al. 2013). While our understanding of Merkel cell physiology and 
differentiation has increased in recent years, the mechanisms underlying 
transformation of MCs to cancerous state remain largely unknown. However, 
the identification of MCV and its key role in most MCC cases is shedding light 
on MCC pathophysiology. 
1.3. Merkel cell carcinoma 
Merkel cell carcinoma is a rare, aggressive skin tumour with increasing 
incidence (Hughes et al. 2014) and a mortality rate higher than malignant 
melanoma (Becker 2010).  
First described as a trabecular skin carcinoma (Toker 1972), MCC was 
subsequently reclassified as a neuroendocrine cancer following discovery of 
neurosecretory granules in MCs (Gould et al. 1985; Becker 2010). However, 
as discussed above, more recent findings are predominantly in favour of an 
11 
 
epidermal origin for MCs. Around 33% of MCC patients exhibit distant 
metastases and outcome for these patients is poor due to the lack of 
effective chemotherapy in metastatic and recurrent cases (Hughes et al. 
2014). Importantly, regression of MCC following improvement in immune 
response (Burack and Altschuler 2003) and association of higher incidence 
of MCC with T-cell dysfunction i.e. in solid organ transplant receivers (5-10 
fold), AIDS patients (11-13 fold) and chronic lymphocytic leukaemia patients 
(Becker 2010), accentuate the significance of the immune system in MCC 
(Hughes et al. 2014). Similar features have been reported in malignancies 
associated with viruses such as KSHV where tumour incidence demonstrates 
positive and negative association with immune compromise and immune 
reconstitution, respectively (Bihl et al. 2007; Hislop and Sabbah 2008; Giffin 
and Damania 2014). These similarities suggest involvement of an infectious 
component in the MCC aetiology.  
In a retrospective population-based study using data gathered over more 
than three decades, it was revealed that MCC was more prevalent in men 
(61.5%) than women (38.5%). Women also had a higher ten-year relative 
survival rate than men (65% versus 50.5%, respectively) (Albores-Saavedra 
et al. 2010). In addition, the study demonstrated a higher prevalence for MCC 
in 60-85 year old white compared to black patients.  MCC is predominantly 
located in the head and neck while the most common non-cutaneous sites 
include lips, salivary glands and lymph nodes, nasal cavity and oesophagus, 
vulva and vagina. The cancer stage was also determined as the best 
prediction factor for survival, where local stage defined as lesions confined to 
the dermis and regional involved the underlying musculoskeletal tissues. 
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Regional lymph nodes were classified as head and neck, trunk (lower and 
upper), extremities (lower and upper) and NOS (not otherwise specified). 
Distant stage comprised metastases and lymph nodes distant from the 
primary tumour site (Albores-Saavedra et al. 2010). Local lesions 
demonstrated the highest relative ten-year survival at 71% whereas distant 
stage showed the poorest rate at 21%. Unknown and regional stages 
reported 40.5% and 47.8% survival rates, respectively (Albores-Saavedra et 
al. 2010).  
Patients refer to medical services due to the rapidly growing painless lesions 
in sun-exposed skin. Indeed, the positive correlation between UVB exposure 
and MCC incidence suggests that sun exposure, especially in fair skinned 
individuals, is a risk factor for MCC (Agelli et al. 2010), although unexposed 
skin might be affected too (Hughes et al. 2014). Recent data suggest an 
increase in the annual incidence of MCC by up to 10% in the US (1992-2001) 
and 8% in Australia (1986-2001). It should be noted, however, that part of 
this increase in the reported incidence is due to improvement in the diagnosis 
of MCC during 1980s and 1990s driven by CK20 staining (Agelli et al. 2010). 
Nevertheless, a more recent study of MCC cases between 2004 and 2013 in 
the east of England noted that the overall age-adjusted incidence of MCC 
has increased by three-fold within ten years, with a concurrent rising 
incidence in other areas of the UK (Goon et al. 2016). This study also 
reported the male to female ratio of MCC incidence in England as 2:3, which 
is contrary to the Agelli et al.’s report regarding gender risk factor. However, it 
must be noted that the sample size in Goon et al.’s study was significantly 
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smaller (73 versus 3870 cases) and therefore might not be a true 
representative of the actual ratio. 
Inefficient or suppressed immune system is associated with increased risk of 
cancer. This correlation has been proved by multitude of reports about 
increased MCC incidence in transplant recipients and autoimmune patients 
which, as part of their treatment, receive long term and often potent 
immunosuppressants (Lentz et al. 1993; Gooptu et al. 1997; Penn and First 
1999; Buell et al. 2002; Lillis et al. 2005; McLoone et al. 2005; Satolli et al. 
2005; Nemoto et al. 2008). In a case report of an HIV-positive and MCC-
positive patient, sustained remission of MCC was observed following highly 
active antiretroviral therapy (HAART) and use of interleukin-2 (IL-2) (Burack 
and Altschuler 2003). This report along with evidence for greater risk of 
developing MCC in HIV patients (Engels et al. 2002; Izikson et al. 2011) 
further underscores the link between an undermined immune system and 
onset of MCC. Based on these observations and the similarity with Kaposi’s 
sarcoma, another common virus-driven malignancy of transplant and HIV 
patients, Feng et al. embarked on their search for an infectious element in 
MCC cases, a study which led to the discovery of MCV.  
1.3.1. Diagnosis of MCC 
MCC predominantly presents as an asymptomatic and rapidly growing red or 
pink cyst or acneiform lesion with an initially non-ulcerated appearance  
(Figure 1.5) and median size of 1.8cm at the time of diagnosis (Heath et al. 
2008).   
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Figure 1.5. Examples of MCC clinical presentation on the eyelid (A), buttock 
in an HIV patient (B), finger (C) and arm (D). Taken from (Heath et al. 2008). 
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Figure 1.6. Body site distribution of primary MCC and MCC in lymph nodes 
with unidentified primary. Taken from (Heath et al. 2008). 
 
 
 
 
 
 
 
 
16 
 
Histopathological features of MCC include a solid nodular and dermal or 
subcutaneous lesion (Figure 1.7). Cells typically appear as uniform, highly 
mitotic and undifferentiated, often apoptotic and occasionally necrotic with 
scant cytoplasm, large oval/round lobulated nuclei, which stain blue on 
haematoxylin.  
 
Figure 1.7. Histologic presentation of MCC with dermal and subcutaneous 
solid nodular lesion (A), small-blue-round-cell on haematoxylin (B) and 
paranuclear dot-like staining (CK20), characteristic of MCC (C). Taken from 
(Kuwamoto 2011). 
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Infiltration of cells to the surrounding stroma and lack of capsule are common 
features of MCC (Kuwamoto 2011). In immunohistochemistry, MCC is 
identified by both epithelial (such as CK20 and AE1/AE3 cytokeratins) and 
neuroendocrine (neuron-specific enolase or NSE, synaptophysin and 
chromogranin A) markers (Table 1.1). NSE is also expressed in other 
neuroendocrine tumours such as small cell lung cancer (SCLC) (Kuwamoto 
2011). CK20 immunohistochemistry results in a paranuclear dot-like staining 
(Figure 1.7 C) and is currently considered the best marker for differential 
diagnosis of MCC from other tumours (Kuwamoto 2011; Lebbe et al. 2015).  
MCV T antigen staining has also been used for identification of MCV-positive 
MCCs (Shuda et al. 2009).  
Table 1.1. Immunohistochemistry markers for MCC diagnosis and differential 
diagnosis. Adapted from (Becker et al. 2013). SCLC, Small cell lung cancer.  
 
MCC Lymphoma Melanoma SCLC 
CK20 + − − − 
Neuron-specific-enolase (NSE) + − − +/− 
Chromogranin A (CgA) +/− − − +/− 
Huntingtin interacting protein 
1 (HIP1) 
+ +/− − − 
Vimentin − + + − 
Melan-A/MART-1 − − + − 
Leucocyte common antigen 
(LCA) 
− + − − 
Thyroid transcription factor-1 
(TTF-1) 
− − − + 
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1.3.2. Prognosis of MCC 
The European consensus-based interdisciplinary guideline recommends 
clinical/histological features, distant tissue involvement and American Joint 
Committee on Cancer (AJCC) staging system be employed for prognostic 
classification of MCC (Lemos et al. 2010; Lebbe et al. 2015). Male gender, 
primary tumour size of more than 2cm and head, neck and trunk tumour 
locations are considered as unfavourable predictors. As mentioned earlier, 
female MCC patients have a higher 10-year survival rate (~65%) compared 
to males (~50%). Upper limb primary skin MCCs have a better 10-year 
survival rate (~61%) compared to skin of unknown site (~38%), trunk (~54%), 
head and lower limbs (~57%) MCCs. It must be noted, however, that the 
difference in survival rates were only statistically significant between head 
and upper limbs and between trunk and upper and lower limbs. Tumour size 
of more than 2cm also has a poorer 10-year survival rate (61% versus 
~40%).  
Differences in 10-year survival rates were most noticeable when the degree 
of primary tumour spread was taken into account. Localised MCCs showed 
the highest survival rate by 71%, followed by regional and unknown tumours 
with ~48% and ~40%, respectively. The poorest prognosis was identified for 
distant spreads with ~20% survival rate. Interestingly, no significant 
difference in the survival rate was observed between three different age 
groups of 0 to 49, 50 to 69 and 70 to 85 plus (Albores-Saavedra et al. 2010).  
Histologically, thus far, no robust prognostic marker has been identified for 
MCC, however, T-cell tumour infiltration and lack of lymphatic system 
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invasion have been reported as favourable indicators for MCC prognosis 
(Sihto et al. 2012; Sihto and Joensuu 2012; Lebbe et al. 2015).  
AJCC classification of MCC staging is based on three indicators of TNM, as 
defined by T for size and invasiveness of primary tumour, N for degree of 
lymph node involvement and M for metastatic state of MCC. Each of these 
criteria are classified to provide a scale for tumour staging and therefore for 
MCC prognosis. According to this staging system, the best 5 year survival 
rate is 79% for stage IA where primary tumour is =<2cm in diameter, there is 
no node involvement in pathologic examination and no distant metastasis. 
Concordant with the Albores-Saavedra et al. analysis, survival chance 
correlates negatively with tumour size (stages IB to IIC), however, the 
prognosis is poorer, regardless of primary tumour size, when nodal 
metastasis is present (stages IIIA and IIIB). When distant metastasis is 
present, the 5-year survival rate plummets to 18% and tumour size and nodal 
involvement are no longer a determinant of survival (Lemos et al. 2010; 
Lebbe et al. 2015). For a detailed TNM-based staging for MCC prognosis, 
refer to Table 1.2.  
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Table 1.2. MCC staging criteria based on TNM system to evaluate the 5 year 
survival rate of MCC patients outlined by AJCC. TIS, tumour in situ (tumour 
has not invaded the host organ supporting tissues, such as basement 
membrane and stroma (Young et al. 2000)); T1, primary tumour <2 cm; T2, 
primary tumour 2-5 cm; T3, primary tumour more than 5 cm; NO, absence of 
regional node metastasis; cNO, clinically detectable node, no pathologic 
examination; pNO, nodes negative clinically and pathologically; N1a, 
micrometastasis; N1b, macrometastasis; N2, transit metastasis; M1, distant 
metastasis. Adapted from (Lemos et al. 2010). 
Stage T N M 
% of 5-year 
survival  
O TIS N0 M0 
 IA T1 pN0 M0 79 
IB T1 cN0 M0 60 
IIA T2/T3 pN0 M0 58 
IIB T2/T3 cN0 M0 49 
IIC T4 N0 M0 47 
IIIA Any T N1a M0 42 
IIIB 
 
N1b/N2 M0 26 
IV 
 
Any N M1 18 
   
Overall, MCC treatment includes standard therapeutic approaches used for 
other malignancies, which routinely include surgical excision, chemotherapy 
and radiation therapy. One of the challenges in the treatment of MCC is the 
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sensitivity of the elderly to toxic side effects of the drugs, and to date there is 
no standardised systemic treatment protocol for MCC (Becker et al. 2013).  
1.3.3. Treatment of MCC  
Chemotherapy remains the main therapeutic approach for advanced MCC, 
however, several studies have reported a low rate of efficacy and high rate of 
mortality (Voog et al. 1999; Tai et al. 2000). Other treatment methods have 
been proposed against several therapeutic targets. It has been shown that a 
higher MCC survival rate is positively associated with infiltration of CD8+ 
lymphocytes into the tumour (Paulson et al. 2011). In another study, 
Afanasiev et al. also showed that MCV-specific T-cells increase or decrease 
alongside tumour progression or treatment-associated regression (Afanasiev 
et al. 2013). Moreover, the authors demonstrated that these T-cells 
expressed high levels of programmed death-1 (PD1) and T-cell 
immunoglobulin and mucin-domain (Tim-3). PD1 and Tim-3 are known as 
markers of T-cell exhaustion and functionality failure (Sakuishi et al. 2010) 
and several studies have shown that targeting PD1 and Tim-3 pathways can 
be a promising and safe therapeutic approach for cancer, including MCC 
(Sakuishi et al. 2010; Ngiow et al. 2011; Brahmer et al. 2012; Topalian et al. 
2012). Dysregulated signalling pathways have been suggested as another 
therapeutic target for MCC. Specifically, studies have shown that 
phosphoinositide 3-kinase (PI3K) is upregulated in MCC (Hafner et al. 2012; 
Nardi et al. 2012). Both groups reported that phosphorylation of protein 
kinase B (PKB or AKT) occurs independently of MCV status in MCC. In this 
regard, the activated PI3K/AKT pathway in MCC has been suggested as a 
potential target for MCC treatment. Successful application of tumour necrosis 
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factor alpha (TNF-α) (Hata et al. 1997),  anti-CD56 antibodies (Shah et al. 
2016) and interferons (Wahl et al. 2016) have been reported, however, these 
alternative methods require further trial at larger scales. Finally, presence of 
MCV in the majority of MCCs and the central role of MCV T antigens in virus 
tumourigenesis may hold promise for novel therapeutic approaches in the 
majority of MCCs (Schrama and Becker 2011). MCV oncogenesis is 
discussed in detail in section 1.4.1. 
1.4. Virology of MCV 
Given that MCC is predominantly detected in immunosuppressed individuals 
and the elderly, Feng et al. hypothesised that an infectious agent is involved 
in the onset of MCC, a hypothesis that led to MCV discovery in 80% of MCCs 
using a novel technique called digital transcriptome subtraction (Feng et al. 
2008). Briefly, the authors generated cDNA libraries from four MCC tumour 
samples and aligned them to human genome sequences. ‘Subtracting’ the 
human genome sequences, a sequence with high homology to African green 
monkey lymphotropic polyomavirus (LPyV) and human BK polyomavirus 
appeared. However, being sufficiently distinct from previously identified 
polyomaviruses the novel sequence was assigned a new place in this virus 
family and termed Merkel cell polyomavirus due to its association with MCC 
(Feng et al. 2008). Following this discovery, Feng et al. showed that MCV 
sequence is clonally integrated into the genome of tumour samples from 8 
out of 10 MCC patients, indicating MCV as the aetiological agent of most 
MCC cases.      
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1.4.1. MCV genome structure 
Merkel cell polyomavirus is an ~40nm non-enveloped double-stranded DNA 
(dsDNA) virus of the polyomaviridae family (Collier et al. 2010). The small 
circular genome of polyomaviruses (~5kb, Figure 1.8) is efficiently organised 
via the association with host cell histones H2A, H2B, H3 and H4, enabling 
the packaging of the virus genome into the capsid in a chromatin-like form 
(Cann 2012). The MCV genome contains early and late regions which code 
for the viral oncoproteins, LT and sT and viral capsid proteins VP1 and 
VP2/3, respectively (Feng et al. 2008; Cann 2012). These regions are under 
the control of a Non-coding Regulatory Region (NCRR) or Non-coding 
Control Region (NCCR), which separates the early and late region and 
functions as a virus origin of replication (ORI).  
 
 
 
 
 
 
 
 
Figure 1.8. Schematic presentation of MCV genome with products of early 
(LT, sT, 57kT and ALTO) and late region (VP1, VP2, VP3 and miRNA). 
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This replication origin contains early and late promoters and is composed of 
ten pentanucleotide sequences, eight of which perfectly match LT-binding  
sequence 5’-GAGGC-3’. It has been shown that a minimum core ORI of 71 
base pairs (bp) is sufficient for efficient LT-mediated DNA replication of MCV 
(Kwun et al. 2009). LT, the largest of all the early proteins, is transcribed from 
two exons and is translated to produce a protein 816 amino acids (aa) in 
length (Stakaityte et al. 2014). Several MCV LT domains are conserved 
among polyomavirus T antigens, including retinoblastoma (pRb, pRB) 
protein-binding (pRb-binding) motif or LXCXE, DnaJ, conserved region 1 
(CR1), origin binding domain (OBD) and helicase/ATPase domain, 
highlighting a number of conserved functions for  MCV LT in the virus life 
cycle (Feng et al. 2008). 
The helicase domain is required for efficient DNA binding activity of LT, since 
lack of this portion of LT results in a marked reduction of DNA recognition by 
LT (Kwun et al. 2009). Binding of ATP to ATP-binding site of LT stimulates 
the binding of OBD to the origin of replication (Borowiec and Hurwitz 1988). 
LT then forms a hexamer ring which binds to OBD and the movement of two 
LT hexamer rings in opposite directions unwinds the circular virus dsDNA 
genome from the origin of replication (Topalis et al. 2013). MCVs with a 
truncated LT lose their replication capacity in MCV-positive MCCs and it has 
been shown that truncated LT is a characteristic of MCV-positive MCC cell 
lines (Shuda et al. 2008; Houben et al. 2010). Nakamura et al. identified a 
conserved and functional Arg–Lys–Arg–Lys sequence between pRb-binding 
and OBD as a nuclear localisation signal (NLS) in MCV-positive MCCs and 
suggested that this plays an important role in oncogenesis of MCV by 
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providing LT with access to the nucleus and consequent binding to pRb 
(Nakamura et al. 2010). pRb is an inhibitor of cellular proliferation (Frolov and 
Dyson 2004)  which is dysregulated in some cancers (Murphree and 
Benedict 1984). It has been shown that pRb associates with Histone 
deacetylase 1 (HDAC1) and recruits it to E2F, a regulator of cyclin E 
promoter, to repress cyclin E expression and hence inhibit cell cycle 
progression (Brehm et al. 1998). In SV40, the OBD and helicase sections of 
LT bind to the cellular proteins p53, p300 and CBP, which has been 
suggested to play a role in T antigen-mediated cell transformation. In this 
complex, SV40 LT Ag is acetylated and it has been shown that the 
acetylation site is conserved in JCV and BKV whose LT also interacts with 
p53 (Poulin et al. 2004). In MCV, a recent study showed that while full length 
MCV LT co-precipitates with p53, it does so at a significantly lower level 
compared to SV40 LT. Interestingly, the authors also showed that MCC-
specific truncated MCV LT does not co-precipitate with p53 (Borchert et al. 
2014), suggesting that similar to SV40, MCV LT OBD and helicase regions 
might interact with p53. Luciferase reporter assays also showed that while 
p53-dependent transcription is reduced by full length MCV LT, the truncated 
LT loses this ability too. In both NLS-containing and NLS-deficient truncated 
MCV LT, a significant portion of LT Ag localises to the cytoplasm. 
Interestingly, MCV LT truncations increase its Rb-binding affinity, leading to a 
significant cytoplasmic re-localisation of Rb (Borchert et al. 2014). In general, 
polyomavirus LT Ags can induce cell proliferation by binding to tumour 
suppressor proteins p53 and Rb and inactivating them (Topalis et al. 2013). 
MCV LT also contains MCV T antigen unique region (MUR), a 200-aa 
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sequence, between its first exon and OBD (Figure 1.9). MUR, conserved in 
MCC-derived MCVs, can bind to the lysosome clustering and fusion promoter 
protein, human Vam6p (hVam6p) and redistribute it to the nucleus (Liu et al. 
2011). Liu et al. suggest that the disruption of lysosome clustering may play a 
role in un-coating or egress of MCV during replication.  
Small T antigen is another product of alternative splicing of the T antigen 
locus, producing a 186aa peptide (Figure 1.9). In addition to CR1 and DnaJ 
domains, which are shared with LT and 57kT, sT also contains a protein 
phosphatase 2 (PP2, PP2A) binding domain at its carboxyl terminus (Kwun 
et al. 2009). PP2A-binding is a conserved characteristic of polyomavirus sT 
Ags and its importance has been shown in cell transformation ability of 
MuPyV and SV40 (Pallas et al. 1990). Interestingly, in MCV the 
transformation ability of sT is independent of PP2A and instead MCV sT 
exerts its transformation effect via several routes that include increasing the 
activity of eukaryotic translation initiation factor 4E (eIF4E) by promoting 
hyperphosphorylation of eIF4E–binding protein 1 (4E-BP1) (Shuda et al. 
2011). In addition, MCV sT plays an important role in efficient MCV 
replication. It has been shown that while sT alone does not have any direct 
effect on MCV-driven replication, it is required for efficient replication activity 
of MCV LT. Details of how this mechanism operates can be found in section 
1.4.2.2: Virus replication. 
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Figure 1.9. Schematic presentation of the T antigen (TAg) locus of MCV. 
Alternative splicing of the TAg locus gives rise to four different proteins, large 
T (LT), small T (sT), 57kT and ALTO. MCV LT contains conserved 
polyomavirus LT domains including, CR1, DnaJ, pRb-binding, nuclear 
localisation signal (NLS), origin binding domain (OBD), and helicase domain 
as well as MCV unique region (MUR) and human Vam6p-binding site. The 
thick black arrow depicts the MCC-specific mutation site. MCV miRNA, MCV-
miR-M1, is located on the opposite strand of LT and is expressed late in the 
infection. sT shares the first exon of LT plus PP2A and PP4C binding site as 
well as LT stabilising domain (LSD). 57kT is identical to LT but with 
incomplete origin binding and helicase domains.  
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MCV sT has also been implicated in disruption of innate immunity, 
inflammatory signalling and MCC metastasis. NF-κB is a protein complex 
with various key roles in regulation of cell proliferation, inflammation, 
immunity and antiviral response (Richards and Macdonald 2011; Griffiths et 
al. 2013). NF-κB remains in a cytoplasmic inhibited state and bound to 
inhibitors of κB (IκB) until activated via a variety of stimuli such as cytokines, 
TNF-α and pattern recognition receptors (PRRs). Activation of TNF-α or 
PRRs (e.g. Toll like receptors, TLRs) triggers a signalling cascade, leading to 
activation of catalytic subunits of IκB kinase (IKK) complex, IKKα and IKKβ 
and the non-catalytic subunit IKKγ. IKK-mediated phosphorylation of IKB 
results in its rapid degradation and release of NF-κB, where NF-κB 
translocates to the nucleus and activates transcription of genes that are 
involved in antiviral response such as type I interferons. IKKγ, also called NF-
κB essential modulator or NEMO, provides a platform for IKKα and β and a 
vehicle to link them to other components of the signalling complex (Griffiths 
et al. 2013). MCV sT has been shown to co-localise with NEMO and cellular 
protein phosphatases 4C (PP4C) and 2A (PP2A) Aβ subunits in cytoplasmic 
puncta preventing phosphorylation of IKKα and β (Griffiths et al. 2013). Given 
the role of PP4C and PP2A in dephosphorylation and inactivation of the IKK 
complex (Barisic et al. 2008; Brechmann et al. 2012) this suggests that sT 
interrupts eventual release and nuclear translocation of NF-κB by preventing 
IkB phosphorylation (Griffiths et al. 2013). Interestingly, PP4C has also been 
implicated in MCV sT-mediated cell migration and motility. Stathmin is a 
microtubule-associated protein which upon dephosphorylation indirectly 
leads to destabilisation of cellular microtubules (Jourdain et al. 1997). 
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Microtubules are key components of cellular shape and motility (Kaverina 
and Straube 2011; Etienne-Manneville 2013). Knight et al. reported that sT 
promotes stathmin-mediated microtubule destabilisation via PP4C and that 
this leads to increased cell motility/migration, suggesting a role for sT in MCC 
metastasis (Knight et al. 2014). In addition to disrupting NF-κB signalling, sT 
expression has been shown to downregulate the expression of several innate 
immunity-associated genes such as, TRAF family member-associated NF-
kappa-B activator (TANK), Chemokine (C-C motif) ligand 2 (CCL2), 
Chemokine (C-X-C motif) ligand 8 and 9 (CXCL8 and CXCL9), suggesting 
yet another key role for sT in MCV life cycle and pathogenesis (Griffiths et al. 
2013).  
Further evidence for MCV manipulating innate immune response comes from 
the observation that MCV T antigen locus downregulates the expression of 
TLR9, a major component of innate immune system. TLR9 is an endosomal 
sensor of nonmethylated CpG motifs, a pathogen-associated molecular 
pattern (PAMP) characteristic of dsDNA viruses and bacteria (Beutler 2004; 
Leifer et al. 2004), which upon stimulation triggers NF-κB signalling and 
inflammatory response (Wagner 2004). Expression of MCV early region, 
particularly LT, has been shown to downregulate TLR9 via downregulation of 
TLR9 transactivator CCAAT-enhancer-binding protein β (C/EBPβ) (Shahzad 
et al. 2013), suggesting that LT too is involved in MCV immune evasion 
mechanism, however, the mechanistic detail and if this is via a direct 
interaction remains unclear.  
In addition to its modulatory effect on the innate immunity, MCV LT plays a 
central role in virus-mediated oncogenesis. MCV-positive MCCs have been 
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shown to undergo apoptosis following LT knockdown, suggesting that LT 
expression is vital for the maintenance of cancerous state in these cells 
(Houben et al. 2010). In addition, inhibition of the oncoprotein survivin results 
in rapid cell death in MCV-positive MCC cells (Arora et al. 2012). 
Interestingly, it has been shown that pRb can repress survivin via interaction 
with its promoter (Jiang et al. 2004), therefore, LT binding and sequestration 
of pRb can upregulate survivin expression leading to promotion of cell 
proliferation. As previously mentioned, MCV LT affinity for p53 is significantly 
weaker than its SV40 homologue and it is lost upon LT truncation in tumours. 
In contrast, LT truncations boost LT binding affinity for pRb (Borchert et al. 
2014). pRb regulates the cell cycle by binding to E2F, an activator of cyclin A, 
cyclin E and dihydrofolate reductase (DHFR). Phosphorylation of pRb 
disrupts pRb-E2F complex leading to E2F-mediated DNA synthesis and 
advancement of cell cycle. SV40 LT has been shown to interact with Heat 
shock 70 kDa protein 8 (HSC70, HSPA8) via its DnaJ domain, and in an 
ATP-dependent manner, leading to dissociation of Rb-E2F complex and 
subsequent cell transformation (Sullivan et al. 2000). Likewise, MCV LT 
binds to pRb and HSC70 and disrupts pRb-E2F complex (Shuda et al. 2008; 
Kwun et al. 2009) suggesting that MCV LT might contribute to cell 
proliferation through the same mechanism (Stakaityte et al. 2014). 
Concordantly, it has been shown that MCV-positive MCCs undergo cell cycle 
arrest when LT binding is lost via mutation in the pRb-binding domain 
(Houben et al. 2012). Moreover,  pRb1 knockdown can rescue MCC growth 
arrest induced by LT knockdown and loss of pRb1 renders LT dispensable 
for MCC growth (Hesbacher et al. 2016).  
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In addition to clonal integration of MCV genome in to the host cell DNA, one 
characteristic feature of all MCV-positive MCCs is loss of essential replication 
domains, OBD and helicase (Figure 1.9). In contrast, those domains of LT 
implicated in tumourigenesis, such as DnaJ and pRb-binding, as well as the 
entire sT open reading frame are preserved. One explanation for the 
observed mutation pattern is that tumours may naturally select for replication-
deficient MCV clones to prevent fatal replication fork collision arising from an 
otherwise actively replicating clone (Shuda et al. 2008). LT truncating 
mutation and viral genome amplification could precede or succeed the 
integration step (Figure 1.10). A preceding random integration will be 
naturally followed by truncating mutation in LT gene to disable any 
unlicensed virus replication. In this model, genome amplification occurs 
subsequent to integration, possibly via a similar mechanism to genome copy 
number amplification of cellular oncogenes such as MYC (DeCaprio and 
Garcea 2013). In contrast, in the second model, LT gene truncation occurs in 
the episomal MCV, leading to rolling circle amplification of the genome rather 
than normal bidirectional replication. As will be discussed in section 1.4.2.2 
(Virus replication), polyomavirus genome replication is initiated by head-to-
head binding of two LT hexamers to OBD which unwind the dsDNA genome 
and proceed in opposite directions (Figure 1.11 C). A ssDNA break in the 
episomal virus can suspend the associated LT hexamer and cease 
replication of the broken strand while the opposite LT hexamer continues 
replicating the intact strand. The elongated multimer of the mutated viral 
genome will eventually integrate in to the host genome, leading to the 
subsequent transformation events (DeCaprio and Garcea 2013).  
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Figure 1.10. Proposed models for MCV LT truncating mutations and virus 
clonal integration in MCC. In the first model, integration precedes LT gene 
mutation and virus amplification (top) whereas in the second model, LT gene 
mutation occurs in the episomal MCV prior to elongation of the mutant virus 
and subsequent clonal integration (bottom).  
 
Currently, the second model is thought to be the more likely, supported in 
part by evidence showing that expression of mutated LT impairs UV-induced 
DNA repair and hampers cell cycle arrest, leading to genomic instability of 
the host cell and subsequent integration of the virus (Demetriou et al. 2012). 
Interestingly, this study also shows that MCV-positive cell line MKL1 is more 
UV-sensitive and exhibits poorer global genomic repair (GGR) compared with 
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the MCV-negative UISO cell line, further corroborating the role of MCV in the 
host genomic instability.  
To date and in contrast to MCV LT and sT no function has been identified for 
MCV 57kT, however, due to its highly conserved sequence in different MCV 
strains it has been suggested to be involved in the virus multiplication and 
survival (Kwun et al. 2009). Moreover, since 57kT is a homologue of SV40 
17kT it is suggested to play a role in host cell proliferation (Zerrahn et al. 
1993; Comerford et al. 2012). SV40 17kT has been demonstrated to 
stimulate hepatocyte proliferation in transgenic mice, however, unlike SV40 
LT is incapable of inducing hepatic dysplasia and hepatocarcinogenesis 
(Comerford et al. 2012). 
ALTO, unlike sT and 57kT, is transcribed from the second exon of LT and 
therefore does not share its N terminal with other MCV early proteins (Figure 
1.9). Despite lack of sequence identity, ALTO is considered evolutionarily 
related to MuPyV middle T (MT) antigen and is assumed to play a role in 
manipulation of host cell signalling and transformation to cancerous state 
(Carter et al. 2013). However, it has been shown that ALTO is dispensable 
for proliferation of MCV-positive MCCs (Houben et al. 2014). 
The late region of MCV genome codes for capsid proteins VP1, VP2 and 
probably VP3, however, the MCV-specific VP3 ORF is either not expressed 
or is non-functional (Spurgeon and Lambert 2013). While VP1 is involved in 
attachment and entry of MCV, VP2 is required for infectivity in some cell lines 
but not in others (Schowalter and Buck 2013; Spurgeon and Lambert 2013). 
Crystal structure of VP1 shows arrangement of five VP1 monomers around a 
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five-fold axis with unique interaction surfaces formed as a result of variable 
loops. The ratio of VP1 to VP2 has been determined as 5 to 2, i.e. two VP2 
molecules for each VP1 pentamer (Neu et al. 2012). VP1 possesses an NLS 
at its N-terminus and localises as a diffuse nuclear pattern, moreover, its 
presence can shift VP2 localisation to the nucleus from an otherwise 
cytoplasmic state (Schowalter and Buck 2013). In keeping with other 
polyomaviruses, MCV also expresses a miRNA from the late region which is 
located opposite to the MUR region of LT that is able to auto-regulate MCV 
LT expression (Seo et al. 2009). This will be discussed in greater detail in the 
following sections.  
1.4.2. MCV life cycle 
As discussed above, MCV was initially identified in MCC as a clonally 
integrated virus genome (Feng et al. 2008). Later studies showed that MCV 
is a commensal virus chronically shed from the skin (Schowalter et al. 2010) 
with infections starting in childhood and persisting into adult life (Tolstov et al. 
2011). However, the cellular tropism of MCV was not evident until recently, 
when dermal fibroblasts were shown to fully support MCV entry, transcription 
and replication, and therefore suggested as the major natural host of MCV 
(Liu et al. 2016). In this section, the life cycle of MCV from entry to egress will 
be discussed.  
1.4.2.1. Virus cell surface binding and entry 
Polyomaviruses bind various cell surface receptors before entering the cell. 
BKV, MuPyV and SV40 use different ganglioside receptors (Tsai et al. 2003; 
Low et al. 2006) while JCV has preferential binding for serotonin receptor 
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(Elphick et al. 2004). Virus entry mechanism is determined by attachment 
receptors, for instance, BKV, MuPyV and SV40 undergo caveolar 
endocytosis (Norkin et al. 2002; Eash et al. 2004; Gilbert and Benjamin 
2004). Caveolar endocytosis depends on caveolin proteins and formation of 
flask-shape invaginations in the cell membrane called caveolae (Pelkmans 
and Helenius 2002), in which gangliosides accumulate (Sapp and Day 2009). 
Caveolae never join lysosomes and therefore viruses using this 
internalisation route avoid lysosomal degradation (Kiss and Botos 2009). 
Following attachment, SV40 virions move to caveolin 1-containing caveolae 
which will then depart from cell membrane and join pre-existing pH-neutral 
and cholesterol-rich stationary organelles called caveosomes (Pelkmans et 
al. 2001). A few hours after SV40 entry, caveosomes transform into long 
tubular membrane structures which no longer contain caveolin-1, detach from 
caveosomes and transport virions to smooth endoplasmic reticulum (ER) 
where SV40 accumulates and disassembles (Pelkmans et al. 2001; Norkin et 
al. 2002). A more recent study revealed that SV40 internalisation still occurs 
in caveolin-deficient cells, suggesting that caveolin-1 is not essential for 
membrane-to-ER transport (Stergiou et al. 2013). The authors also 
demonstrated that SV40 binding of integrins, a type of bidirectional signalling 
and adhesion receptor (Hynes 2002), triggers recruitment of PI3K 
(Phosphatidylinositol-4,5-bisphosphate 3-kinase) to the membrane, leading 
to de-phosphorylation of Ezrin, a member of ezrin-radixin-moesin (ERM) 
family (Stergiou et al. 2013), which are important regulators of membrane 
domains (Fehon et al. 2010). Stergiou et al. suggest that Ezrin de-
phosphorylation has several consequences including disconnection of 
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cortical actin from plasma membrane and membrane tubulation, both of 
which are required for SV40 internalisation (Ewers et al. 2010; Stergiou et al. 
2013). Inhibition of actin filaments with jasplakinolide resulted in reduced 
BKV infectivity, suggesting that BKV too utilises the actin cytoskeleton for 
virus infection (Eash and Atwood 2005).  
Unlike other polyomaviruses, JCV utilises clathrin-dependent endocytosis 
(Pho et al. 2000), an endocytosis mode which involves formation of clathrin-
coated pits and various adaptor proteins such as eps15 (epidermal growth 
factor receptor pathway substrate clone 15), adaptor protein complex 1 
(AP1), AP2 and AP180 (Motley et al. 2003; Ungewickell and Hinrichsen 
2007; Schelhaas 2010). Studies have shown that JCV infectious entry to glial 
cells requires clathrin, eps15 and activated tyrosine kinase signalling 
(Querbes et al. 2004). In addition, JCV infection of glial cells activates 
mitogen-activated protein kinases 1 (MAPK1) and MAPK2, probably to 
facilitate efficient virus internalisation, cellular trafficking and replication 
(Querbes et al. 2004).  
MCV attachment and entry is comprised of two steps in which the virus 
sequentially binds to glycosaminoglycans and sialylated oligosaccharides 
before cell entry. The initial attachment occurs via binding of MCV capsid 
protein VP1 to heparan sulfate (HS) and chondroitin sulfate (CS) (Schowalter 
et al. 2011), then VP1 via its apical shallow binding site binds Neu5Ac-α2,3-
Gal, a linear motif of N-acetyl neuraminic acid (Neu et al. 2012). Interestingly, 
while the sialylated oligosaccharides are not required for the initial entry they 
are indispensable for the follow-up infectious entry of the virus (Schowalter et 
al. 2011). To date, there is no data available for MCV internalisation route.  
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1.4.2.2. Virus replication 
Like other polyomaviruses, MCV requires the expression of LT to initiate 
replication and is largely dependent on the host cell machinery for successful 
transcription and replication of its genome. Virus replication is a delicately 
coordinated process in polyomaviruses, which begins with transcription of the 
early region upon nuclear entry of the genome, followed by oligomerisation of 
LT antigen in the form of hexamers (DeCaprio and Garcea 2013). In SV40, 
binding of ATP to LT triggers interaction between two LT hexamers and ORI 
followed by movement of hexamers in opposite directions, which combined 
with helicase activity unwinds the viral genome and advances bi-directional 
genome replication (Borowiec and Hurwitz 1988; Wessel et al. 1992). As 
mentioned in section 1.4.1, a minimum core region of 71bp in the MCV ORI 
has been reported as sufficient for initiation of the virus replication. This core 
region is composed of ten G(A/G)GGC pentamer (P1 to P10) repeats, as 
recognition sites for LT OBD,  and flanking AT-rich sites. As can be seen in 
Figure 1.11 B, LT OBD binds the central P1, P2 and P4 sites. In fact, these 
three sites, along with P7, are indispensable for origin replication, although 
P7 is located further and outside the origin centre (Harrison et al. 2011). OBD 
recognition of the essential pentanucleotides leads to binding of LT hexamers 
in an apex-to-apex orientation while wrapping around the dsDNA genome 
(Figure 1.11 C). It has been suggested that the flanking AT-rich sequences 
(Figure 1.11 A) allow for easier melting of the core origin and hence 
facilitates replication initiation (Kwun et al. 2009).  
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Figure 1.11. The minimum core region of MCV origin of replication required 
for efficient virus replication (A), schematic presentation of LT OBD binding to 
the central pentanucleotides P1, P2 and P4 based on X-ray crystallography 
(B) and LT hexamers binding, genome unwinding and replication initiation 
(C). The pentanucleotide repeats (P) are boxed and essential Ps are 
highlighted in red. Adapted from (Harrison et al. 2011) and (DeCaprio and 
Garcea 2013).  
 
Other polyomaviruses such as BKV, JCV and SV40 have the same origin 
pentamer repeats, but unlike MCV, these are in a symmetrical arrangement 
with different inter-pentamer spacing. Moreover, while in BKV, JCV and SV40 
the indispensable P1-P4 repeats are juxtaposed and show no overlapping, in 
MCV the essential P1, P2, P4 and P7 are separated by the second AT-rich 
site and the dispensable overlapped P5/P6 (Figure 1.11 A). The importance 
of such structural distinctions in the replication origins of polyomaviruses has 
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remained unexplained to date, however, what is clear is that despite perfect 
identity of the binding sites and noticeable identities among OBDs in MCV 
and SV40, cross replication does not occur by heterologous LTs (Harrison et 
al. 2011).  
In tumour derived MCV, replication capacity is lost following a single point 
mutation in essential pentanucleotides (Kwun et al. 2009). Furthermore, 
consistent with the observation in MCV-positive MCC, loss of OBD and 
helicase domains renders MCV non-replicative (Shuda et al. 2008). 
Interestingly, whilst LT alone is sufficient for virus replication, efficient 
genome replication is achieved only in the presence of both sT and LT. In 
contrast, 57kT does not improve replication capacity of LT, and sT or 57kT 
alone cannot initiate or drive replication. As mentioned earlier, LT shares the 
first exon, and therefore some domains such as DnaJ with sT (Figure 1.9). 
DnaJ is a conserved motif in polyomaviruses and is required for efficient 
replication in SV40 (Sheng et al. 1997). It has been shown that, despite 
sharing the DnaJ domain, replication efficiency is significantly reduced 
following mutation in LT DnaJ whereas mutation of sT DnaJ does not alter 
the enhancing capacity of sT in LT-driven replication (Kwun et al. 2009). In 
contrast, a mutated sT PP2A domain does eliminate the replication 
enhancing capacity of sT, suggesting a role for sT and PP2A in efficient LT 
replication (Kwun et al. 2009). However, a later study revealed via domain 
mutation that any such effect is not mediated by sT PP2A, but rather by a 
domain located on the opposite side of PP2A termed LSD or LT-stabilisation 
domain (Kwun et al. 2013). 
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SCF (SKP1, CUL1 and F-box containing complex) is a conserved ubiquitin 
ligase complex and FBW7 (F-box and WD repeat domain-containing 7) is a 
subunit of SCF which regulates proto-oncogenes and proteins involved in cell 
division, growth and differentiation (Welcker and Clurman 2008). FBW7 
dysregulation and mutation has been shown in several malignancies 
including T-cell acute lymphoblastic leukaemia/lymphoma (Maser et al. 
2007), breast and colorectal cancers (Wood et al. 2007), 
cholangiocarcinomas and tumours of endometrium and stomach (Akhoondi 
et al. 2007). These studies suggest that FBW7 is an important tumour 
suppressor which promotes degradation of proto-oncogenes in a 
phosphorylation-dependent manner (Koepp et al. 2001; Strohmaier et al. 
2001; Yada et al. 2004). Strikingly, LSD inhibits SCFFBW7-mediated 
proteasomal degradation of LT, hence indirectly enhancing MCV replication 
by promoting the accumulation of LT. Interestingly, sT-mediated SCFFBW7 
inhibition also reduces turnover of cellular proto-oncogenes c-Myc and Cyclin 
E (Kwun et al. 2013), a process which can promote cell transformation.  
T antigen-mediated hijacking of cellular machinery in favour of virus 
replication is not limited to SCFFBW7. DNA damage response (DDR) 
machinery governs the recognition and repair of DNA damage in the cell. 
Ataxia telangiectasia mutated (ATM) and ATM- and Rad3-related (ATR) 
kinases are two important components of DDR, which can mediate cell cycle 
arrest and apoptosis upon activation (Ciccia and Elledge 2010; Tsang et al. 
2014). MCV LT has been shown to interact and co-localise with DDR 
elements in the nucleus in an ORI and replication-dependent manner. 
Furthermore, inhibition of DDR and elimination of ATM and ATR abolishes 
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MCV genome replication (Tsang et al. 2014), indicating the importance of 
DDR in MCV life cycle. This crucial role for DDR in the replication of 
polyomaviruses has also been described in SV40 (Sowd et al. 2013), MuPyV 
(Dahl et al. 2005), JCV (Orba et al. 2010) and BKV (Jiang et al. 2012). 
Another cellular protein contributing to MCV replication is bromodomain and 
extra terminal domain (BET) family member, Bromodomain-containing 
protein 4 or Brd4. Brd4 has been implicated in cell cycle progression to S 
phase (Mochizuki et al. 2008) and cancer (French et al. 2001; Zuber et al. 
2011). It has also been associated with oncogenic viruses such as EBV, 
KSHV and papillomaviruses (Ottinger et al. 2006; Wu et al. 2006; Lin et al. 
2008). Replication factor C (RFC) is a chaperone-like protein complex, which 
upon recognition of template-primer 3’ ends, recruits and loads Proliferating 
cell nuclear antigen (PCNA) to DNA. PCNA is a DNA clamp which encircles 
and slides along DNA like a ring while acting as a tether for DNA 
polymerases (Moldovan et al. 2007). Wang et al. showed both in vivo and in 
vitro that MCV LT interacts with Brd4 at MCV replication sites and that this 
interaction is required for virus replication, since knockdown of Brd4 markedly 
reduces virus replication. Furthermore, similar to SV40 (Wold and Kelly 
1988), MCV LT recruits replication protein A 70 (RPA70) to stabilise the 
nascent unwound viral ssDNA and prevent it from reannealing (Wold 1997). 
Directly interacting with LT, Brd4 then recruits RFC, PCNA and DNA 
polymerase delta to replication sites and facilitates viral DNA elongation 
(Wang et al. 2012).    
Unlike the proteins described so far, hVam6p, which is a cellular vacuolar 
sorting protein, reduces MCV replication. hVam6p is part of HOPS or 
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homotypic fusion and protein sorting complex which modulates lysosome and 
late endosome fusion (Caplan et al. 2001). Direct interaction of MCV LT and 
hVam6p via a site near LT pRb-binding domain (Figure 1.9) re-localises 
hVam6p to the nucleus in an LT NLS-dependent manner and prevents 
lysosome clustering (Liu et al. 2011). While overexpression of hVam6p 
dramatically reduces MCV replication, loss of LT-hVam6p interaction 
enhances virion production by up to 6-fold (Feng et al. 2011). In addition, 
hVam6p isoforms have been shown to be involved in mechanistic target of 
rapamycin (mTOR) and transforming growth factor-β (TGF-β) signalling 
pathways, however, the interaction between MCV LT and hVam6p does not 
seem to affect these (Liu et al. 2011). Although further studies are required 
with regards to MCV dependence on hVam6p for cell growth and 
proliferation, current data suggest that MCV-driven tumourigenesis is not 
mediated by this cellular protein since mutation-driven loss of LT-hVam6p 
interaction does not affect cell viability or proliferation (Feng et al. 2011). 
Therefore, from a cellular point of view, the LT-hVam6p interaction might be 
important in the context of innate immunity, i.e. preventing persistent infection 
via disruption of MCV replication (Stakaityte et al. 2014). A second possibility 
is that MCV-mediated disruption of lysosome clustering might be important 
for virus uncoating or egress (Liu et al. 2011).  
1.4.2.3. Virus assembly and egress 
The mechanisms underpinning MCV assembly and egress are yet to be fully 
elucidated. In SV40, the major viral capsid protein, VP1, has been shown to 
self-assemble without the requirement of post-translational modifications 
(Salunke et al. 1986). So far, it has only been shown that prior to egress 
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MCV virions localise to the nuclear periphery (Neumann et al. 2011). SV40, 
BKV and JCV are known to code for a late protein called agnoprotein, which 
in case of SV40 facilitates virus particle formation and maturation via 
interaction with VP1 (Khalili et al. 2005). SV40 also codes for the very late 
protein, VP4, which is required for efficient propagation and timely lytic 
release of the progeny (Daniels et al. 2007). However, MCV does not encode 
either of these proteins or functional homologues. It has been proposed that, 
similar to other polyomaviruses, MCV might use a lytic mechanism or, 
depending on the host cell, be shed from the skin (Stakaityte et al. 2014). 
Interestingly, a recent study identified dermal fibroblasts as the natural host 
of MCV and the authors suggest that MCV might be released to the skin 
surface by fibroblasts residing adjacent to hair follicle and/or sebaceous and 
sweat glands, or alternatively, differentiating keratinocytes might function as 
the carrier for viruses released from dead infected dermal fibroblasts (Liu et 
al. 2016).  
Virus replication is in fact a cascade of ordered events, from initiation of virus 
gene transcription to virus assembly and egress. In polyomaviruses, the 
importance of temporal organisation is highlighted by arrangement of the viral 
genome in to early and late regions. Extensive dependence of 
polyomaviruses on the host DNA replication and growth machinery presents 
the challenge of being detected and eliminated by the host immune system 
and therefore forcing the virus to a tightly coordinated replication process. 
Thus far, study of MCV replication using a synthetic virus has revealed that 
early gene expression begins with consecutive expression of LT, 57kT and 
sT followed by expression of the late protein VP1. Furthermore, eliminating 
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the replication capacity significantly attenuates 57kT and renders sT and VP1 
undetectable. In contrast to the situation in SV40, this suggests that splicing 
of early transcripts and transcription of the late region is replication-
dependent (Keller and Alwine 1984; Feng et al. 2011). A tightly regulated 
switch between early and late gene expression is therefore critical for 
efficient replication of polyomaviruses. Whilst the mechanism underpinning 
this vital process is not fully understood, it is possible that expression of the 
miRNA from the late region decelerates early gene transcription and viral 
replication to prepare for subsequent virus assembly and release (Seo et al. 
2009). In addition to the auto-regulatory effect on viral transcripts, 
polyomavirus miRNAs might play an important role in virus 
latency/persistence in the host. Indeed, direct involvement of polyomavirus 
miRNAs in immune evasion has become evident in BKV and JCV (Bauman 
and Mandelboim 2011; Bauman et al. 2011) and preliminary data suggest 
that MCV-miR-M1 might similarly facilitate virus persistence (Theiss et al. 
2015). The physiology of miRNAs and their significance in virus life cycle and 
pathogenesis will be discussed in the following sections. 
1.5. miRNAs 
Structurally, miRNAs are small 21-25 nucleotide (nt) non-coding single-
stranded RNAs (ssRNA) which are functionally involved in a variety of 
cellular processes, including regulation of gene expression via post-
transcriptional repression or degradation of their target mRNAs (Bartel 2009; 
Wahid et al. 2010; Lagatie et al. 2013). Generally, biogenesis of miRNAs 
includes canonical and non-canonical pathways, however, several alternative 
pathways have also been described. In this section, miRNA processing 
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pathways and mechanisms of miRNA-mediated RNA interference (RNAi) will 
be discussed. 
1.5.1. Canonical miRNA processing pathway 
In the canonical pathway, a miRNA-coding gene is transcribed by RNA 
polymerase II (PolII), spliced, and undergoes 5’ capping and 3’ 
polyadenylation (Cai et al. 2004). This primary miRNA (pri-miRNA) transcript 
is usually more than 1kb long and contains a stem-loop structure comprised 
of a terminal loop and a 33-35bp stem which embeds mature miRNA 
sequences at 5’ and 3’ sides (Ha and Kim 2014). Next, a miRNA processing 
(Microprocessor) complex of Drosha (nuclear RNase III RNASEN) and 
DGCR8 (DiGeorge syndrome critical region gene-8) recognises the ssRNA 
tails and stem-loop of pri-miRNA (Ha and Kim 2014). In this process, the C-
terminus of DGCR8 binds to the middle region of Drosha whilst the RNA 
binding domains (RBD) of Drosha and DGCR8 interact with pri-miRNA 
(Yeom et al. 2006). The Microprocessor then measures ~11bp away from the 
intersect of ssRNA tail and dsRNA stem (basal junction) and ~22bp from the 
junction between dsRNA stem and the terminal loop of pri-miRNA (apical 
junction) (Ha and Kim 2014). Aligned to the stem, tandem RNase III domain 
a (RIIIDa) and RIIIDb of Drosha cleave pri-miRNA 3’ and 5’ strands, 
respectively, and generate a 2nt overhang at the 3’ end (Blaszczyk et al. 
2001; Han et al. 2004; Zhang et al. 2004). The resulting ~70-80nt hairpin-
shape precursor miRNA (pre-miRNA) is then recognised via its 3’ overhang 
and exported to the cytoplasm by complex of exportin-5 (EXP5) and GTP-
binding Ras-related Nuclear protein (RAN.GTP). Crystallography studies 
have shown that pre-miRNA sits in a positively charged groove formed by 
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EXP5-RAN.GTP complex with pre-miRNA 3’ overhang placed in a tunnel-like 
structure at the bottom of the groove (Okada et al. 2009). Upon nuclear 
export, GTP hydrolysis triggers disassembly of the complex and cytosolic 
release of pre-miRNA (Bohnsack et al. 2004; Lund et al. 2004). Interestingly, 
it has been demonstrated that EXP5 gene knockdown reduces both nuclear 
export and nuclear accumulation of pre-miRNA suggesting that in addition to 
nuclear export EXP5 may also play a role in nucleolysis protection of pre-
miRNA (Yi et al. 2003). Dicer is a cytosolic RNase III endoribonuclease 
whose N-terminus helicase domain interacts with pre-miRNA terminal loop 
(Tsutsumi et al. 2011). A conserved domain of Dicer called PAZ (PIWI–
AGO–ZWILLE) has two basic pockets with a spatial arrangement which 
allows simultaneous binding to the phosphorylated 5’ end and 2nt 3’ 
overhang of pre-miRNA (Zhang et al. 2004; Macrae et al. 2006; Park et al. 
2011; Tian et al. 2014). With PAZ located ~22bp away from catalytic 
domains, Dicer acts like a ‘molecular ruler’ and cleaves off the pre-miRNA 
terminal loop using its RIIIDa and RIIIDb domains, releasing a mature miRNA 
duplex (Zhang et al. 2002; Zhang et al. 2004; Macrae et al. 2006; Macrae et 
al. 2007). In Drosophila, longer miRNAs can be trimmed to ~22bp by a 3’-to-
5’ exonuclease called Nbr (Nibbler) (Han et al. 2011). Dicer is associated 
with dsRNA-binding-domain (dsRBD)-containing cofactors including TRBP 
(trans-activation response RNA-binding protein) and Protein ACTivator of the 
interferon-induced protein kinase (PACT) (Chendrimada et al. 2005; Haase 
et al. 2005; Lee et al. 2013). It has been demonstrated that TRBP is not 
essential for pre-miRNA processing by Dicer, since the level of pre-miRNA 
processing is comparable for Dicer alone or Dicer-dsRBD complex (Lee et al. 
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2006). However, consistent with its D. melanogaster homologue, Loquacious 
(Loqs), it is suggested that TRBP which has three dsRBDs plays a role in 
efficient miRNA processing by stabilising Dicer (Fukunaga et al. 2012; Ha 
and Kim 2014). The role of PACT in miRNA processing is yet to be 
elucidated (Ha and Kim 2014). 
The mature miRNA duplex, comprised of a guide and a passenger (star) 
strand, is then loaded onto Argonaute (AGO or Ago) protein to form RNA-
induced silencing complex (RISC) (Hammond et al. 2001; Mourelatos et al. 
2002). In Drosophila species, central base mismatches 9-10 lead miRNA 
duplex to AGO1 whereas siRNA (small interfering RNA) duplexes are loaded 
onto AGO2 (Tomari et al. 2007; Czech et al. 2009; Ghildiyal et al. 2010). In 
human, all four AGO proteins haphazardly associate with miRNA and siRNA 
duplexes, however with a preference for central (nts 8-11) mismatches (Liu et 
al. 2004; Meister et al. 2004; Yoda et al. 2010). The process of miRNA 
duplex loading is mediated by the HSC70-HSP90 chaperone complex which 
force a conformational opening in AGO proteins in an ATP-dependent 
manner (Iwasaki et al. 2010). Crystallography studies have shown that AGO 
proteins have a bilobal structure. The N-terminus lobe is composed of N-
terminus domain and a PAZ domain whereas C-terminus contains a middle 
domain (MID) and a PIWI domain. Threaded along the two lobes of AGO, the 
guide strand 5’ monophosphate is firmly fixed in the MID-PIWI interface while 
its 3’ end binds PAZ domain in the opposite lobe (Song et al. 2004; Wang et 
al. 2008a; Wang et al. 2008b; Wang et al. 2009; Elkayam et al. 2012; 
Nakanishi et al. 2012; Schirle and MacRae 2012). It has been shown that an 
active site in the AGO PIWI domain governs cleaving of target mRNAs 
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between 10th and 11th nts relative to guide strand 5’ end (Liu et al. 2004; 
Song et al. 2004; Parker et al. 2005). Interestingly, while all four human AGO 
proteins induce target mRNA repression and decay only AGO2 can cleave 
mRNAs with perfect miRNA complementarity (Liu et al. 2004).   
In D. melanogaster, RISC loading complex (RLC) is composed of Dcr2 and 
R2D2 (contains two dsRBD (R2) and is associated with Dcr2 (D2)) which 
respectively bind the less stable and thermodynamically stable ends of 
duplexes to load siRNA onto AGO2 (Pham et al. 2004; Liu et al. 2009), 
whereas the role of RLC in AGO1 loading of miRNA duplexes is yet to be 
defined. In human, in vitro binding of Dicer–TRBP complex to siRNA 
duplexes and its role in pre-miRNA processing and target cleavage has been 
reported (Gredell et al. 2010; Noland et al. 2011; Liu et al. 2012). However, in 
Dicer-deficient murine embryonic stem cells siRNA-mediated repression is 
still detectable (Murchison et al. 2005), suggesting that Dicer is dispensable 
for AGO small RNA loading. Furthermore, Dicer is not necessary for 
determining the guide strand based on the thermodynamic asymmetry 
(asymmetric RISC assembly) of the strands of a small RNA duplex (Schwarz 
et al. 2003; Betancur and Tomari 2012). Therefore, RLC may not be 
essential for miRISC (miRNA-RISC complex) formation in D. melanogaster 
and human.  
Following miRNA loading onto AGO proteins the passenger strand is 
removed to generate a mature miRISC. In siRNAs, absence of central base 
mismatches leads to cleavage of passenger strands by AGO2 (Rand et al. 
2005; Leuschner et al. 2006) prior to their removal by C3PO (component 3 of 
promoter of RISC) endonuclease (Liu et al. 2009). However, due to lack of 
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cleaving activity in human AGO1, AGO3 and AGO4 and presence of central 
mismatches in most miRNA duplexes this mechanism is scarcely used in 
miRISC maturation process (Liu et al. 2004; Meister et al. 2004). Unlike 
loading process, the miRNA duplex unwinding is a passive ATP-independent 
event. It has been suggested that loading of a rigid miRNA duplex onto a 
force-opened AGO protein puts the duplex under a structural tension similar 
to a stretched rubber band. Therefore, with the guide strand firmly docked in 
place the unanchored passenger strand is easily ejected (Iwasaki et al. 
2010). Base mismatches in seed (2-8) or 3’-mid (12-15) of guide strand have 
also been shown to promote duplex unwinding (Yoda et al. 2010).  
An important event during the AGO loading step is selection of the guide 
strand. Thus far, two criteria have been described to determine the guide 
strand: lower relative thermodynamic stability (also referred to as 
thermodynamic asymmetry) at the 5’ end (Schwarz et al. 2003) and 
preference of AGO proteins for a U at position 1 (Czech et al. 2009; Okamura 
et al. 2009; Ghildiyal et al. 2010). The MID domain of human AGO2 
demonstrates a greater affinity for first A and U nts at 5’ ends (Frank et al. 
2010). However, strand selection is not a strict process since the less 
favoured strand may be incorporated into miRISC and, with less frequency, 
participate in silencing (Ha and Kim 2014). For instance, several mouse and 
fly pre-miRNAs have been shown to give rise to mature miRNAs from both 
guide and passenger strands in vivo (Aravin et al. 2003; Schwarz et al. 2003; 
Ro et al. 2007). Where structural elements favouring one strand are absent 
roughly equal amounts of both mature miRNAs accumulate in vivo as 
witnessed by D. melanogaster  miR-10 and miR-10* (Schwarz et al. 2003). 
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Interestingly, tissue-dependent strand switching has also been reported. For 
example, study of mouse tissues revealed miR-142-5p as the dominant 
strand in brain, testes and ovaries whereas miR-142-3p was more frequently 
detected in newborn and embryonic samples (Chiang et al. 2010).  Similarly, 
while mice miR-194-5p and -3p are co-expressed in uterus, ovaries, heart, 
lung and small intestine, other tissues including testes, brain, liver, spleen 
and stomach selectively express miR-194-5p (Ro et al. 2007). The strand 
switching phenomenon has been attributed to alterations in the relative 
thermodynamic stability of the strands due to alternative processing by 
Drosha-DGCR8 (Wu et al. 2009). These observations strongly suggest that 
miRNA strand selection is also determined by cell, tissue and developmental 
stage. miRNA maturation and turnover can be also affected by sequence or 
structural changes in the host RNA molecule. Examples of these changes 
include single nucleotide polymorphisms (SNPs), RNA 3’-end modification 
via uridylation and adenylation, RNA editing and RNA methylation.  
CNNC is a conserved motif in bilaterian animals, located 17-18 nts 
downstream of the Drosha cleavage site of pri-miRNA (Auyeung et al. 2013). 
Splicing factor, arginine/serine-rich 3 (SFRS3 or SRp20) is a protein 
implicated in various RNA processing activities such as splicing (Zahler et al. 
1993; Cavaloc et al. 1994) and translation initiation (Swartz et al. 2007). It 
has been shown that a C → T SNP in the 5’ C of CNNC motif of human miR-
16-1 abolishes recruitment of SFRS3 to CNNC, leading to downregulation of 
miR-16-1 (Auyeung et al. 2013) whose reduced expression has been 
associated with chronic lymphocytic leukaemia (Calin et al. 2002; Calin et al. 
2005).  
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Uridylation of let-7 pre-miRNA (pre-let-7) has been shown to prevent Dicer 
processing and promote let-7 degradation, a process mediated by binding of 
LIN28 proteins to pre-let-7 terminal loop and recruitment of terminal uridylyl 
transferase 4 (TUT4) and TUT7 (Heo et al. 2008; Hagan et al. 2009). In 
contrast, in the absence of LIN28, monouridylation of group II pre-let-7 
miRNAs by TUT7, TUT4 and TUT2 promotes biogenesis of let-7 miRNA 
(Heo et al. 2012). Similarly, adenylation can bring about both positive and 
negative regulation of the target miRNA. For instance, 3’ adenylation of miR-
122 after duplex unwinding by the cytoplasmic poly(A) polymerase GLD-2 
(Germ Line Development 2) stabilises the mature miR-122 in human and 
mouse hepatocytes (Katoh et al. 2009), whereas polyadenylation of host cell 
miRNAs by the vaccinia virus VP55/VP39 heterodimeric poly(A) polymerase 
results in their degradation (Backes et al. 2012). 
Adenosine Deaminases Acting on RNA (ADAR) are dsRNA-binding enzymes 
that are involved in RNA editing by catalysing the conversion of adenosine 
(A) to inosine (I), a process which can replace a Watson-Crick pair with a 
wobble pair (Wagner et al. 1989; Hough and Bass 1994). Such structural 
change in nucleotide positions -1 and +3 relative to 5’ end of miR-151-3p has 
been demonstrated to prevent Dicer cleavage and drive accumulation of pri-
miR-151 (Kawahara et al. 2007), whereas in the case of pri-miR-142, A → I 
conversion in nucleotide positions +4 and +5 relative to 5’ end of miR-142-5p 
(Drosha cleaving site) inhibits Drosha-DGCR8 processing and results in 
degradation of pri-miR-142 by the nuclease enzyme Tudor-SN (tudor 
staphylococcal nuclease), a subunit of RISC (Caudy et al. 2003; Yang et al. 
2006).  
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RNA methylation as a miRNA regulatory mechanism has also been 
described. An example of such intrinsic regulation is BCDIN3 domain 
containing RNA methyltransferase (BCDIN3D) which blocks Dicer access to 
5’ monophosphate of pre-miR-145 and thus prevents miR-145 biogenesis 
and maturation both in vitro and in vivo (Xhemalce et al. 2012). Importantly, 
expression of several miRNAs including miR-145 is deregulated in breast 
cancer (Iorio et al. 2005). It has been demonstrated that BCDIN3D depletion 
in breast cancer cells leads to concomitant reduction of pre-miR-145 and 
increased expression of mature miR-145. Consistent with this, malignancy 
phenotypes such as colony formation in soft agar (anchorage-independent 
growth assay) and penetration through basement membrane matrix (invasion 
assay) were also reduced (Xhemalce et al. 2012), suggesting that 
interruption of Dicer-dependent miRNA processing may be associated with 
tumourigeneis.  
1.5.2. Non-canonical miRNA processing pathways 
The major characteristic of non-canonical pathways is processing of miRNAs 
from the introns of protein-coding genes (mirtrons) in a Microprocessor-
independent manner. Accordingly, the pri- to pre-miRNA step is instead 
processed in the spliceosome and gives rise to an intermediate lariat 
structure which after debranching by lariat debranching enzyme (Ldbr or 
DBR) forms a pre-miRNA-resembling hairpin (Okamura et al. 2007; Ruby et 
al. 2007). In some cases such as Drosophila spp. miR-1017, an exonuclease 
trimming step precedes dicing step to remove the 3’ tail of the pre-miRNA 
(Flynt et al. 2010). The pre-miRNA export and miRNA maturation steps are 
shared between non-canonical and canonical pathways (Figure 1.12).  
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Alternative miRNA processing mechanisms have also been identified. 
Examples of these include miR-320 and miR-451 biogenesis pathways. 
Following Pol II-mediated transcription and 5’ capping human and mouse 
pre-miR-320 are exported to the cytosol by EXP1 where Dicer cleaving 
selectively gives rise to miR-320-3p, presumably due to interference of 5’ cap 
with Dicer interaction (Xie et al. 2013). In the case of miR-451, Drosha 
processing of pri-miR-451 generates an unusual 41-42nt pre-miR-451 with a 
17nt stem and perfectly complement strands. Due to its short stem pre-miR-
451 cannot be processed by Dicer and therefore is directly loaded onto and 
cleaved by AGO2, producing a 30nt intermediate RNA termed AGO-cleaved 
pre-miR-451 or ac-pre-miR-451 (Cheloufi et al. 2010; Cifuentes et al. 2010). 
Ac-pre-miR-451 is then trimmed down by poly(A)-specific ribo-nuclease 
(PARN) at its 3’ end to give rise to mature miR-451 (Yoda et al. 2013).  
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Figure 1.12. Schematic presentation of animal miRNA biogenesis pathways 
and proposed model for miRNA-mediated inhibition of translation initiation. In 
canonical pathway, PolII-transcribed miRNA gene is 5’ capped, 3’ 
polyadenylated and folds on itself to form a dsRNA hairpin called pri-miRNA. 
Pri-miRNA is then cleaved at 5’ and 3’ ends by Drosha-DGCR8 complex to 
give rise to an ~70 nt stem loop structure known as pre-miRNA. This miRNA 
precursor is then recognised and exported to the cytoplasm by exportin 5, 
where Dicer-TRBP further process it into a miRNA duplex, containing a guide 
(red in this Figure) and passenger (grey) strand. Passenger strand is usually 
degraded and guide strand joins RISC complex to form miRISC. miRNA then 
guides the complex to target mRNAs for repression of translation or mRNA 
degradation. Non-canonical pathway is generally dedicated to miRNAs that 
occur in mirtrons (intronic regions of protein-coding genes) and therefore pri- 
to pre-miRNA conversion is processed in spliceosome. The remaining of the 
pathway is similar to the canonical pathway. GW182 co-localises with 
miRISC-bound mRNA and decapping and deadenylation factors in GW 
bodies. Recruitment of eIF4AII to 5’-cap by CCR4-NOT-CAF1 complex 
enforces a molecular conformation which inhibits initiation of translation by 
preventing 43S ribosomal subunit binding to the mRNA. CCR4-NOT-CAF1 
complex also binds DDX6 and links decapping and deadenylation processes 
together to promote mRNA degradation. AGO, Argonaute protein; CAF1, 
CCR4-associated factor 1; CCR4, C-C chemokine receptor type 4; DDX6, 
DEAD-box helicase 6; eIF4F, eukaryotic initiation factor 4F; EXP5, exportin-
5; RAN.GTP, GTP-binding RAs-related Nuclear protein; m7G, 7-
Methylguanosine; NOT1, negative regulator of transcription 1; PABP, 
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poly(A)-binding protein, PAN2 & PAN3, PAB-dependent poly(A)-specific 
ribonuclease subunit 2 & 3; PolII, RNA polymerase II; pre-miRNA, precursor 
miRNA; pri-miRNA, primary miRNA; RISC, RNA-Induced Silencing Complex; 
miRISC, complex of miRNA and RISC; TRBP, trans-activation response 
RNA-binding protein.  
 
1.5.3. miRNA-mediated RNA interference 
Generally, miRNAs exert their effect via base pairing with binding sites in the 
3'untranslated region (3'UTR) of the target messenger RNAs. Central to this 
interaction are nucleotides 2-8 of the mature miRNA, which constitute the 
seed region (Lewis et al. 2003) while nucleotides 13-17, which are located 
near the 3’ end of the miRNA, can augment target recognition by providing 
‘supplementary’ binding and hence are called 3'-supplementary sites 
(Grimson et al. 2007). In some cases, 3' supplementing can ‘compensate’ for 
seed region single nucleotide mismatches and thus called 3’-compensatory 
site (Yekta et al. 2004; Grimson et al. 2007). Examples of this include 
mammalian miR-196 targeting of Homeobox B8 (HOXB8) mRNA (Yekta et 
al. 2004) and C. elegance let-7 miRNA targeting of lin-41 mRNA (Lewis et al. 
2003). These observations suggest that algorithm-based prediction of targets 
based solely on seed-sequence may be misleading. 
Combined in silico-in vitro investigation has also identified other enhancing 
characteristics of target sites, including adjacent AU-rich regions and 
proximity to co-expressed miRNA sites. In addition, target sites located away 
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from the centre of and at least 15nt from the stop codon of 3'UTR 
demonstrate improved binding efficiency (Grimson et al. 2007). 
It is generally accepted that partial miRNA-mRNA base pairing drives 
repression of mRNA translation whereas a perfect or near perfect pairing, 
e.g. in the case of siRNAs, can lead to cleavage of targeted mRNAs 
(Hutvagner and Zamore 2002; Zeng et al. 2002; Zeng et al. 2003; Bartel 
2004; Bartel 2009). The process of miRNA-mediated regulation of gene 
expression has been subject to extensive investigation. Thus far, it has been 
established that RISC is central to the complex machinery of translation 
repression and mRNA degradation (Meijer et al. 2013; Wilczynska and 
Bushell 2015). A key component of the RISC is a protein complex of 182kD 
with multiple repeats of glycine (G)-tryptophan (W) called GW182 (Eystathioy 
et al. 2002). GW182 (Trinucleotide repeat-containing gene 6 or TNRC6 in 
human) contains an RNA recognition motif (RRM) and co-localises with 
mRNA degradation associated proteins Dcp1/Dcp2 (mRNA-decapping 
enzymes 1 and 2), LSm (Sm-like) proteins, 5'-3' exoribonuclease 1 (XRN1), 
Enhancer of mRNA-decapping protein 4 (EDC4 or Ge-1) and AGO2 in GW 
bodies (GWBs) (Ingelfinger et al. 2002; Eystathioy et al. 2003; Zee et al. 
2008). GWBs are the mammalian homologue of eukaryotic processing 
bodies (P-bodies)  which are involved in mRNA turnover and their loss upon 
GW182 knockdown suggests that GW182 is an indispensable component of 
this critical cellular domain (Yang et al. 2004). Importantly, a recent study 
using live imaging in D. melanogaster early embryos showed that GWBs and 
P-bodies are structurally and dynamically distinct and whereas P-bodies are 
mostly cytoplasmic, GWBs localise to both nucleus and the cytoplasm (Patel 
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et al. 2016). Several studies have shown that miRISC binding triggers 
deadenylation and decay of the target mRNAs. Poly(A)-binding protein 
(PABP) is an RNA-binding protein involved in eIF4G-mediated initiation of  
translation (Imataka et al. 1998) and mRNA poly(A) shortening by recruiting 
and stimulating PAB-dependent poly(A)-specific ribonuclease subunit 3 
(PAN3) and its catalytic subunit PAN2 (Boeck et al. 1996; Brown et al. 1996; 
Uchida et al. 2004; Yamashita et al. 2005). C-C chemokine receptor type 4 
(CCR4) is also an important deadenylase which along with CCR4-associated 
factor 1 (CAF1) and negative regulator of transcription 1 (NOT1) forms a 
poly(A)-nuclease complex (Tucker et al. 2001; Yamashita et al. 2005). 
Complex of AGO and GW182 has been shown to concert a rapid biphasic 
mRNA deadenylation by recruiting PABP-PAN3/PAN2 and CCR4-CAF1-NOT 
complexes, respectively, followed by DCP1/DCP2-mediated mRNA 
decapping (Tucker et al. 2001; Yamashita et al. 2005; Chen et al. 2009), a 
process  which leads to the eventual degradation of miRNA-targeted mRNA 
by exoribonucleolytic activity of XRN1 (Arribas-Layton et al. 2013; Wahle and 
Winkler 2013). However, data from several studies suggest mRNA 
degradation may not be necessary for repression (Mathonnet et al. 2007; 
Fabian et al. 2009; Djuranovic et al. 2012; Meijer et al. 2013). In addition, it 
has been shown that translation repression of miRNA-targeted mRNAs 
precedes mRNA deadenylation and degradation (Bethune et al. 2012; 
Djuranovic et al. 2012) and that these two steps occur independently of each 
other (Zdanowicz et al. 2009). Consistent with this observation, 
deadenylation inhibition by protecting the poly(A) tail with a downstream non-
poly(A) sequence does not prevent translation repression (Fukaya and 
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Tomari 2011; Bazzini et al. 2012; Mishima et al. 2012) and GW182 depletion 
restores expression of both polyadenylated and non-polyadenylated target 
reporters (Eulalio et al. 2008). Interestingly, it has also been demonstrated 
that 5’-cap-indepenedent translation is refractory to repression (Pillai et al. 
2005; Meijer et al. 2013) and mRNA degradation even when an mRNA is 
bound by miRISC, suggesting that degradation of miRNA-targeted mRNAs is 
dependent on repression of translation (Meijer et al. 2013). Notably, however, 
translation repression does not always promote mRNA degradation and 
translation of miRNA-repressed mRNAs may be reactivated (Braun et al. 
2011; Braun et al. 2013; Wilczynska and Bushell 2015). In addition to 5’-cap, 
secondary structure of an mRNA 5'UTR and the type of promoter from which 
it is transcribed determine the outcome and mechanism of translation 
repression, respectively. In an in silico study, the authors predicted 
secondary structure of the 5'UTR of human mRNAs deposited in RefSeq 
database using RNAfold web-based tool. When sorted these mRNAs based 
on presence or absence of TargetScan-predicted miRNA sites in their 3'UTR, 
a correlation was revealed between presence of secondary structures in 
5'UTR and miRNA sites in 3'UTR of the mRNA. Interestingly, this correlation 
was stronger with shorter 5'UTRs (shorter than 100nt). According to authors, 
this is probably due to greater dependence of mRNAs with shorter 5'UTR on 
miRNA-mediated repression (Meijer et al. 2013). Moreover, an in vitro study 
demonstrated that translation of miRNA-targeted mRNAs transcribed from 
SV40 and TK (thymidine kinase) promoters is repressed at the initiation and 
post-initiation steps, respectively, suggesting that the mode of mRNA 
repression is determined by the coding gene promoter (Kong et al. 2008). 
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eIF4F is a 5’-cap-binding protein complex which plays an important role in 
promoting mRNA translation initiation and is comprised of eIF4A and eIF4E 
subunits and the scaffold subunit eIF4G (Grifo et al. 1983; Merrick 2015). 
eIF4A is an RNA helicase implicated in unwinding of secondary and tertiary 
structures of mRNA 5’-cap and 5'UTR which promotes binding of 43S 
ribosome subunit to the mRNA (Ray et al. 1985; Linder 2003). Using siRNA-
knockdown studies it has been demonstrated that eIF4AII, an isoform of 
eIF4A, is the only component of eIF4F to be necessary for miRNA-mediated 
repression of translation (Meijer et al. 2013). DEAD-box RNA helicase 6 
(DDX6) is a decapping factor whose involvement in miRNA-mediated gene 
silencing via interaction with CCR4-NOT complex has been described (Haas 
et al. 2010; Chen et al. 2014; Mathys et al. 2014; Rouya et al. 2014) . It has 
been suggested that CCR4-NOT-CAF1 interaction with eIF4AII and its 
associated factors enforces a structural conformation which can inhibit 43S 
binding and scanning of miRNA-targeted mRNAs whereas its association 
with DDX6 facilitates mRNA degradation by linking mRNA 5’ decapping and 
deadenylation (Basquin et al. 2012; Wilczynska and Bushell 2015).  
The activity of miRNAs and the ultimate result of this activity should be 
considered in the context of the cell type and activity. Examples of such 
context-dependent miRNA-mediated gene regulation include tumour 
suppressor p27 and transcription factor Krüppel-like factor 4 (KLF4). P27 
downregulation is required for cell cycle progression (Hengst and Reed 1996; 
Chu et al. 2008) and it has been shown that in quiescent cells, due to 
inaccessibility of its 3'UTR target sites, p27 and its inhibitors miR-221 and 
miR-222 are concurrently expressed at high levels. Pumilio homolog 1 
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(PUM1) is an RNA-binding protein which is upregulated upon growth factor 
induction. Strikingly, upregulation and phosphorylation of PUM1 triggers a 
conformational change in p27 3'UTR which allows miR-221 and miR-222 
access to their cognate sites, resulting in p27 downregulation and 
consequent cell cycle entry (Kedde et al. 2010). KLF4 is also an important 
regulator of cell fate in cancer and development. It has been shown to act as 
a tumour suppressor in colorectal cancer (Dang et al. 2003; Zhao et al. 2004) 
while promoting malignancy in breast cancer (Foster et al. 2000; Pandya et 
al. 2004). Interestingly, KLF4 expression is upregulated by miR-206 in non-
cancerous mammary epithelial cells whereas miR-206 downregulates KLF4 
in breast cancer cells, suggesting that miRNA-mediated regulation of KLF4 is 
also determined by the cell type (Lin et al. 2011).  
While the majority of miRNA target sites thus far identified reside in the 
3'UTR of the mRNAs (Agarwal et al. 2015; Wilczynska and Bushell 2015), a 
few studies have reported functional miRNA binding sites within the 5'UTR of 
the target transcripts. For instance, an in vitro study demonstrated that 
association of miR-10a with 5'UTR of a set of ribosomal protein (RP) mRNAs 
promotes their translation (Orom et al. 2008). Similarly, binding of miR-122 to 
HCV mRNA 5'UTR is required for the activation of virus mRNA translation 
(Jopling et al. 2005; Roberts et al. 2011). Translation repression following 
5'UTR binding of miRNAs has also been reported. Human cytomegalovirus 
(HCMV) miR-US25-1 has been demonstrated to downregulate expression of 
several genes associated with cell cycle control including cyclin E2 (CCNE2) 
and tripartite motif-containing 28 (TRIM28) via binding to their mRNA 5'UTR 
(Lytle et al. 2007; Grey et al. 2010). Finally, it is important to note that the 
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extent to which a given miRNA can modulate the expression of its target 
transcripts may be influenced by the abundance of its target sites in a certain 
cell type or during a certain phase of the cell growth, since competition 
between binding sites to recruit the miRNA can attenuate its regulatory effect 
(Seitz 2009). Indeed, such competing effect has been reported in Arabidopsis 
thaliana (A. thaliana) where IPS1 (Induced by Phosphate Starvation 1), a 
non-protein-coding gene, acts as a target for miR-399. IPS1-mediated 
sequestration of miR-399 results in accumulation of PHO2 (Phosphate 2) 
mRNA which is a protein-coding target of miR-399, resulting in reduced 
inorganic phosphate in the plants shoots (Bari et al. 2006; Franco-Zorrilla et 
al. 2007). In addition, artificial miRNA sponges which are routinely utilised in 
miRNA inhibition experiments exploit the phenomenon of competitive miRNA 
target binding (Ebert et al. 2007).  
1.6. Viral miRNAs 
The process of miRNA biogenesis initiates in the nucleus. Viral miRNAs, like 
their cellular counterparts, are dependent on the host cell miRNA processing 
machinery (Kincaid and Sullivan 2012). Given the requirement of host cell 
miRNA processing mechanisms, it is not surprising that almost all viral 
miRNAs thus far have been identified in DNA viruses, which replicate in the 
host-cell nucleus (Cann 2012). One notable exception is the retrovirus, 
bovine leukaemia virus (BLV) which, despite being a single stranded RNA 
virus, encodes five miRNAs. To avoid cleavage of its genome BLV 
circumvents the Drosha-mediated pri- to pre-miRNA stage of miRNA 
processing by coding for smaller miRNAs which are instead transcribed by 
RNA polymerase III (Pol III) (Kincaid et al. 2012). It has been demonstrated 
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that BLV-miR-B4 joins the RISC and downregulates expression of tumour 
suppressors HMG-box transcription factor 1 (HBP1) and peroxidasin 
homolog (PXDN) in vitro by specific binding to their 3'UTR luciferase 
reporters (Kincaid et al. 2012). Interestingly, while BLV-miR-B4 and miR-29a 
have an identical seed sequence (Kincaid et al. 2012), miR-29a 
overexpression in lymphocytes has been associated with downregulation of 
HBP1 and PXDN and induction of hyperproliferative malignancies in mouse 
and human (Han et al. 2010; Santanam et al. 2010). Importantly, nuclear 
access and a DNA genome do not guarantee the existence of viral miRNAs. 
Despite prediction of miRNAs for some papillomaviruses (Gu et al. 2011), in 
at least one papillomavirus, HPV31, no miRNA is present (Cai et al. 2006). 
Similarly, varicella zoster virus (VZV) is a non-miRNA-encoding herpesvirus 
(Umbach et al. 2009).  
Viral miRNAs can be classified as host miRNA analogues or virus-specific 
miRNAs. As mentioned in section 1.5, the seed region of a miRNA plays a 
pivotal role in target recognition by miRISC. Therefore, virus-mediated 
translational regulation of host transcripts could be achieved via encoding 
virus miRNAs with seed region similarity to host miRNAs. Such a mechanism 
has been shown to exist in several herpesviruses and BLV. For example, 
KSHV-miR-K12-11 is an orthologue of human miR-155, sharing the same 
seed sequence as well as a common set of targets (Nair and Zavolan 2006; 
Gottwein et al. 2007; Skalsky et al. 2007). miR-155 is an important immune 
modulator which is involved in development of immune cells such as B and 
T-cells and macrophages in the haematopoietic system and its 
overexpression has been implicated in several lymphomas and other human 
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malignancies. Given that memory B cells are the natural reservoir of KSHV, 
mimicking this host miRNA can be of physiological significance to KSHV 
persistence (Grundhoff and Sullivan 2011). As explained earlier, BLV-miR-B4 
is also a homologue of bovine miR-29a with identical seed sequence and 
common targets whose miR-29a-driven suppression has been associated 
with B cell-like malignancies, suggesting that BLV-miR-B4 may drive 
leukaemia by mimicking miR-29a  (Kincaid et al. 2012). 
One interesting question is whether host cell miRNAs exert an effect on viral 
transcripts, especially those cellular miRNAs with orthology to virus miRNAs. 
Currently, there is scant evidence for such a cellular miRNA effect, however, 
it has been shown that the human liver-expressed miR-122 targets the 5'UTR 
of hepatitis C virus genome and promotes viral replication (Jopling et al. 
2005).  
Cellular miRNAs are capable of targeting hundreds of mRNAs, therefore, 
mimicking host miRNAs provides a virus with a means to regulate large 
numbers of cellular transcripts. According to a gross estimate, almost a 
quarter of the identified human virus-miRNAs carry host-identical seed 
regions (Kincaid and Sullivan 2012). However, this estimate can be 
challenged by revisiting how these analyses were performed, i.e. based on 
hexameric or heptameric seed region, or by considering determinant factors 
other than seed matching and that some miRNAs might not be bona fide or 
functional (Grimson et al. 2007; Kincaid and Sullivan 2012). Nevertheless, 
encoding an endogenous miRNA provides considerable advantages to the 
virus, due to its small footprint on genome size and low immunogenicity. This 
is particularly important in herpesviruses, which express miRNAs 
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predominantly during the latent phase of the virus lifecycle. By employing 
such a strategy, herpesviruses can remain undetected by the host immune 
system, yet continue to regulate expression of host transcripts to their own 
advantage. Moreover, in γ-herpesviruses, such as EBV and KSHV, the latent 
state is associated with oncogenicity, raising an intriguing hypothesis that 
virus-encoded miRNAs may have a causal role in cancer and host cell 
transformation (Grundhoff and Sullivan 2011). The roles and functions of 
virus miRNAs are discussed in more detail below. 
1.6.1. The functions of viral miRNAs 
In addition to their regulatory role in virus replication and life cycle, viral 
miRNAs have been implicated in modulating host gene expression (Seo et al. 
2009; Bauman et al. 2011). Three major functional roles have been assigned 
to viral miRNAs, based on their impact on the virus-host interaction and the 
associated outcomes: increasing host cell longevity, evasion of host-cell 
immune response and attenuation of lytic infection (Kincaid and Sullivan 
2012). Below I consider each of these functional roles in more detail.   
1.6.1.1. Increasing host cell longevity 
Longer lifespan of the host cell is clearly beneficial to latent/persistent 
viruses. The regulatory role of cellular miRNAs in apoptosis, by targeting pro-
apoptotic and anti-apoptotic genes, is well documented (Subramanian and 
Steer 2010). Interestingly, some γ-herpesviruses have managed to usurp the 
host-cell apoptosis regulatory system. For example, KSHV-miR-K12-1, miR- 
K12-3 and miR-K12-4-3p have been shown to specifically target 3'UTR of the 
pro-apoptotic gene caspase3 (casp3) mRNA and downregulate its 
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expression (Abend et al. 2010; Suffert et al. 2011).  In EBV, it has been 
shown that the viral BART miRNAs miR-BART1, miR-BART3, miR-BART9, 
miR-BART-11 and miR-BART12 are able to prevent cell death by targeting 
and downregulating Bcl-2 interacting mediator of cell death (Bim) (Marquitz et 
al. 2011), whereas miR-BART5 downregulates p53 upregulated modulator of 
apoptosis (PUMA) (Choy et al. 2008). Marek’s disease virus 1 (MDV1), a 
tumour-associated α-herpesvirus in chicken, downregulates the expression 
of the TGF-β signalling pathway protein, SMAD2, rendering the anti-cancer 
drug cisplatin ineffective (Xu et al. 2011). BCL2-associated transcription 
factor 1 (BCLAF1 or BTF) is a pro-apoptotic protein whose sustained 
overexpression has been shown to lead to apoptosis and it has been 
suggested to be a tumour suppressor (Kasof et al. 1999; Sarras et al. 2010). 
BTF has also been demonstrated to be a target for miRNAs of the above-
mentioned herpesviruses as well as the β-herpesvirus, HCMV (Ziegelbauer 
et al. 2009; Lee et al. 2012; Riley et al. 2012).  
Viral miRNAs are not only associated with derailing programmed cell death, 
there is also evidence supporting an association with oncogenesis. For 
instance, KSHV and MDV1, although infecting different species, encode 
miRNAs analogous to the host cell miR-155 (Boss et al. 2009; Du et al. 2011; 
Zhao et al. 2011) which when aberrantly expressed is associated with tumour 
formation (Faraoni et al. 2009; Tili et al. 2009). Interestingly, lack of miR-M4 
expression (the orthologue of miR-155) or mutating the miR-M4 seed region 
in MDV1 renders the virus non-tumorigenic (Zhao et al. 2011). Although the 
exact mechanism of MDV1-miR-M4-mediated tumorigenesis has not been 
identified, Zhao et al. suggest that the virus miRNA exploits the host miR-155 
67 
 
pathway. C/EBPβ is a regulator of lymphoid and myeloid maturation whose 
miR-155-mediated downregulation has been associated with 
lymphoproliferative disorder in mice (Screpanti et al. 1995; Costinean et al. 
2009).  Interestingly, it has been demonstrated that while overexpression of 
miR-155 and KSHV-miR-K12-11 downregulates C/EBPβ, antagomir-
mediated abolition of KSHV-miR-K12-11 in human primary effusion 
lymphoma cell lines leads to C/EBPβ derepression (Boss et al. 2011). These 
observations suggest a cardinal role for MDV1-miR-M4 and KSHV-miR-K12-
11 in the oncogenic potential of the encoding virus. Furthermore, seed region 
similarities have been identified between cellular miRNAs and some other 
lymphotropic virus-encoded miRNAs. These include miR-BART1-3p of EBV, 
miR-rL1-6-3p of Rhesus Lymphocryptovirus (RLCV), and miR-M21 of MDV2 
with seed similarities to miR-29 which has been shown to be overexpressed 
in human chronic lymphocytic leukaemias (CLLs) (Kincaid and Sullivan 
2012). To date, there is no evidence for direct association of polyomavirus 
miRNAs with apoptotic or oncogenic states in their host cells.  
1.6.1.2. Host immune evasion 
Evading host immune detection and elimination is vital to 
persistence/latency-establishing viruses. As discussed earlier, miRNAs 
possess advantages over proteins in this regard, since their expression does 
not elicit an immune response and they occupy very little genomic real-estate 
(Kincaid and Sullivan 2012). 
In vitro studies carried out on two members of the polyomavirus family, JC 
virus (JCV) and BK virus (BKV), demonstrated that these viruses 
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downregulate the immune ligand ULBP3 and as a result significantly reduce 
elimination of virus infected cells (Bauman et al. 2011). JCV and BKV cause 
severe life threatening diseases in immunosuppressed patients in the central 
nervous system and kidneys, respectively (Nickeleit et al. 1999; Jiang et al. 
2009). It has been shown that SV40 miRNA is associated with reduced killing 
effect of cytotoxic T-cells (Sullivan et al. 2005). JCV and BKV also encode for 
a miRNA  whose 3p strand is highly similar to SV40 miRNA 3p strand (Seo et 
al. 2008). Interestingly, the seed region of 5p strands of JCV and BKV 
miRNAs and their entire mature 3p strands are identical (Bauman et al. 2011) 
suggesting a common function. The JCV/BKV miRNA 3p strand was shown 
to map to a target site in the 3'UTR of ULBP3 and, despite an increase in the 
mRNA levels of ULBP3 following JCV infection, it was demonstrated that 
concurrent with increasing 3p expression, ULBP3 protein level was 
significantly reduced.  This change in ULBP3 expression resulted in reduced 
efficacy of natural killer (NK) cytotoxic T-cells, an effect that was reversed 
following inhibition of 3p with a miRNA sponge. Bauman et al. suggest that 
the 3p strand of JCV miRNA exerts its regulatory effect on ULBP3 expression 
via inhibition of translation as well as other posttranscriptional mechanisms 
such as protein sequestration and degrading newly synthesised proteins 
(Bauman et al. 2011). They also conclude that since the ULBP3-mediated 
immune detection of infected cells is achieved via ULBP3 receptor NKG2D, a 
killer-cell receptor expressed by a variety of T-cells, JCV and BKV manage to 
remain undetected by adaptive as well as innate immune responses and 
hence establish a latent/persistent infection in immunologically healthy 
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individuals. To date, there is no evidence for similar activity of other 
polyomavirus miRNAs against host-cell immune-related transcripts. 
1.6.1.3. Attenuating lytic replication 
Viruses that establish a persistent infection avoid immune detection by 
downregulating the expression of antigenic viral proteins, host immune 
response proteins, or both. Therefore, if the host immune surveillance 
machinery is normally active and efficient, switching from lytic replication to a 
latent form is an effective strategy for evading host immune elimination. 
Virus-encoded miRNAs are predominantly found in viruses with a latent life-
cycle, suggesting that their main evolutionary purpose is to enable the 
encoding virus to enter and maintain latency (Grundhoff and Sullivan 2011). 
In support of this hypothesis, the auto-regulation of viral immediate early 
transcripts has been predicted, in silico, to be the major role of some 
herpesvirus miRNAs (Murphy et al. 2008). The auto-regulatory effect of viral 
miRNAs against viral proteins has also been experimentally validated in vitro 
in several herpesviruses and polyomaviruses. KSHV miRNAs are able to 
negatively regulate the expression of the viral replication and transcription 
activator (RTA), a protein responsible for switching from latent to lytic 
replication (Sun et al. 1998). KSHV-miR-K12-9-5p directly targets the 3'UTR 
of RTA and reduces its expression. It has also been shown that antagomir-
mediated inhibition of this interaction and mutation of miR-K12-9-5p seed 
match results in a significant increase in lytic state activation (Bellare and 
Ganem 2009). KSHV miRNAs can also stabilise latent infection indirectly and 
through cellular factors. Retinoblastoma-like protein 2 (Rbl2) is a repressor of 
DNA methyl transferases (DNMT) 3a and 3b. KSHV-miR-K12-4-5p directly 
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binds to the 3'UTR of Rbl2 leading to its translational repression and 
subsequently upregulation of DMNT3a, DMNT3b and DNMT1. This results in 
increased virus and host DNA methylation and inhibition of transcription (Lei 
et al. 2010; Lu et al. 2010b). In addition, KSHV-miR-K12-1-5p represses IkBα 
by targeting its 3'UTR, hence preventing lytic replication via NF-kB activation 
(Lei et al. 2010). Furthermore, it has been demonstrated that KSHV-miR-
K12-3-5p downregulates nuclear factor I/B (NFIB) by directly targeting its 
3'UTR. NFIB is an activator of RTA promoter, thus by suppressing NFIB, 
KSHV indirectly downregulates RTA, resulting in stabilisation of virus latency 
(Lu et al. 2010a). These mechanisms alongside RTA downregulation help 
KSHV maintain the latent state. 
Similarly, EBV, HCMV and HSV (herpes simplex virus) miRNAs have also 
been demonstrated to target viral proteins which govern switching from latent 
to lytic replication. EBV-miR-BART-20-5p suppresses EBV immediate-early 
proteins ZTA (bZip transcription transactivator) and RTA by directly targeting 
3'UTR of their transcripts, leading to stabilisation of latent infection (Jung et 
al. 2014). In HCMV, it has been shown that miR-UL112-1 downregulates 
expression of immediate-early (IE) proteins IE1, UL112/113 and UL120/121 
by directly targeting their 3'UTR s in luciferase assays, indicating that HCMV-
miR-UL112-1 may be involved in regulating viral replication (Murphy et al. 
2008). Infected cell polypeptide 0 (ICP0) and ICP34.5 are key HSV-2 
transactivator and neurovirulence factors. HSV-2 latency-associated 
transcript (LAT) encodes miR-I and miR-II which directly target ICP34.5 as 
well as miR-III which directly targets ICP0, leading to efficient downregulation 
of their expression and hence limiting HSV-2 lytic replication (Tang et al. 
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2008; Tang et al. 2009).  The single miRNA of polyomaviruses is expressed 
from the late region and due to its perfect sequence complementarity against 
LT Ag can post-transcriptionally repress its expression (Lagatie et al. 2013).  
Thus far, the miRNA-mediated cleavage of LT transcripts has been described 
for SV40, JCV, BKV, MuPyV and MCV (Sullivan et al. 2005; Seo et al. 2008; 
Sullivan et al. 2009; Broekema and Imperiale 2013; Theiss et al. 2015). As 
described in section 1.4.1, polyomavirus LT antigens initiate viral genome 
replication, therefore their downregulation can restrict genome replication and 
subsequently limit virus detection by host immune surveillance (Seo et al. 
2008). This has been confirmed by a recent study in BKV, which occurs 
naturally as both archetype and rearranged variants. Archetype BKV is the 
persistent variant and exhibits very low replication and T antigen levels, in 
contrast the rearranged variants are associated with lytic infection and renal 
disease (Gosert et al. 2008). In their novel study, Broekema and Imperiale 
showed that flipping the NCCR could reverse the mode of replication in both 
archetype and rearranged BKV virus (Broekema and Imperiale 2013). 
Archetype NCCR is comprised of five DNA sequence blocks (O (for origin of 
replication), P, Q, R and S) which act as enhancer and binding regions for 
transcription factors. The situation differs in rearranged variants where some 
sequence blocks have been deleted or duplicated. Interestingly, expression 
of early and late genes show opposite patterns, with rearranged variants 
exhibiting high early, low late region expression associated with high 
cytopathologic effects, whereas archetype variants are characterised by high 
late and low early region activity (Figure 1.13).  
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Figure 1.13. Suggested model for miRNA-mediated replication control. High 
activity of early promoter in rearranged variants results in high expression 
level of T Ag which in turn increases DNA replication by binding to replication 
origin (top). In archetype variants high miRNA expression level leads to early 
transcript degradation and abolishment of DNA replication (bottom). T Ag, 
Tumour antigen; NCCR, Non-coding control region. 
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As one would expect, in archetype BKV, miRNAs are generated before 
transcription of T Ag, readily directing cleavage of early transcripts, resulting 
in a very low replication rate. By flipping NCCR in both variants the  activity of 
both regions under opposite conditions can be assessed, i.e. late region 
under late or early promoter and vice versa (Broekema and Imperiale 2013). 
This provided the first evidence that polyomavirus miRNAs can be expressed 
prior to virus DNA replication, suggesting a key role for BKV miRNA in virus 
persistence. Furthermore, the use of rearranged polyomavirus variants in 
previous studies may explain the failure to observe the regulatory role of viral 
miRNAs in virus replication. It remains to be determined if this mechanism is 
conserved in other polyomaviruses. In addition, it is not clear yet whether 
polyomavirus miRNAs can be, under certain cellular conditions, expressed 
independently from late proteins that would otherwise be immunogenic and in 
obvious opposition to miRNA-mediated persistence/latency. However, a 
recent study in MCV provided in vitro evidence for origin-independent 
expression of viral miRNA and its essential role in MCV establishment of 
persistent infection (Theiss et al. 2015).  
Variations in the sequence of virus-encoded miRNA have also been 
described for several polyomaviruses. In JCV, miRNA polymorphisms have 
been reported in the 5p strand, although these fall outside the seed and loop 
regions of the pre-miRNA, suggesting that this may have limited functional 
effect (Lagatie et al. 2013). However, one must be cautious when making 
such assumptions as SV40 miRNA variants have been shown to target 
distinct host transcripts while their auto-regulatory effect against early genes 
remains unaltered (Chen et al. 2013).  
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Given the causal association of MCV with the majority of MCC cases, it is 
important to identify mechanisms underlying MCV pathogenesis and its role 
in cellular transformation. To date, the majority of MCV research has been 
focused on the role of viral T antigens in MCC, and to some degree, in 
immune modulation. Studies focused on MCV-miR-M1 have predominantly 
been limited to auto-regulation of LT Ag (Seo et al. 2009; Lee et al. 2011; 
Theiss et al. 2015). Using a synthetic MCV genome (MCVSyn) and its 
miRNA mutant (MCVSyn-hpko), an important recent study confirmed that 
miRNA-mediated downregulation of LT is sufficient to diminish episomal 
replication (Theiss et al. 2015). The authors also provided compelling in vitro 
evidence for the essential role of MCV-miR-M1 in establishing persistent 
infection (Theiss et al. 2015) by showing that MCVSyn-hpko episomes are 
cleared from cultured cells by four months post-transfection, whereas the wild 
type MCVSyn episome was retained and remained replication-competent six 
months post-transfection. However, this study did not investigate the 
mechanism by which MCV-miR-M1 drives latency/persistence. Therefore, a 
key outstanding question is whether the role of MCV-miR-M1 in persistent 
infection is solely due to downregulation of LT and genome replication or if 
MCV-miR-M1 modulation of cellular transcripts that regulate antiviral 
response also contribute to persistent infection of MCV. 
1.7. Project aims 
The underlying hypothesis of this PhD thesis is that MCV-miR-M1 may 
modulate the expression of cellular transcripts in order for MCV to evade the 
host immune response and establish persistent infection and latent 
replication. In this regard, the project aims can be summarised as follows: 
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• Generation and validation of tools required for expression of MCV-
miR-M1 in vitro. This will be achieved by generating plasmid 
constructs and inducible cell lines incorporating MCV-miR-M1 
sequence and validating MCV-miR-M1-5p and -3p expression in each 
system. In addition, MCV-miR-M1 mimics will be used as an 
alternative expression tool and MCV-miR-M1 relative expression will 
be compared to determine and use the most efficient expression 
system in follow-up experiments. 
• Investigating global transcriptomic changes of the host cell induced by 
MCV-miR-M1 via RNA-Seq. This will be determined by deep 
sequencing of total RNA harvested from 293 cells expressing MCV-
miR-M1, followed by in silico analysis of the data to identify the degree 
of MCV-miR-M1-induced modulation and cellular pathways affected by 
such changes. 
• Validation of RNA-Seq data at mRNA and protein expression levels 
using qRT-PCR and western blotting, respectively.  
• Identifying and validating MCV-miR-M1 specific targets in 3'UTR of 
altered transcripts. This will be assessed using dual luciferase assay 
in 293 cells transfected with luciferase response elements of putative 
targets and in the presence or absence of MCV-miR-M1. 
• Investigating functional significance of MCV-miR-M1-induced 
changes. 
• Confirming the data obtained from validation and functional studies in 
the context of MCV replication using wild type and miRNA-mutant 
MCV synthetic genomes.  
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2. Materials and methods 
2.1. Cell lines 
Unless stated otherwise, cells were supplied from ATCC and maintained in 
Dulbecco’s Modified Eagle Medium (DMEM). Growth media were 
supplemented with 10% fetal bovine serum (FBS) (PAA, The Cell Culture 
Company), 100 U/ml of penicillin and 100 µg/ml of streptomycin (PenStrep) 
(Thermo Fisher Scientific). Where indicated Zeocin, Blasticidin and 
Hygromycin B selection reagents (Thermo Fisher Scientific) were used at 
100 µg/ml, 15 µg/ml and 100µg/ml, respectively. All cell lines were cultured at 
37˚C and 5% CO2 and passaged at ~80% confluency. For a list of cell lines 
and growth media used in this study see Table 2.1. 
Table 2.1. List of cell lines with growth media and supplements. DMEM, 
Dulbecco’s Modified Eagle Medium; FBS, Fetal Bovine Serum; Pen Strep, 
Penicillin Streptomycin; Tet-Free, Tetracyclin-free; RPMI, Roswell Park 
Memorial Institute. 
Cell line Growth media and supplements 
HEK293 (Human 
Embryonic Kidney cells) DMEM, FBS, PenStrep 
Flp-In™ T-REx™ 293 DMEM, Tet-Free FBS, PenStrep, Zeocin, Blasticidin (Thermo Fisher Scientific)  
Flp-In™ T-REx™ 293 -
MCV-LT 
DMEM, Tet-Free FBS, PenStrep, Blasticidin, 
Hygromycin B  
Flp-In™ T-REx™ 293-
MCVmiR 
DMEM, Tet-Free FBS, PenStrep, Blasticidin, 
Hygromycin B 
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2.2. Primers and oligonucleotides 
Primers and oligonucleotides were designed using online primer design tools 
Primer-BLAST (National Center for Biotechnology Information, NCBI) and 
Primer3Plus (http://primer3plus.com/) and supplied by SIGMA-ALDRICH. 
miRNA primers were designed using miRNA Primer Design Tool accessible 
at http://genomics.dote.hu:8080/mirnadesigntool/ (Czimmerer et al. 2013). 
For a list of primers and oligonucleotides see Tables 2.2 to 2.5.  
Table 2.2. List of oligonucleotides for qRT-PCR of MCV and cellular 
transcripts. 
Target  Forward Reverse 
MCV LT  TTCCAGCAAAATATCCACAAGC TGGATTGGGCCCATATTCGT 
MCV sT  AAGTTGTCTCGCCAGCATTG GCCACCAGTCAAAACTTTCCC 
MCV VP1 AAAACACCCAAAAGGCAATG GCAGAGACACTCTTGCCACA 
ACTB GGGAAATCGTGCGTGACATT GACTCCATGCCCAGGAAGG 
ADRA1D CCGCTCGGCTCCTTGTTC CACGCAGCTGTTGAAGTAGC 
AMBRA1 ATTCACTCAGGAGGAGGCTG TCTGTTGGTAGCGCATGGAG 
C/EBPα  CTAGAGATCTGGCTGTGGGG TCATAACTCCGGTCCCTCTG 
C/EBPβ  CAGCGACGAGTACAAGAT CTGCTCCACCTTCTTCTG  
CCDC85A  GCCAGCCAGAATAGAAGGCA AAGAACCCGGGAGAGTAGGC 
CTSS  CACCACTGGCATCTCTGGAA  AGCACCACAAGAACCCATGT 
79 
 
CXCL8 ATGACTTCCAAGCTGGCCG ACTGCACCTTCACACAGAGC 
CYB5R2 AGACCAGACCAGACGAGTGA AACATGGGTGTGATGCCTGT 
DENND2D  CTTCGTTCTGACCAATGT TGATGTCTCTTCTCCACTT  
DMBT1 ACGACAGATTGGTGGCATCC GTATGCAGGGTAGGATGGGC 
DPP6  CCAACTTACACCGGCTCCAT TGAGGATGGACACGTTCTGC 
FOX2 ACCATCCCATTTCCACCACC TGTGCTCCACCTTCTGTCTG 
GAPDH CGGAGTCAACGGATTTGGTC GGATCTCGCTCCTGGAAGATG 
IFI30  TACGGAAACGCACAGGAACA CCCCATTGCACACTCCATGA 
IFIH1 AGTGATTCAGGCACCATGGG GCTGGGCAACTTCCATTTGG 
KCNA1 CATCGCTGGTGTGCTAAC GGTCACTGTCAGAGGCTAA 
KLLN CGAGGAGACCTAGGAGGGTT ACCCCGAGCAAAGGAAGAAG 
LILRB5  TTCCATCCACGGTGTATGACAG GAGGGAGGGCTTCCTAGACA 
LMO3 CACCAAGCCGAAAGGTTGTG CCGTTACACCAAAGAGCCTCA 
MAPK10 GGCTACAAGGAGAACGTGGA TGGGCCGATTCTCCACATAG 
MECP2 GGTAGCTGGGATGTTAGGGC ATGTCTCTGCTTTGCCTGCC 
OSR1 GGCCCTACACCTGTGACATC AGTGAATATATCTGTGGTCTCGCA 
PIK3CD ATGTCACCGAGGAGGAGCA CAGCAGGTAGAGCATCTGGG 
RUNX1 AACAAGACCCTGCCCATCG ACTTCGACCGACAAACCTGA 
SCN1A  TCCTCCCCACACCAGTCTTT TCGGGGCACAAACAAGGAAT 
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SELPLG TCCTGTTGCTGATCCTAC CTTTCTCGGCTTCATCTG 
SOX10 TCTGGAGGCTGCTGAACGAA CTTGTAGTGGGCCTGGATGG 
SP100 AGCACTGTTCAGCGATGTCA GTGGGGTTGTACCAGCATGA 
TIGIT  GTGCCAGGTTCCAGATTCCA GGGCTTTCTTCTTTCTAGTCAACG 
TLR9 GGGCTGGGAAACCTCCGAGT CGACCAGGCTCCCGAAGGAA 
 RAET1G 
(ULBP5) GGGCAGAAGGAGTGCTAGAG CAAAGAGAGTGAGGGTCGGC 
  
Table 2.3. List of oligonucleotides for MCV-miR-M1 stem loop cDNA and 
stem loop qRT-PCR. F, forward; R, reverse. 
Name  Sequence 
MCV-miR-M1-5p 
stem loop primer 
GTTGGCTCTGGTGCAGGGTCCGAGGTATTCGCACCAGAG
CCAACAGTGTA 
MCV-miR-M1-3p 
stem loop primer 
GTTGGCTCTGGTGCAGGGTCCGAGGTATTCGCACCAGAG
CCAACTTCAGG 
GAPDH R (for stem 
loop cDNA) 
CGTTCTCAGCCTTGACGGTG 
MCV-miR-M1-5p GTTTGGTGGAAGAATTTCTAGG 
MCV-miR-M1-3p GGGTGTGCTGGATTCTCTT 
Universal reverse GTGCAGGGTCCGAGGT 
GAPDH F CTCTGGTAAAGTGGATATTGT 
GAPDH R GGTGGAATCATATTGGAACA 
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Table 2.4. List of oligonucleotides for the cloning of 
pcDNA5/FRT/TO/MCVmiR and psiCHECK-2 constructs. Mutation sites of 
mutant psiCHECK-2-mcv-miR-concatemer oligonucleotide are underlined 
and marked in bold. 
Name  Sequence  
MCV-miR-M1 
(BamHI) 
GATCAGGTGCCATACGTTCTGGAAGAATTTCTAGGTACACTGG
TTCCATTGGGTGTGCTGGATTCTCTTCCTGAATTGGTGGTCTCC
TCTCTGC 
MCV-miR-M1 
(XhoI) 
TCGAGCAGAGAGGAGACCACCAATTCAGGAAGAGAATCCAGC
ACACCCAATGGAACCAGTGTACCTAGAAATTCTTCCAGAACGT
ATGGCACCT 
psiCHECK-2-
MCV-miR- 
Concatemer 
(XhoI) 
TCGAGAACCAGTGTACCTAGAAATTCTTCCAGAACGGAACCAG
TGTACCTAGAAATTCTTCCAGAACGGATATCACCAATTCAGGAA
GAGAATCCAGCACACCCAAACCAATTCAGGAAGAGAATCCAGC
ACACCCAAGC 
psiCHECK-2-
MCV-miR- 
Concatemer 
(NotI) 
GGCCGCTTGGGTGTGCTGGATTCTCTTCCTGAATTGGTTTGGG
TGTGCTGGATTCTCTTCCTGAATTGGTGATATCCGTTCTGGAAG
AATTTCTAGGTACACTGGTTCCGTTCTGGAAGAATTTCTAGGTA
CACTGGTTC 
Mutant 
psiCHECK-2-
MCV-miR- 
Concatemer 
(XhoI) 
TCGAGAACCAGTGTACCTAGAAATTCCCCCAGAACGGAACCAG
TGTACCTAGAAATTCCCCCAGAACGGTCGACACCAATTCAGGA
AGAGAATCCAGACCACCCAAACCAATTCAGGAAGAGAATCCAG
ACCACCCAAGC 
Mutant 
psiCHECK-2-
MCV-miR- 
Concatemer 
(NotI) 
GGCCGCGCTTGGGTGGTCTGGATTCTCTTCCTGAATTGGTTTG
GGTGGTCTGGATTCTCTTCCTGAATTGGTGTCGACCGTTCTGG
GGGAATTTCTAGGTACACTGGTTCCGTTCTGGGGGAATTTCTA
GGTACACTGGTTC 
SP100 XhoI CCGCTCGAGCGGTGAAGAGGATGAACAAGAGGAGGAA 
SP100 NotI ATAAGAATGCGGCCGCTAAACTATGAAGATTGCTAACCCAACACCAGC 
CXCL8 XhoI CCGCTCGAGCGGAAAAATTCATTCTCTGTGGTATCC 
CXCL8 NotI ATAAGAATGCGGCCGCTAAACTATTTACTTTGACAACAAATTATATTT 
MAPK10 XhoI CCGCTCGAGCGGTCATTTTCTTAGCACAGGTGCA 
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MAPK10 NotI ATAAGAATGCGGCCGCTAAACTATGTGCCTGAAAACTGTTACCCAC 
TLR9 XhoI CCGCTCGAGCGGCCGTGAGCCGGAATCCTGCACGGT 
TLR9 NotI ATAAGAATGCGGCCGCTAAACTATGCCTTCGGTAGCATTTATTGAGTG 
CYB5R2 XhoI CCGCTCGAGCGGCACCAGGCCACACCCTGCCG 
CYB5R2 NotI ATAAGAATGCGGCCGCTAAACTATTGCTTTGTACTTGAGTTTATTTCA 
KLLN XhoI CCGCTCGAGCGGGACCTGAGACTCACTCCTTGCTCT 
KLLN NotI ATAAGAATGCGGCCGCTAAACTATTGGAGAATGTCTTAAAATTATCTT 
OSR1 XhoI CCGCTCGAGCGGTCAAGTGTCAAGAGTGTGGGAA 
OSR1 NotI ATAAGAATGCGGCCGCTAAACTATCAGAGAAACCTGGTCCTCTCAA 
SELPLG XhoI CCGCTCGAGCGGGTAATTACTCCCCCACCGAGATGG 
SELPLG NotI ATAAGAATGCGGCCGCTAAACTATAAAGTGCTGGGATTACAGGCATGA 
RAET1G 
(ULBP5) XhoI  
CCGCTCGAGCGGTGGTTCCCTGGGCCCAGCTGTCTTTTCTTCC
GTC 
RAET1G 
(ULBP5) NotI  
ATAAGAATGCGGCCGCTAAACTATGACGGAAGAAAAGACAGCT
GGGCCCAGGGAACCA 
C/EBPα PmeI AGCTTTGTTTAAACGGCGCGCCGGGCCAGAGAGCTCCTTGGTCA 
C/EBPα NotI ATAAGAATGCGGCCGCTAAACTATGTGAGACTCTACGTTCTCCCC 
C/EBPβ XhoI CCGCTCGAGCGGTGCGGAACTTGTTCAAGCAG 
C/EBPβ NotI ATAAGAATGCGGCCGCTAAACTATGCCAATTACTGCCCCCAAAA 
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Table 2.5. List of site-directed mutagenesis oligonucleotides for the cloning 
of mutant psiCHECK-2 constructs.  
 Forward  Reverse  
SP100 CAACCATGTCTATTAGCTCCACAAAGCCAATC 
AAGACTGACCTGGTACCTTGTCT
ACACAG 
MAPK10 
5p 
CTTCAACCAATGATGCTTACTACA
GAAAG 
ACCAAAGCAAGAGCAACTAGAAG
TTAAATATAC 
MAPK10 
3p 
ATCCAAAATTGTGTGTCTCTATCT
TGCATC 
GGGGCCACTGCACACCTTGTCAT
GCCA 
 
2.3. Plasmid propagation  
All plasmids were propagated in NEB 5-alpha Competent E. coli (High 
Efficiency) (New England BioLabs, NEB). E. coli competent cells were 
transferred to ice from -80°C storage. After a gentle mix with a sterile and 
cold pipette tip 50µl of thawed cells per transformation were pipetted into an 
ice-cold 1.5ml microfuge tube and kept on ice. 100ng of plasmid DNA was 
transferred to transformation tube using an ice-cold pipette tip, the tube was 
flicked gently 5 times and incubated on ice for 30 minutes. Cells were then 
heat shocked at 42˚C for 30 seconds and returned to ice for a further 5 
minutes. 950µl of room temperature SOC medium was added to each tube 
and cells were incubated at 37˚C in a shaking incubator at 250 revolutions 
per minute (rpm) for 60 minutes, prior to 100µl of cells being plated on 37˚C 
pre-warmed Luria-Bertani (LB) agar plates containing 100µg/ml ampicillin 
(SIGMA-ALDRICH) or 50µg/ml kanamycin (SIGMA-ALDRICH). Plates were 
incubated at 37˚C overnight (o/n). From the o/n LB agar cultures single 
colonies were transferred to sterile falcon tubes containing LB broth 
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supplemented with same concentration of ampicillin or kanamycin and 
incubated at 37˚C in a shaking incubator at 250rpm o/n. In every case, an LB 
agar plate was inoculated with pUC19-transformed E. coli and in the case of 
cloning or sub-cloning control plates for vector only and insert only were also 
included.  
2.4. Plasmid isolation  
Plasmid isolation was carried out in small scale and medium scale using 
PureLink Quick Plasmid Miniprep Kit (Thermo Fisher Scientific) and 
PureYield™ Plasmid Midiprep System (Promega), respectively.  
2.4.1. Small scale plasmid isolation 
Briefly, 1ml of o/n E. coli LB broth culture was pelleted at 13,000×g, 
resuspended in R3 resuspension buffer containing RNase A and lysed with 
L7 lysis buffer. Lysate was then precipitated with N4 precipitation buffer, 
homogenised by inverting several times and centrifuged at 13,000xg for 10 
minutes. Supernatant was transferred to a binding column and centrifuged at 
12,000xg for 1 minute, washed with W9 wash buffer containing 100% ethanol 
and centrifuged at 12,000xg for 1 minute two times. 50µl of TE elution buffer 
was added to the column in a new sterile microfuge tube, incubated at room 
temperature (RT) for 1 minute then centrifuged at 12,000xg for 2 minutes. 
Eluted plasmid was stored at -20°C.  
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2.4.2. Medium scale plasmid isolation 
50ml of o/n culture was pelleted at 5,000xg for 10 minutes using a Beckman 
Avanti J25, resuspended in Cell Resuspension Solution then lysed by mixing 
with Cell Lysis Solution, inverting several times and incubating at RT for 3 
minutes. Lysate was then neutralised by mixing with Neutralization Solution, 
inverted 5 times and incubated at RT for 3 minutes then centrifuged at 
15,000xg for 15 minutes. Supernatant was transferred to a clearing column 
stacked on top of a binding column and connected to a vacuum manifold. 
Vacuum was applied until the entire liquid passed through both columns. 
Clearing column was discarded and binding column was washed by 
consecutive addition of Endotoxin Removal Wash and Column Wash 
Solution (contains 60% of 95% ethanol). Vacuum was applied for a further 30 
seconds to allow the membrane to dry then 400µl nuclease-free water was 
added to the column, stacked on top of an Eluator™ Vacuum Elution Device 
and vacuum applied until all the liquid passed through the column and 
collected in a 1.5ml microfuge tube. For a list of plasmids and miRNA mimics 
see Table 2.6. 
Table 2.6. List of plasmids, expression constructs and miRNA mimics. 
Plasmid name Supplier 
pcDNA3.1 Thermo Fisher Scientific 
pcDNA3.1/MCVmiR Generated during this study 
pcDNA5/FRT/TO Thermo Fisher Scientific 
pcDNA5/FRT/TO/MCVmiR Generated during this study 
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pOG44 Thermo Fisher Scientific 
pEGFP-C2 Clontech  
pMK-MCVSyn and pMK-MCVSyn-hpko Kindly provided by Prof. A. Grundhoff 
MCV-miR-M1-5p mimic (ID:MC15405) Thermo Fisher Scientific 
MCV-miR-M1-3p mimic (ID:MC15468) Thermo Fisher Scientific 
mirVana miRNA mimic Negative 
Control #1 Thermo Fisher Scientific 
psiCHECK-2 Promega 
psiCHECK-2/wt-MCV-miR-concat Generated during this study 
psiCHECK-2/mut-MCV-miR-concat Generated during this study 
psiCHECK-2/SP100-3'UTR (WT and 
Mut) Generated during this study 
psiCHECK-2/CXCL8-3'UTR (WT and 
Mut) Generated during this study 
psiCHECK-2/TLR9-3'UTR (WT and Mut)  Generated during this study 
psiCHECK-2/MAPK10-3'UTR (WT and 
Mut)  Generated during this study 
psiCHECK-2/KLLN-3'UTR Generated during this study 
psiCHECK-2/RAET1G3'UTR Generated during this study 
psiCHECK-2/OSR1-3'UTR Generated during this study 
psiCHECK-2/SELPLG-3'UTR Generated during this study 
psiCHECK-2/CYB5R2-3'UTR Generated during this study 
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2.5. Agarose gel electrophoresis  
1% agarose (Thermo Fisher Scientific) gel was prepared in 100ml of 1x Tris 
Acetate EDTA (TAE) buffer (40mM Tris, 20mM acetic acid, 1mM EDTA pH 
8.0) by boiling in microwave until completely dissolved. Ethidium bromide 
was added and thoroughly mixed at 5%v/v of gel (Thermo Fisher Scientific). 
DNA was electrophoresed at 120 Volt (v) for 45 minutes, visualised by Uvitec 
transilluminator and analysed using the Essential software package (UVItec 
Limited, Cambridge, United Kingdom). 
2.6. DNA gel extraction  
DNA fragments were extracted from agarose gel using PureLink Quick Gel 
Extraction Kit (Thermo Fisher Scientific). Briefly, the DNA fragment of interest 
was excised using a clean scalpel and transferred to pre-weighed nuclease-
free microfuge tube. The tube was then re-weighed and the weight of the gel 
slice calculated. Gel Solubilisation Buffer L3 was added to the gel slice at a 
3:1 ratio (w/v), tube was then incubated at 50°C for 10 minutes, inverting 
every 3 minutes to expedite dissolving the gel. Sample was incubated for a 
further 5 minutes and isopropanol added in 1:1 ratio (w/v) of the gel weight 
and mixed well. This solution was pipetted to a Quick Gel Extraction Column, 
centrifuged at 13000xg for 1 minute, flow-through discarded and 500μl of 
Wash Buffer W1 added to the column stack. Subsequent centrifugation at 
13000xg for 1 minute and 15000xg for 2 minutes were performed with flow-
through discarded after each spin. The Column was then transferred to 
nuclease-free microfuge tube and 50µl of elution buffer was added to the 
centre of the column stack prior to incubation at RT for 1 minute and elution 
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of the purified DNA fragment by centrifugation at 13000xg. DNA fragments 
were stored at -20°C. 
2.7. Annealing of complementary oligonucleotides  
Complementary oligonucleotides were diluted to 1µM concentration in T4 
Polynucleotide Kinase Reaction Buffer (NEB) and mixed together in a 1:1 
ratio at a final volume of 50µl prior to incubation in a T100 Thermal Cycler 
(BIO-RAD) as follows: 
1. 95°C for 5 minutes  
2. 95°C (-1°C/cycle) 1 minute for 70 cycles 
3. 4°C for 30 minutes 
Annealed oligonucleotides were stored at -20°C.  
2.8. Cloning of plasmid constructs 
Cloning of plasmid constructs was carried out as described below. 
Appropriate restriction enzyme sites were designed into 5’ end of 
complementary oligonucleotides or oligonucleotides from which the DNA 
sequences of interest (insert sequence) were PCR amplified. PCR-amplified 
DNA or annealed complementary oligonucleotides and plasmid vectors 
(parent vectors) were digested with appropriate restriction enzymes (NEB) at 
the recommended temperature for 1h in the presence of CutSmart buffer 
(NEB). If required, restriction enzymes were deactivated at 65°C for 20 
minutes. Digestion reactions were run on 1% agarose gel to confirm 
digestion and to gel-purify digested DNA prior to ligating the insert and vector 
using Instant Sticky-end Ligase Master Mix (NEB). Up to a total of 100ng of 
vector and insert DNA were mixed at a range of molar ratios from 1:3 to 1:6 
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and reaction volume adjusted to 5μl with nuclease-free water. 5µl of Ligase 
Master Mix was added to this vector-insert mixture, mixed by gently pipetting 
up and down 10 times and used immediately for transforming competent E. 
coli. For subcloning, insert sequence was obtained by digesting the plasmid 
construct containing the sequence and the new parent vector with same 
enzymes prior to ligating the insert and vector as described above.  
2.8.1. Site-directed mutagenesis 
miRNA recognition site mutated psiCHECK-2 constructs of cellular 3'UTRs 
were generated using Q5® Site-Directed Mutagenesis Kit (NEB). Briefly, 
back to back site mutation primers were designed with nucleotide 
replacements in miRNA seed and 3'UTR sequence matches (Table 2.5). 
Using WT psiCHECK-2-3'UTR constructs as template site mutated 
constructs were PCR amplified prior to degrading WT templates using DpnI 
for 5 minutes at RT. E. Coli competent cells were immediately transformed 
using 1µl of DpnI-treated reactions as described in section 2.3 and site 
mutated constructs were purified as described in section 2.4.1 All plasmid 
constructs generated during this study were confirmed via sequencing at 
DNA Sequencing facility, University of Dundee, Dundee, UK. For a list of 
plasmid constructs see Table 2.6.  
2.9. Cell transfection  
Lipofectamine 3000 Reagent (Thermo Fisher Scientific) was used for nucleic 
acid transfection. Briefly, plasmid DNA (250ng/1x105 cells) or miRNA mimics 
(30pmoles) were diluted in recommended volumes of 100, 50, 25 and 12.5µl 
of antibiotic and serum free growth medium for 6, 12, 24, and 48 well plates, 
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respectively. P3000 Reagent was added at 2μl/μg of diluted DNA and mixed 
well. Lipofectamine 3000 Reagent was diluted at the same concentration and 
in growth medium, mixed with DNA master mix at 1:1 ratio, incubated at RT 
for 5 minutes and added to cells at ~80% confluency. To determine 
transfection efficiency, pEGFP-C2 was transfected into HEK293 cells grown 
on poly-L-lysine (SIGMA-ALDRICH) coated 22x22x0.17mm glass coverslips 
(Thermo Fisher Scientific) as follows. Glass coverslips were soaked in 95% 
ethanol, left to air-dry, covered with poly-L-lysine (0.1% (w/v) in H2O) and 
incubated at 37˚C for 1h. Next, coverslips were placed in a 6-well plate, cells 
were seeded at 3x105 cells per well and grown on glass coverslips. Cells 
were transfected 24h (hour) later at 80% confluency with 500ng of pEGFP-
C2 and incubated for a further 24h. Transfected cells were then fixed using 
4% formaldehyde in PBS for 15 minutes, washed with PBS and treated with 
1% Triton-X 100 for 15 minutes. After a final PBS wash coverslips were 
mounted on glass slides in mounting medium for fluorescence with DAPI 
(Vector Laboratories, USA) and visualised using a Nikon ECLIPSE 80i 
fluorescent microscope. Transfection efficiency was calculated by scoring the 
number of GFP-positive cells and determined to be over 80%.  
2.10. Cell proliferation assays (BrdU Cell Proliferation ELISA Kit) 
BrdU (bromodeoxyuridine) cell proliferation assay was carried out to 
determine the impact of MCV-miR-M1 overexpression or MCVSyn replication 
on cell proliferation using Abcam colorimetric BrdU Cell Proliferation ELISA 
Kit. BrdU is a thymidine analogue which replaces thymidine by incorporating 
into DNA of replicating cells and can be detected using specific antibodies 
(Crane and Bhattacharya 2013). Briefly, 100µl of 293 cells were seeded in a 
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96 well plate at 1x105/ml concentration and 24h later were either transfected 
with MCV-miR-M1 and scramble mimics or MCVSyn and MCVSyn-hpko or 
mock transfected. BrdU was added to the transfected cells and medium only 
wells 24h prior to fixing the cells with 200µl/well of fixing solution for 30 
minutes at RT. The wells were then washed three times using supplied Wash 
Buffer and blotted dry prior to 1h RT incubation with 100μl/well of anti-BrdU 
monoclonal Detector Antibody. After a second wash and dry step, 100μl/well 
of 1:2000 Peroxidase Goat Anti-Mouse IgG Conjugate in Conjugate Diluent 
was added and plate was incubated for 30 minutes at RT prior to final wash 
and dry step. Next, the plate was exposed to 100μl/well TMB Peroxidase 
substrate for 30 minutes in the dark followed by 100μl/well of Stop Solution. 
The absorbance was recorded at 450/550nm dual wavelength. Cell 
proliferation was evaluated by plotting BrdU positive absorbance versus 
transfection condition at each time point. In addition, data was analysed by 
normalising BrdU positive to BrdU negative absorbance for each transfection 
condition.  
2.11. Total RNA extraction  
Total RNA was extracted from 1x106 cells in 6-well plates using Aurum Total 
RNA Mini Kit (BIO-RAD). Briefly, after washing cells with sterile PBS, 350µl 
of lysis buffer (supplemented with 1% β-mercaptoethanol) was added to each 
well and cells were homogenised by pipetting. 350µl of 70% ethanol was 
added to cell lysate and pipetted up and down until the viscous lysate mixed 
thoroughly with alcohol and formed a non-viscous homogenous liquid. 
Lysates were transferred to an RNA binding column stacked on top of a cap-
less wash tube and centrifuged at 13000xg for 30 seconds. Flow through 
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(collected in wash tube) was discarded, 700µl of low stringency solution was 
added to column and centrifuged at 13000xg for 30 seconds. 80µl of 1:15 
(v/v) diluted DNase1 in DNase1 dilution solution was pipetted to the centre of 
column and incubated at RT for 15 minutes. Column was washed by 
consecutive addition of 700µl of high stringency solution and low stringency 
solution and centrifugation at 13000xg for 30 seconds. Column was 
centrifuged for a further 60 seconds and wash tube was discarded. Column 
was transferred to a nuclease-free 1.5ml microfuge tube, 80µl of elution 
buffer was pipetted to the centre of column and incubated at RT for 1 minute 
prior to centrifuging for 2 minutes at 13000xg at RT. Extracted total RNA was 
quantified (see section 2.12) and was immediately used for first strand cDNA 
synthesis. For smaller plates the amount of reagents used was scaled down 
accordingly. 
2.12. Quantification of RNA and DNA 
DNA and RNA concentrations were measured by NanoPhotometer P330 
(Implen GmbH, Munich, Germany). Briefly, after programing the instrument to 
measure the concentration at 0.2mm path length, 1µl of reference sample 
(elution buffer or nuclease-free water) was pipetted onto the centre of 
measuring window, concentration was measured with Lid 50 and the 
instrument was blanked. Reference sample was wiped off and concentration 
of DNA or RNA was measured and recorded as ng/µl. A260/280 absorbance 
was read and recorded for each sample.  
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2.13. First strand cDNA synthesis  
cDNA was generated using iScript Select cDNA Synthesis Kit (BIO-RAD). 
Briefly, reactions were set up in a nuclease-free 200µl PCR tube by mixing 
5x iScript select reaction mix (4μl), Oligo(dT)20 primer or random primer 
mixes (2μl), nuclease-free water (up to 20µl), RNA (500ng) and iScript 
reverse transcriptase (1μl). In reverse transcriptase negative (NRT) 
reactions, reverse transcriptase was replaced with 1µl of water. Reactions 
were incubated as follows, 
Primed with Oligo(dT)20 
1. 42˚C for 30 minutes 
2. 85˚C for 5 minutes 
Primed with random primer mix 
1. 25˚C for 5 minutes  
2. 42˚C for 30 minutes 
3. 85˚C for 5 minutes 
cDNA samples were stored at -20˚C. 
2.14. Stem loop cDNA synthesis  
Stem loop cDNA was synthesised for detection of MCV-miR-M1 expression. 
Reactions were set up using iScript Select cDNA Synthesis Kit (BIO-RAD) by 
mixing 5x iScript select reaction mix (4μl), MCV-miR-M1-5p or -3p stem loop 
primer (500nM), gene specific primer enhancer solution (2μl), nuclease-free 
water (up to 20µl), RNA (500ng) and iScript reverse transcriptase (1μl). 
Reactions were incubated as follows, 
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1. 42˚C for 30 minutes 
2. 85˚C for 5 minutes 
2.15. Quantitative Real Time PCR (qRT-PCR)  
qRT-PCR reactions were set up for two different quantitative assays as 
follows.  
2.15.1. qRT-PCR for stem loop cDNA  
qRT-PCR reactions were set up for detection of MCV-miR-M1-5p and -3p 
expression (Czimmerer et al. 2013) using SsoAdvanced Universal Probes 
Supermix (BIO-RAD) and ProbeLibrary probe #21 (Roche). Master mixes 
(MM) were prepared by mixing components in a sterile nuclease-free 0.5ml 
microfuge tube according to the following scale, 2x SsoAdvanced Universal 
Probes Supermix (10µl), MCV-miR-M1-5p or -3p forward primer (400nM), 
universal reverse primer (400nM), Universal ProbeLibrary probe #21 
(200nM), nuclease-free water (up to 20µl). 5µl of each stem loop cDNA was 
added to 15µl of MM in each well of a BR Clear 96-well PCR plate (BIO-
RAD), briefly mixed and centrifuged and incubated in a CFX Connect Real-
Time PCR Detection System (BIO-RAD) as follows, 
1. Initial denaturation and polymerase activation at 95°C for 30 seconds, 
1 cycle 
2. Denaturation at 95°C for 15 seconds followed by annealing and 
extension at 60°C for 30 seconds, 40 cycles with plate read 
3. 65-95°C (+0.5°C increments, 5 seconds/increment) with plate read for 
melting curve  
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2.15.2. qRT-PCR for first strand cDNA  
qRT-PCR reactions were set up for expression analysis of genes of interest 
using iTaq Universal SYBR Green Supermix (BIO-RAD). Briefly, reaction 
MMs were prepared according to the following scale, 2x iTaq Universal 
SYBR Green Supermix (10µl), forward and reverse primers (300nM each), 
nuclease-free water (up to 20µl). 1µl of first strand cDNA was added to 19µl 
of each MM in each well of a BR Clear 96-well PCR plate (BIO-RAD). 
Reactions were briefly mixed and centrifuged and incubated in a CFX 
Connect Real-Time PCR Detection System (BIO-RAD) as follows, 
1. Initial denaturation and polymerase activation at 95°C for 30 seconds, 
1 cycle 
2. Denaturation at 95°C for 5 seconds followed by annealing and 
extension at 62°C for 30 seconds, 40 cycles with plate read 
3. 65-95°C (+0.5°C increments, 5 seconds/increment) with plate read for 
melting curve  
For both real time qRT-PCR assays data were viewed and analysed using 
BIO-RAD CFX Manager software (version 3). Gene expression was analysed 
using ΔΔCT (normalised expression) method. 
2.16. Dual luciferase assay (DLA)  
Luciferase assay was performed using Dual-Luciferase Reporter Assay 
System (Promega) and analysed using a TECAN infinite M 200 plate reader 
(Tecan, Männedorf, Switzerland) and data was obtained using Magellan 
software (Version 6.6). Briefly, 3x105 293 cells were seeded per well of a 6-
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well plate and after 24h were co-transfected in triplicates according to 
following conditions,  
1. For MCVmiR plasmid construct assays, either of pcDNA3.1 (control) 
or pcDNA3.1/MCVmiR plus either psiCHECK-2/wt-MCV-miR-concat or 
psiCHECK-2/mut-MCV-miR-concat 
2. For MCV-miR-M1 mimics assays, either of 5p, 3p or control mimics 
plus either psiCHECK-2/wt-MCV-miR-concat or psiCHECK-2/mut-
MCV-miR-concat 
24h after transfection cells were washed with sterile PBS and lysed with 1x 
Passive Lysis Buffer (PLB) for 30 minutes on a plate shaker. Cell lysates 
were transferred to sterile microfuge tubes. 100µl of Luciferase Assay 
Reagent II (LAR II) and 20µl of cell lysates were manually pipetted to the 
wells of a 96-well flat bottom black microplate (Thermo Fisher Scientific). 
After measuring firefly luciferase (Fluc) activity, 100µl of Stop & Glo Reagent 
was dispensed to each well and activity of Renilla luciferase (Rluc) was 
measured. Data were exported to an Excel sheet and analysed as follows. 
Luciferase activity was normalised by dividing each Rluc value by 
corresponding Fluc value. Relative luciferase activity was calculated by 
dividing mean average of normalised Rluc values of MCV miRNA-transfected 
cells by that of control cells.    
2.17. Generation of stable cell line (SCL) for inducible expression of 
MCV-miR-M1-5p and MCV-miR-M1-3p (Flp-In™ T-REx™ 293-MCVmiR)  
Stable cell lines were generated according to Flp-In™T-REx™ Core Kit 
guidelines (Thermo Fisher Scientific). Flp-In™T-REx™293 cells were seeded 
97 
 
in 500µl of complete DMEM containing 100µg/ml Zeocin and 15µg/ml 
Blasticidin in a 24-well plate at 2x105 cell/well concentration. At 70% 
confluency the cells were exposed to Hygromycin B in duplicate wells at 0, 
10, 50, 100, 150, 200, 250, 300, 350, 400, 450 and 500µg/ml concentrations. 
Growth media was replaced with fresh DMEM containing the same amount of 
selection reagent every 3 days for 2 weeks. The minimum concentration at 
which all cells were dead after one week was determined as 50µg/ml. Flp-
In™T-REx™293 cells were seeded in a 6-well plate with 15µg/ml Blasticidin 
but without Zeocin and co-transfected with pOG44 (a plasmid expressing Flp 
recombinase) and pcDNA5/FRT/TO/MCVmiR at 9:1 ratio using 
Lipofectamine 3000. Non-transfected and pcDNA5/FRT/TO/MCVmiR only 
(no pOG44) transfected wells were included as negative and positive 
controls, respectively. Cells were washed with sterile PBS after 24h and 
growth media was replaced. 48h post transfection cells were washed again, 
trypsinised and reseeded at 30% confluency. Hygromycin B was added to 
cells at 100µg/ml concentration and media was replaced every 3 days with 
fresh DMEM containing Hygromycin and Blasticidin until cell foci emerged. 
Cell foci were then transferred to new plates and tested for Zeocin sensitivity 
and Hygromycin resistance. Zeocin sensitive, Hygromycin resistant cells 
were expanded and maintained in complete DMEM containing 100µg/ml 
Hygromycin and 15µg/ml Blasticidin. Expression of MCV-miR-M1-5p and -3p 
was assessed via stem loop qRT-PCR as explained in section 2.15.1.  
2.18. Construction of MCVSyn and MCVSyn-hpko 
WT and miRNA-mutant  Synthetic consensus MCV genome (MCVSyn and 
MCVSyn-hpko, respectively) were  constructed  as described previously 
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(Neumann et al. 2011). Briefly, pMK-MCVSyn and pMK-MCVSyn-hpko (a 
kind gift of Prof. Adam Grundhoff, Heinrich-Pette-Institute, Leibniz Institute for 
Experimental Virology, Hamburg, Germany) were digested with SacI (NEB) 
at 37°C for 1h followed by enzyme inactivation at 65°C for 20 minutes. The 
larger of the two DNA fragments was gel purified and recircularised using T4 
DNA Ligase (Thermo Fisher Scientific) by mixing 5x Ligase Reaction Buffer 
at 1:5 ratio and DNA and T4 DNA Ligase at final concentrations of 1ng/µl and 
5x10-3U/µl, respectively with sterile nuclease-free water, then incubated at 
24°C for 1h. DNA was purified from ligation reaction using PureLink® PCR 
Purification Kit (Thermo Fisher Scientific) and stored at -20°C.  
2.19. RNA sequencing  
Total RNA samples were sequenced as described below at the Next 
Generation Sequencing facility based at Leeds Institute of Molecular 
Medicine (Saint James’s University Hospital) under the supervision of Dr 
Sally Fairweather. Total RNA samples were assessed via the following steps 
prior to RNA sequencing.  
2.19.1. Assessing RNA quality  
RNA quality was assessed using RNA 6000 Nano Chip (Agilent 
Technologies, USA). Briefly, room temperature Agilent RNA 6000 Nano gel 
matrix was spin filtered at 4000rpm for 10 minutes. RNA 6000 Nano dye 
concentrate was thoroughly mixed with filtered gel at 1:65 ratio and 
centrifuged at 14000rpm for 10 minutes. On chip priming station 9µl of gel-
dye mix was added to the well of the chip marked as black G, pressurised for 
30 seconds and 9ul of gel-dye mix was added to other G wells. 5µl of RNA 
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6000 Nano marker was added to the rest of the wells prior to addition of 1µl 
of RNA samples to sample wells and 1µl of RNA ladder to ladder well. 
Loaded chip was vortexed at 2400rpm for 60 seconds then placed in an 
Agilent 2100 Bioanalyzer and RNA quality was analysed using 2100 expert 
software according to the supplier’s guidelines.  
2.19.2 RNA quantification  
RNA samples were quantified using Qubit RNA Broad Range Assay Kit 
(Thermo Fisher Scientific) as follows. To prepare Qubit® working solution, 
Qubit® RNA BR Reagent and Qubit® RNA BR Buffer were mixed at 1:200 
ratio. Standards were prepared by mixing each Qubit® RNA BR Standard 
(#1 and #2) with working solution at 1:19 ratio. 1-20µl of each RNA sample 
was added to 199-180µl of working solution, respectively, vortexed and 
incubated at RT for 2 minutes. Standards and samples were analysed 
consecutively using a Qubit® 2.0 Fluorometer (Thermo Fisher Scientific). 
Concentration of samples was calculated using the equation below,  
Sample concentration=QF value × 200/V  
(QF value: the value (μg/ml) obtained from Qubit® 2.0 Fluorometer; V: 
volume (µl) of the sample).  
2.19.3. Preparation of total RNA library  
Total RNA libraries were prepared using TruSeq Stranded Total RNA Sample 
Prep Kit (Illumina, USA) as follows.  
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2.19.3.1. Ribosomal RNA (rRNA) removal and RNA fragmentation  
Total RNA was diluted with ultrapure nuclease-free water to a final volume of 
10µl then mixed with 5µl of rRNA binding buffer and 5µl of Ribo-Zero rRNA 
removal mix by pipetting up and down prior to denaturation in a pre-heated 
T100™ Thermal Cycler (BIO-RAD) at 68˚C for 5 minutes. Denatured RNA 
was thoroughly mixed with 35µl of rRNA removal beads in a new tube and 
incubated at RT for 1 minute then placed on a magnetic stand for 1 minute 
and supernatant was transferred to a new tube. rRNA removal was repeated 
twice then 99µl of RNAClean XP beads was added to the sample, gently 
mixed and incubated at RT for 15 minutes followed by 5 minutes on magnetic 
stand. Supernatant was removed and discarded. Without disturbing the 
beads, 200µl fresh 70% ethanol was gently added to the tube on magnetic 
stand and incubated at RT for 30 seconds. Supernatant was removed and 
discarded and beads were left to air-dry for 15 minutes. After removing from 
magnetic stand, 11µl of Elution Buffer was gently mixed with beads and 
incubated at RT for 2 minutes. Tube was placed on magnetic stand for 5 
minutes then 8.5µl of supernatant and 8.5µl of Elute, Prime, Fragment High 
Mix were mixed in a new tube and incubated as follows, 94˚C for 8 minutes 
then 4˚C on hold. At 4˚C, sample was removed from thermal cycler and 
immediately proceeded to the next step. 
2.19.3.2. Synthesis of first and second strand cDNA  
SuperScript II was gently mixed with First Strand Synthesis Act D Mix at 1:9 
ratio then 8µl of mix was added to fragmented RNA sample, gently pipetted 
up and down 6 times and incubated in a T100™ Thermal Cycler as follows, 
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1. Lid pre-heat, 100˚C 
2. 25˚C for 5 minutes 
3. 42˚C for 15 minutes 
4. 70˚C for 15 minutes 
5. Hold at 4˚C 
At 4˚C, sample was removed from thermal cycler and 5µl of Resuspension 
Buffer plus 20µl of Second Strand Marking Master Mix was added to tube, 
gently mixed and incubated in pre-heated thermal cycler at 16˚C for 1h.  
2.19.3.3. Double-stranded cDNA (dscDNA) clean up  
90µl of thoroughly dispersed room temperature AMPure XP beads was 
gently mixed with 50µl of dscDNA and incubated at RT for 15 minutes then 
placed on magnetic stand for 5 minutes and 135µl of supernatant was 
removed and discarded. Without disturbing the beads, 200µl fresh 80% 
ethanol was added to tube and incubated at RT for 30 seconds prior to 
discarding the supernatant. Ethanol wash was repeated twice and tube was 
left on magnetic stand for a further 15 minutes to air-dry, then removed from 
stand and 17.5µl of Resuspension Buffer was added and gently mixed with 
beads followed by incubating at RT for 2 minutes. Tube was placed on 
magnetic stand for 5 minutes then 15µl of supernatant was transferred to a 
new tube.  
2.19.3.4. Verification of dscDNA presence 
Prior to proceeding to adenylation step, presence of dscDNA was confirmed 
using High Sensitivity DNA 1000 Tape (Agilent Technologies, USA) as 
follows. Briefly, 2µl of High Sensitivity D1000 Sample Buffer was mixed with 
102 
 
2µl High Sensitivity D1000 Ladder and 2µl of dscDNA in separate tubes. 2µl 
of each mix was loaded onto a High Sensitivity D1000 ScreenTape, placed in 
Agilent 2200 TapeStation system, run and analysed using Agilent 2200 
TapeStation Software.  
2.19.3.5. Adenylation of 3’ ends  
Briefly, 2.5µl of Resuspension Buffer and 12.5µl of A-Tailing Mix was added 
to dscDNA and gently mixed by pipetting up and down 10 times then 
incubated in a pre-heated thermal cycler as follows, 
1. Lid pre-heat, 100˚C 
2. 37˚C for 30 minutes 
3. 70˚C for 5 minutes 
4. Hold at 4˚C 
 
2.19.3.6. Adapter ligation  
Immediately after adenylation and at 4˚C, dscDNA was gently mixed with 
2.5µl of each of Resuspension Buffer, Ligation Mix and an RNA Adapter 
Index (Table 2.7) then incubated in a thermal cycler at 30˚C for 10 minutes 
(with lid pre-heat at 100˚C) prior to mixing with 5µl of Stop Ligation Buffer. 
42µl of AMPure XP beads was added and thoroughly mixed with ligation 
reaction then incubated at RT for 15 minutes. Tube was placed on magnetic 
stand for 5 minutes and 79.5µl of supernatant was removed and discarded. 
Then 200µl fresh 80% ethanol was added to the tube without disturbing the 
beads and incubated for 30 seconds. Supernatant was discarded and 
ethanol wash was repeated twice prior to leaving beads to air-dry on 
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magnetic stand. Tube was removed from stand and beads were 
resuspended in 52.5µl Resuspension Buffer by gentle pipetting and 
incubated at RT for 2 minutes then placed back on magnetic stand for 5 
minutes and 50µl of supernatant was transferred to a new tube. 50µl of 
mixed AMPure XP beads was added to each tube for a second clean up (as 
explained above but 95µl supernatant was removed and discarded before 
ethanol wash). Following third ethanol wash and removal, beads were air-
dried, tube was removed from magnetic stand and 22.5µl of Resuspension 
Buffer was added and gently mixed with beads by pipetting and incubated at 
RT for 2 minutes. Tube was placed back on magnetic stand for 5 minutes 
and 20µl of supernatant was transferred to a new tube for PCR amplification. 
 
Table 2.7. RNA Adapter Indices used in adapter ligation step. 
Sample 
ID Index No. 
Index 
Sequence 
Control 1 2 CGATGT 
Control 2 4 TGACCA 
Control 3 5 ACAGTG 
3p1 6 GCCAAT 
3p2 7 CAGATC 
3p3 12 CTTGTA 
5p1 14 AGTTCC 
5p2 15 ATGTCA 
5p3 19 GTGAAA 
 
2.19.3.7. PCR amplification of adapter ligated samples  
Adapter ligated dscDNA was amplified via PCR as follows. 5µl of PCR 
Primer Cocktail and 25µl of PCR Master Mix was added to dscDNA and 
mixed gently then incubated in a thermal cycler as follows, 
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1. Lid pre-heat, 100˚C 
2. 98˚C for 30 seconds 
3. 15 cycles of  
a. 98˚C for 10 seconds 
b. 60˚C for 30 seconds 
c. 72˚C for 30 seconds 
4. 72˚C for 5 minutes 
5. Hold at 4˚C 
Following PCR run, 50µl of AMPure XP beads was added to tube and gently 
mixed then proceeded to clean up step as explained above, but 95µl 
supernatant was removed and discarded before ethanol wash. Following 
third ethanol wash and removal and an air-dry step, tube was removed from 
magnetic stand and 32.5µl of Resuspension Buffer was added and gently 
mixed then incubated at RT for 2 minutes. Tube was returned to magnetic 
stand for 5 minutes and30µl of cleaned up PCR product was transferred to a 
new tube. 
2.19.3.8. Verification of final libraries  
Final libraries were verified using DNA 1000 Chip (Agilent Technologies, 
USA) as follows. Briefly, 25μl of room temperature DNA dye Concentrate 
was added to a vial of DNA Gel Matrix, mixed well and transferred to a spin 
filter then centrifuged at 2300xg for 15 minutes. On chip priming station 9µl of 
gel-dye mix was pipetted to the well of DNA chip marked with black G and 
pressurised for 60 seconds. After releasing the pressure, 9µl of gel-dye mix 
was pipetted to the other two wells marked as G. To the rest of the wells 5µl 
of marker, to ladder well 1µl of DNA ladder, and to sample wells 1µl of final 
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library (or deionised water to unused wells) was added. After vortexing for 1 
minute at 2400rpm, DNA chip was run in Agilent 2100 Bioanalyzer, DNA 
sizes were read and analysed using 2100 expert software. 
2.19.3.9. Quantification of final libraries  
Final libraries were quantified using Quant-iT™ PicoGreen ® dsDNA Kit 
(Thermo Fisher Scientific) as follows. Quant-iT™ PicoGreen® reagent 
working solution was prepared by diluting the reagent in 1xTE buffer at 1:200 
ratio in a plastic container and protected from light, 5 serial dilutions of 
dsDNA in TE were prepared according to Table 2.8. To each dilution, 1ml of 
Quant-iT™ PicoGreen® reagent working solution was added, mixed well and 
incubated in the dark at RT for 5 minutes.  Fluorescence was measured for 
dilutions at standard fluorescein wavelengths (480nm excitation, 520nm 
emission), normalised by subtracting the fluorescence value of the blank from 
that of each of the dilutions and a standard curve was plotted for 
fluorescence versus DNA concentration. dscDNA was diluted in TE to a final 
volume of 1ml, mixed with 1ml of Quant-iT™ PicoGreen® reagent working 
solution and incubated in the dark at RT for 5 minutes. Fluorescence was 
measured and normalised as above and concentration of dscDNA was 
determined using standard curve. 
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Table 2.8. Protocol for preparing standard curve for final library 
quantification. Volumes are in µl. 
TE volume 
Volume of 
2μg/ml DNA 
Stock 
Volume of 
Diluted Quant-
iT PicoGreen 
Reagent 
Final 
Concentration of 
DNA in Quant-iT 
PicoGreen 
Assay 
0 1000 1000 1μg/ml 
900 100 1000 100ng/ml 
990 10 1000 10ng/ml 
999 1 1000 1ng/ml 
1000 0 1000 blank 
 
Libraries were normalised to 10nM using Tris-Cl 10mM, pH 8.5 (with 0.1% 
Tween 20) and 10µl of each was pooled for sequencing on an Illumina HiSeq 
2500 platform. 
2.20. Enzyme-linked immunosorbent assay (ELISA) 
ELISA was carried out for CXCL8 using Human IL-8 ELISA Ready-SET-Go! 
(2nd Generation) (eBioscience) according to the supplier’s protocol. Briefly, 
ELISA was performed for growth media of transfected 293 cells as follows. 
Growth media of TNF-α stimulated (10ng/µl) or non-stimulated 293 cells were 
included as positive and negative controls, respectively. A 96-well Nunc 
Maxisorp ELISA plate (SIGMA-ALDRICH) was coated overnight at 4°C with 
100μl/well of Anti-Human IL-8 capture antibody in Coating Buffer followed by 
3x wash with 270μl/well Wash Buffer. The plate was blotted on absorbent 
paper prior to blocking with 200μl/well of 1x ELISA/ELISPOT Diluent for 1h, 
then washed once. To the appropriate wells was added 100μl/well of the 
following in technical duplicates, Human IL-8 top standard diluted with 
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ELISA/ELISPOT Diluent in 2-fold serial dilutions for 8 dilution points including 
diluent only as blank, samples including positive and negative controls. Plate 
was sealed and incubated at RT for 2h prior to 5x wash. After blotting on 
absorbent paper, to each well was added 100μl of Anti-Human IL-8 Biotin 
detection antibody diluted in 1X ELISA/ELISPOT Diluent, sealed and 
incubated at RT for 1h, then washed 5x and 100μl/well of Avidin-HRP diluted 
in 1X ELISA/ELISPOT Diluent was added to the plate. After a final 5x wash 
and blotting, the plate was incubated with 100μl/well of 1X TMB Solution for 
15 minutes at RT, then 50μl/well of Stop Solution was added to the plate and 
absorbance was recorded immediately at 450nm using a TECAN infinite M 
200 plate reader. A standard curve was plotted using absorbance versus 
concentration of the 8-point top standard dilutions and the concentration of 
samples was calculated using the obtained standard curve formula.  
2.21. Western blotting 
SDS-PAGE and western blotting was carried out to determine and quantify 
the expression of MCV-miR-M1 target genes at protein level. Briefly, 293 
cells were transfected with MCV-miR-M1 mimics and control miRNA or WT 
and mutant MCVSyn. Cells were lysed using Radioimmunoprecipitation 
assay (RIPA) buffer (SIGMA-ALDRICH) containing protease inhibitor 
(cOmplete Protease Inhibitor Cocktail, Roche) for 30 minutes on ice. Whole 
cell lysates (WCL) were then centrifuged at 15000rpm at 4°C for 20 minutes 
and supernatants were transferred to fresh microcentrifuge tubes prior to 
protein quantification (see section 2.21.1). Laemmli buffer was added to each 
sample at 1x final concentration and samples were boiled at 100°C for 5 
minutes prior to being aliquoted and stored at -20°C. 20μg of total protein 
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were loaded on to sodium dodecyl sulfate (SDS) polyacrylamide gel and run 
at 100V for 2h then transferred to a polyvinylidene fluoride (PVDF) 
membrane (BIO-RAD) prior to blocking with 5% dry low fat milk or bovine 
serum albumin (BSA) in TBST (Tris-buffered saline (TBS) and 0.1% Tween 
20) for 1h at RT. Blocked membranes were then washed 3x5 minutes with 
TBST, incubated with 1:500 or 1:2000 of primary antibody in blocking 
solution overnight at 4°C on a shaker. Membranes were washed again using 
TBST prior to incubating with 1:1000 or 1:2000 of secondary antibodies for 
1h at RT. Finally, membranes were washed 3x5 minutes with TBST, 
incubated with Clarity™ Western ECL Substrate (BIO-RAD) for 5 minutes at 
RT and visualised and pictured using a Gel Doc XR+ imager (BIO-RAD). 
Images were analysed using Image Lab™ Software (BIO-RAD). Where 
required, membranes were stripped using Restore™ Western Blot Stripping 
Buffer (Thermo Fisher Scientific) and reprobed with appropriate Ab’s. For a 
list of antibodies and dilutions used refer to table 2.9. 
Table 2.9. List of primary and secondary antibodies with dilution ratios.  
Antibody (supplier) Dilution ratio (v/v) 
GAPDH (mouse monoclonal, 2mg/ml, abcam) 1:2000 
CM2B4 (mouse monoclonal, 200µg/ml, Santa Cruz), 
a kind gift of Prof. A. Whitehouse (University of 
Leeds) 
1:500 
SP100 (rabbit polyclonal, 200µg/ml, Santa Cruz) 1:500 
TLR9 (rabbit polyclonal, 200µg/ml, Santa Cruz) 1:500 
Goat Anti-Mouse IgG (H+L)-HRP Conjugate (BIO- 1:1000 and 1:2000 
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RAD) 
Goat Anti-Rabbit IgG (H+L)-HRP Conjugate (BIO-
RAD) 
1:1000 
 
2.21.1 Protein quantification 
Protein quantification was carried out using Pierce® Microplate BCA Protein 
Assay Kit (Thermo Fisher Scientific). Briefly, protein standards were prepared 
as 8 point serial dilutions of BSA in RIPA buffer (0, 125, 250, 500, 750,1000, 
1500 and 2000μg/ml). 9μl of protein standards and total protein samples 
were transferred to the wells of a clear 96 well plate in duplicates. BCA 
Working Reagents (WR) A and B were mixed at 50:1 ratio and 260μl of WR 
mix was added to each well, mixed with protein samples for 1 minute on a 
shaker prior to incubation at 37ºC for 30  minutes. The plate was then cooled 
at RT for 5 minutes prior to recording the absorbance at 562nm on a TECAN 
infinite M 200 plate reader. Using RIPA buffer absorbance (0μg/ml of BSA 
protein standard) as blank, a standard curve was plotted for absorbance 
versus concentration of protein standards. Concentration of total protein 
samples was calculated using formula of the standard curve and 
concentrations were normalised to 1µg/µl using Laemmli buffer prior to 
aliquoting and storing at -20ºC.  
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2.22. In silico identification of MCV-miR-M1 putative matches in 3'UTR 
of cellular transcripts 
RNAhybrid online tool (Rehmsmeier et al. 2004) was utilised to identify 
putative seed matches of MCV-miR-M1-5p and MCV-miR-M1-3p in 3'UTR of 
qRT-PCR-validated targets. Briefly, 3'UTR sequences of interest  and MCV-
miR-M1-5p or -3p sequences were copied in FASTA format into the ‘target 
sequence(s)’ and ‘miRNA sequence(s)’ boxes of RNAhybrid tool, 
respectively, prior to proceeding to select ‘hits per target’ and ‘3utr-human’ 
option. Finally, predicted MCV-miR-M1 matches were obtained and 
downloaded via ‘start calculation’ tab which included predicted matches, 
minimum free energy (mfe) and miRNA seed match position relative to 5’ end 
of the 3'UTR.   
2.23. Neutrophil isolation from peripheral blood 
Neutrophils were isolated from peripheral blood as previously described (Lau 
and Hunstad 2013). Briefly, fresh blood was obtained from University of 
Bradford Ethical Tissue Bank (Ethical Tissue, REC Ref 07/H1306/98+5). 
Equivalent volumes of blood and 3% dextran (w/v) in 0.9% NaCl were mixed 
in a sterile conical tube prior to RT incubation for 20 minutes. The upper layer 
was carefully transferred to a new tube and cells were pelleted at 300xg for 
10 minutes prior to resuspending in 0.9% NaCl. Equivalent volume of density 
centrifugation solution was carefully layered under cell suspension, to 
preserve the interphase, and centrifuged at 400xg for 30 minutes. To lyse red 
blood cells (RBC), supernatant was discarded and cell pellet underwent 
several rounds of consecutive resuspension in equivalent volumes of cold 
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0.2% NaCl (30 seconds) and 1.6% NaCl followed by 6 minute centrifugation 
at 300xg until cell pellet appeared RBC-free. Cell pellet was resuspended in 
appropriate volume of DMEM containing 10% FBS and 1% PenStrep prior to 
counting cells with haemocytometer. Neutrophil purity was confirmed by 
Giemsa smear staining as described by Bain et al. (Bain et al. 2012) and 
determined as 90 percent. Briefly, a smear was prepared from cell 
suspension on a glass slide and air dried prior to methanol fixation for 30 
seconds followed by immersing in Giemsa stain for 20 minutes. Slide was 
flushed with water, air dried and examined under light microscope using 
immersion oil.  
2.24. Transwell migration assay  
In vitro neutrophil migration was measured using transwell (Boyden) 
chambers (BD Falcon Cell Culture Inserts, BD Biosciences) as described 
previously (Alfaro et al. 2016). Briefly, neutrophils were seeded (2x106 
neutrophils in 500µl DMEM) into the top chamber and migration stimuli (cell 
growth media) were placed in the lower chamber. Where appropriate, 
CXCR2 antagonist SB265610 (SIGMA-ALDRICH) was added to the top 
chamber at 1000nM final concentration. Plate was incubated at 37ºC and 5% 
CO2 for 2h prior to mixing the lower chamber contents with equal volume of 
CellTiter-Glo® 2.0 reagent (Promega). The mixtures were then transferred to 
the wells of a 96-well plate (100µl in technical triplicates) and luminescence 
was recorded for each sample using a TECAN infinite M 200 plate reader. 
The chemotactic index was measured as the ratio of luminescence in the 
presence to that of the absence of MCV-miR-M1.  
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3. MCV-miR-M1 expression tools 
3.1. Generation and validation of tools required for expression of MCV-
miR-M1 
When this project commenced in October 2013 there were no MCV-miR-M1 
expression constructs described in the literature. This necessitated the 
development of several MCV-miR-M1 expression tools for use in subsequent 
screening experiments to examine the functional consequences of MCV-miR-
M1 on cellular mRNA transcripts. 
3.1.1. Construction of tools 
3.1.1.1. Construction of pcDNA5/FRT/TO/MCVmiR and 
pcDNA3.1/MCVmiR for expression of MCV-miR-M1 
With a view to promote the transcription of pre-miRNA loop, the full predicted 
MCV-miR-M1 pre-miRNA sequence was cloned into pcDNA5/FRT/TO and 
pcDNA3.1 which would then be processed by cellular miRNA pathways to 
produce the mature MCV miRNA. To this end, pcDNA5/FRT/TO/MCVmiR 
was constructed by inserting MCV-miR-M1 sequence into HindIII/XhoI site of 
pcDNA5/FRT/TO. Briefly, pcDNA5/FRT/TO was digested with HindIII and 
XhoI enzymes at 37˚C for 1h, run on agarose gel and gel extracted. Forward 
MCV-miR-M1 and reverse MCV-miR-M1 oligonucleotides (incorporating a 
HindIII and a XhoI compatible overhang, respectively) were annealed and 
ligated into the digested pcDNA5/FRT/TO vector. E. coli competent cells 
were transformed with the ligation products and recombinant plasmid was 
selected via antibiotic resistance and plasmid DNA extracted. The extracted 
plasmid was digested with HindIII + XhoI and run on agarose gel along with 
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undigested plasmid. Presence of the insert was confirmed by observing a 
94bp fragment in HindIII/XhoI digested plasmid (Figure 3.1 A). DNA 
sequencing verified presence of MCV-miR-M1 sequence prior to using 
pcDNA5/FRT/TO/MCVmiR to generate Flp-In™ T-REx™ 293-MCVmiR cell 
line for inducible expression of MCV-miR-M1 (see section 3.1.1.2).   
To generate a tool for transient expression of MCV-miR-M1 a plasmid 
construct was generated by subcloning MCV-miR-M1 into pcDNA3.1. Briefly, 
pcDNA3.1 and pcDNA5/FRT/TO/MCVmiR were digested with KpnI + XhoI 
and run on agarose gel. Digested pcDNA3.1 and the smaller DNA fragment 
(102bp) from pcDNA5/FRT/TO/MCVmiR were gel-purified, ligated and used 
for transformation of E. coli competent cells. Plasmid construct was extracted 
from the cells, digested with KpnI + XhoI and run on agarose gel along with 
undigested plasmid and pcDNA3.1. In addition to size difference with the 
undigested plasmid and parent vector (pcDNA3.1), a 102bp fragment was 
observed in the digested construct lane. pcDNA3.1/MCVmiR was verified via 
DNA sequencing. For a map of pcDNA5/FRT/TO/MCVmiR and 
pcDNA3.1/MCVmiR see Figure 3.1. 
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Figure 3.1.  Generation of MCV-miR-M1 plasmid constructs. (A) 
pcDNA5/FRT/TO and putative pcDNA5/FRT/TO/MCVmiR construct were 
digested with HindIII, XhoI and HindIII + XhoI. A 94bp fragment (red arrows, 
lanes 8 and 11) was observed only in HindIII + XhoI digested construct. 
Lanes 9-11 were loaded with lower concentration of digested construct. (B 
and C) Schematic representation of pcDNA5/FRT/TO/MCVmiR and 
pcDNA3.1/MCVmiR (generated by SnapGene software).  
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3.1.1.2. Generation of Flp-In™ T-REx™ 293-MCVmiR cell line for 
inducible expression of MCV-miR-M1 
In addition to pcDNA3.1/MCVmiR, it was desirable to generate a stable cell 
line that would allow inducible expression of MCV-miR-M1 from the 
integrated MCV pre-miRNA (MCV-miR-M1) sequence. This would not only 
eliminate the need for plasmid transfection and facilitate the quantitative 
expression of the virus miRNA, but also would have the benefit of assessing 
the effect of an endogenously expressed MCV-miR-M1 on cellular 
transcripts. Flp-In™T-REx™293 cells were co-transfected with pOG44 and 
pcDNA5/FRT/TO/MCVmiR and integrants selected for via Hygromycin B 
resistance and Zeocin sensitivity. Six Hygromycin-resistant Zeocin-sensitive 
cell foci were expanded and assessed for MCV-miR-M1 expression via stem-
loop qRT-PCR (See section 3.1.2.1).   
3.1.1.3. Construction of MCVSyn 
When studying functional significance of miRNA targets it is necessary to 
assess the miRNA expression at endogenous levels. In addition, it is 
important to assess the effect of polyomavirus miRNAs on host cell 
transcripts in the context of virus replication due to their modulatory effect on 
virus early transcripts and replication (Lagatie et al. 2013). However, one of 
the challenges in the field of MCV research (until very recently) is the lack of 
a permissive virus cell line to facilitate analysis of MCV replication and virus-
host cell interactions. During the lifetime of this project novel tools were 
published that permitted the generation of miRNA-positive and -negative 
synthetic virus genomes, termed MCVSyn and MCVSyn-hpko, respectively 
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(Theiss et al. 2015). Therefore, to assess the impact of MCV-miR-M1 
expression on host cell transcripts in a virus-relevant context a collaboration 
was established with Prof. Adam Grundhoff (Heinrich Pette Institute, 
Hamburg). MCVSyn and MCVSyn-hpko were generated from parental pMK-
MCVSyn and pMK-MCVSyn-hpko, respectively, as detailed in section 2.18. 
Briefly, pMK-MCVSyn and pMK-MCVSyn-hpko were digested with SacI and 
the larger of the two linear DNA fragments (5387bp) was gel extracted and 
recircularised with T4 DNA ligase prior to purification. To confirm the 
generation of MCVSyn, purified DNA was digested with EcoRI and run on 
agarose gel. As can be seen in Figure 3.2, a 5387bp band representing 
MCVSyn was observed, this contrasts with what would be expected if the 
MCVSyn genome was in a linear form where two bands of 3599bp and 
1788bp would be detected. 293 cells were transfected with 250ng/1x105 cells 
of the recircularised MCVSyn or MCVSyn-hpko vector and virus gene 
expression, including MCV-miR-M1 expression, assessed.               
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Figure 3.2. The synthetic MCV consensus construct, MCVSyn. (A) 
Schematic representation of MCVSyn as described by Neumann et al. (B) 
Size difference between the EcoRI digested and un-digested recircularised 
MCVSyn. The upper bands in both lanes correspond to the expeceted 
5387bp  size of MCVSyn. The lower bands in lanes 1 and 2 represent linear 
and supercoiled forms of MCVSyn, respectively.  
 
3.1.2. Validation of tools 
3.1.2.1. Detecting the expression of MCV-miR-M1-5p and -3p via stem 
loop qRT-PCR for plasmid constructs, stable cell lines, and MCV-miR-
M1 mimics 
To determine if MCV-miR-M1 was expressed from pcDNA3.1/MCVmiR, 293 
cells were transfected with pcDNA3.1/MCVmiR or pcDNA3.1 as described in 
section 2.9. Expression of both strands was confirmed via stem loop qRT-
PCR in pcDNA3.1/MCVmiR (Figure 3.3 A) whereas no MCV-miR-M1 
expression was detected in pcDNA3.1-transfected, NTC and NRT controls. In 
addition, expression of MCV-miR-M1 was assessed in uninduced and 
doxycycline-induced Flp-In™ T-REx™ 293-MCVmiR cell line. Expression of 
MCV-miR-M1-5p and -3p was confirmed in induced but not uninduced cells 
(Figure 3.3 B).  To test the specificity of miRNA detection system, stem loop 
qRT-PCR for each strand was performed using stem loop cDNA and forward 
primer of the other strand, i.e. 5p stem loop cDNA as a template for 3p 
primer, and vice versa. Stem loop cDNA and forward primer of 5p could only 
detect expression of MCV-miR-M1-5p and not that of MCV-miR-M1-3p. 
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Similarly, MCV-miR-M1-3p was only detectable with 3p stem loop cDNA and 
3p forward primer but not with those of the 5p strand. These results indicate 
specificity of the stem loop qRT-PCR for detection of each of the MCV-miR-
M1 strands.   
miRNA mimics are routinely used for overexpression of endogenous cellular 
miRNAs and due to more stable modified chemical structure and more 
efficient expression are a suitable substitute for plasmid constructs. In 
addition, the mirVana™ miRNA Mimics used in this study display excellent 
specificity for the chosen guide strand due to inactivation of the star strand by 
proprietary chemical modifications. Moreover, unlike MCVSyn, Flp-In™ T-
REx™ 293-MCVmiR and pcDNA3.1/MCVmiR, miRNA mimics would allow 
identification of specific targets and exclusive study of each of the MCV 
miRNA strands, this was highly desirable given that the JC/BK-encoded 
miRNA is reported to exert major function in host-immune evasion via the 3p 
strand (Bauman et al. 2011). To confirm specific expression of MCV-miR-M1 
mimics in our 293 transfection system, MCV-miR-M1-5p, -3p and scramble 
control mimic were transfected into 293 cells. Exclusive expression of either 
the 5p or 3p strands was confirmed in the corresponding MCV-miR-M1-5p or 
-3p mimic samples via stem loop qRT-PCR (Figure 3.3 C). Comparison of 
the relative expression of MCV-miR-M1 revealed significantly lower levels in 
Flp-In™T-REx™293-MCVmiR SCLs compared to pcDNA3.1/MCVmiR and 
MCV-miR-M1 mimics (Figure 3.3 D). Given such low levels of expression, the 
decision was taken to exclude the Flp-In™T-REx™293-MCVmiR SCL from 
further analysis and instead focus on the other expression systems.  
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Figure 3.3. Relative expression of MCV-miR-M1-5p and -3p in 
pcDNA3.1/MCVmiR (MCV miR)-transfected 293 cells (A), Flp-In™ T-REx™ 
293-MCVmiR stable cell lines (SCL) (B), MCV-miR-M1-5p and -3p mimics-
transfected 293 cells and comparison of MCV-miR-M1 expression between 
the three systems (D).  
 
3.1.2.2. Assessing the regulatory effect of MCV-miR-M1 on MCV LT 
transcripts in Flp-In™ T-REx™ 293-MCV-LT stable cell line (LT SCL) 
Having confirmed the expression of MCV-miR-M1-5p and MCV-miR-M1-3p 
via stem-loop qRT-PCR in a variety of different systems, it was important to 
confirm the functionality of MCV-miR-M1 by assessing their effect on the 
expression of their cognate target, the MCV LT transcript. To achieve this, an 
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inducible Flp-In™T-REx™293-MCV-LT stable cell line (a kind gift of Prof. 
Adrian Whitehouse, University of Leeds) that expresses MCV LT under a 
regulatable promoter was used. Since MCV-miR-M1 is encoded from the 
opposite strand of LT one of the challenges in the study of MCV LT is 
concomitant expression of MCV-miR-M1 (Figure 3.4 A). Therefore, to assess 
the regulatory effect of MCV-miR-M1 against MCV LT necessitated MCV-
miR-M1 overexpression in Flp-In™T-REx™293-MCV-LT cells. Data shown in 
Figure 3.3 demonstrate that the highest expression of MCV-miR-M1 is 
achieved via transient transfection of mimics. Moreover, the use of mimics 
also enables the exclusive assessment of the regulatory effect for each 
strand. MCV-miR-M1 was overexpressed by transfecting MCV-miR-M1 
mimics into induced (1µg/ml doxycycline) and uninduced Flp-In™T-
REx™293-MCV-LT cells. Expression of MCV-miR-M1 and MCV LT was 
assessed via qRT-PCR and normalised against GAPDH. As can be seen in 
Figure 3.4 B, in induced Flp-In™T-REx™293-MCV-LT cells, MCV LT 
expression shows a small but statistically significant downregulation (less 
than 2-fold, p-value<0.0001) in MCV-miR-M1-5p and -3p mimics versus 
control mimic. Although MCV LT expression was detectable in uninduced 
Flp-In™T-REx™293-MCV-LT cells, it was significantly lower compared to 
induced LT cell line (up to 60-fold, Figure 3.4 B). In addition, relative 
expression level of endogenous MCV-miR-M1-3p was higher than that of 
MCV-miR-M1-5p by 2-fold (Figure 3.4 A) which is reflected in relatively lower 
LT expression in 3p- versus 5p-transfected induced LT SCL (Figure 3.4 C). 
These results confirm that both MCV-miR-M1-5p and -3p are able to 
negatively regulate the MCV LT expression.   
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Figure 3.4. Expression of MCV-miR-M1 in induced and uninduced Flp-In™T-
REx™293-MCV-LT stable cell line (LT SCL) (A).  MCV LT expression in 
MCV-miR-M1 mimic-transfected induced and uninduced LT SCL. MCV LT 
mRNA level in uninduced LT SCL is significantly lower than that of induced 
cells (B). MCV LT is downregulated following transfection of MCV-miR-M1 
mimics in induced (C). 5p and 3p, MCV-miR-M1-5p and -3p mimics; Ctrl, 
control mimic; NS, no significance.  
 
3.1.2.3. MCV-miR-M1 directly targets MCV LT recognition sequence in 
dual luciferase assay  
MCV-miR-M1 is located antisense to MCV LT second exon and therefore 
exhibits perfect complementarity to the LT transcript (Figure 1.9). To confirm 
that MCV-miR-M1 directly targets MCV LT recognition sequence in our 293 
system, wild type psiCHECK-2/wt-MCV-miR-concat reporter plasmid 
construct was generated by inserting a concatemerised sequence of MCV LT 
complementary to MCV-miR-M1-5p and -3p into psiCHECK-2 and 3'UTR of 
Renilla luciferase. For negative control, a mutant (Mut) construct (psiCHECK-
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2/mut-MCV-miR-concat) was also generated by substituting two nucleotides 
in the seed region of each miRNA binding site (see Table 2.4) as described 
by Bauman et al. (Bauman et al. 2011). 293 cells were co-transfected with 
psiCHECK-2/wt-MCV-miR-concat and either pcDNA3.1/MCVmiR or 
pcDNA3.1 parental control. As can be seen in Figure 3.5 A, relative 
luciferase activity was decreased 40% (p-value<0.05) in cells co-transfected 
with pcDNA3.1/MCVmiR versus control. This assay was then repeated using 
MCV-miR-M1 mimics and relative luciferase activity compared with cells 
transfected with a control scramble mimic. We observed a striking reduction 
in relative luciferase activity of around 50- and 20-fold (p-value<0.0001) in 
cells transfected with MCV-miR-M1-5p and -3p mimics, respectively (Figure 
3.5 B).  
To confirm that the effect of MCV-miR-M1 in our DLA reporter system was 
specific, the assays were repeated with the mutant construct, psiCHECK-
2/mut-MCV-miR-concat. In contrast to cells co-transfected with the WT 
construct, cells expressing psiCHECK-2/mut-MCV-miR-concat showed no 
statistically significant change in normalised luciferase activity when co-
transfected with either pcDNA3.1/MCVmiR or MCV-miR-M1 mimics (Figure 
3.5 A & B). Together these data confirm that MCV-miR-M1 tools generated 
are able to downregulate MCV LT and that this occurs via direct targeting of 
the MCV LT recognition sequence. 
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Figure 3.5. Assessing functionality of MCV-miR-M1 using dual luciferase 
assay (DLA). WT and Mut psiCHECK-2/MCV-miR-concat were co-
transfected with either pcDNA3.1 and pcDNA3.1/MCVmiR (A) or with MCV-
miR-M1 and control mimics (B). Normalisation of Renilla luciferase activity to 
that of firefly luciferase showed a significant reduction in luminescence in WT 
construct in the presence of MCV-miR-M1 (A & B, WT) whereas in Mut 
construct luminescence signal remains unchanged in the presence and 
absence of MCV-miR-M1 (A & B, Mut).  
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3.1.2.4. Assessing the effect of MCV-miR-M1 on cell proliferation 
As part of the functional assessment, it was of interest to determine if MCV-
miR-M1 affected cell proliferation. In this regard, 293 cells were mock-
transfected or transfected with MCV-miR-M1 and control miRNA mimics prior 
to adding BrdU to the cells. Analysis of BrdU incorporation into the DNA of 
293 cells, as described in section 2.10, revealed that overexpression of MCV-
miR-M1-5p and -3p mimics did not alter cell proliferation when compared to 
control miRNA mimic and mock 24h post-transfection.  
In addition, BrdU assay was repeated for MCVSyn and MCVSyn-hpko. 
Similarly to MCV-miR-M1 mimics, no difference was observed in terms of cell 
proliferation between MCVSyn-, MCVSyn-hpko- and mock-transfected cells 
at 24, 48 and 72h post-transfection. These data indicate that cell proliferation 
is not affected by MCVSyn replication or MCV-miR-M1 expression within the 
tested time period (Figure 3.6). 
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Figure 3.6. BrdU cell proliferation assay in 293 cells mock transfected or 
transfected with MCV-miR-M1 and control mimics (A) and MCVSyn and 
MCVSyn-hpko at 24h to 72h time points (B). BrdU absorbance remained 
unchanged across transfection conditions at each time point for mock- or 
MCVSyn-transfected cells as well as MCV-miR-M1 and control miRNA 
mimics. 
 
3.1.2.5. Expression of MCV early and late transcripts in MCVSyn 
MCV-miR-M1 mimics are a powerful tool for the study of MCV-miR-M1-
dependent modulation of host cell transcripts, however, given the high 
expression levels of mimics it was important to validate mimic-dysregulated 
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transcripts in a virus-relevant context. To address this, I took advantage of 
the MCVSyn system, which I go on to describe in detail below. However, it is 
important to state that MCV-miR-M1 mimics remain crucial for subsequent 
validation and functional studies, as in addition to any direct effect it might 
have on host cell mRNA, MCV-miR-M1 also regulates expression of MCV LT 
and by extension virus DNA replication (Seo et al. 2009; Theiss et al. 2015). 
This is potentially problematic as the MCV T Ags have themselves been 
associated with changes in host cell proliferation and immune response 
(Griffiths et al. 2013; Shahzad et al. 2013). This necessitates careful scrutiny 
of any observed MCV-miR-M1-related phenotypic effects and while 
investigating such effects in the context of virus replication is ideal, the 
importance of attributing any observed miRNA effects as direct, as opposed 
to modulation of its cognate target, LT, must be considered.  
MCVSyn is a synthetic MCV clone generated based on the consensus MCC 
sequences to facilitate in vitro study of the biology and replication of MCV 
(Neumann et al. 2011). Efficient DNA replication, early and late gene 
expression and virus particle production of MCV was shown by Neumann 
and colleagues in human cell lines including 293 cells. In a more recent 
study, MCVSyn-hpko was generated by disrupting the hairpin structure of 
MCV-miR-M1 (hpko: hairpin knockout) and it was shown that MCVSyn-hpko 
fails to establish long term persistence in PFSK cells (Theiss et al. 2015). 
Whilst MCV-miR-M1-exclusive alterations in the host cell transcripts could be 
monitored via MCV-miR-M1 mimics, MCVSyn and MCVSyn-hpko allow 
investigation of such changes in the absence of MCV-miR-M1 but presence 
of other MCV components. Therefore, not only can MCVSyn be used to 
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validate MCV-miR-M1 mimics data in the context of virus replication but also 
by comparing the data from MCVSyn and MCV-miR-M1 mimic experiments it 
is possible to identify any synergy or antagonism between MCV-miR-M1 and 
MCV T Ags. With this view, following confirmation of MCVSyn 
recircularisation via agarose gel electrophoresis (Figure 3.2 B), 293 cells 
were transfected with MCVSyn and MCVSyn-hpko in a 48-well plate, RNA 
was extracted at 24h intervals for 3 days and stem loop and oligo(dT) cDNAs 
generated prior to analysis of MCV-miR-M1, MCV LT, sT and VP1 
expression via stem loop qRT-PCR and qRT-PCR, respectively (Figure 3.7). 
In cells harbouring MCVSyn, MCV-miR-M1 expression increased over the 
course of MCV replication, by ~200-fold and ~3-fold for 5p and 3p strands, 
respectively (Figure 3.7 A). In contrast, no MCV-miR-M1 expression was 
detected in MCVSyn-hpko at any time point (data no shown). In addition, 
MCV-miR-M1-5p was identified as the dominant strand with increasing 
expression (up to 8-fold) compared to MCV-miR-M1-3p (Figure 3.7 B). 
Consistent with MCV-miR-M1 expression, MCV LT showed a mild but steady 
and significant (p-value<0.05) downregulation and upregulation in MCVSyn 
and MCVSyn-hpko, respectively, over 72h (Figure 3.7 C). MCV sT 
expression demonstrated a fluctuating trend in cells harbouring MCVSyn with 
a nominal decrease in expression at 48h and similar expression levels at 24h 
and 72h p.t. Interestingly, MCV sT was steadily upregulated in cells 
harbouring MCVSyn-hpko over the duration of the time course (Figure 3.7 D). 
MCV VP1 transcripts showed increasing amounts over the time course in 
cells harbouring both MCVSyn and MCVSyn-hpko, however, this increase 
was more pronounced in MCVSyn-hpko (Figure 3.7 E).  
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Figure 3.7. Detection of MCV early and late transcripts in MCVSyn and 
MCVSyn-hpko. 293 cells were transfected with MCVSyn or MCVSyn-hpko, 
stem loop and oligo(dT) cDNAs were generated using 1µg of total RNA of 24 
to 72h time points and used as template in stem loop qRT-PCR or qRT-PCR 
reactions. MCV-miR-M1-5p and -3p expression increased by 200- and 3-fold 
over 72h, respectively (A). 5p was identified as dominant strand with 8 fold 
upregulation relative to 3p at 72h p.t. (No MCV-miR-M1 was detected in 
MCVSyn-hpko at any time point ) (B). MCV LT was steadily downregulated in 
MCVSyn and upregulated in MCVSyn-hpko over 72h p.t. (C). MCV sT mRNA 
expression in MCVSyn showed a small drop at 48h, but at 72h returned to 
levels similar to 24h p.t. whereas in MCVSyn-hpko it was steadily 
upregulated over the 72h time course (D). MCV VP1 demonstrated a steady 
increase in both MCVSyn and MCVSyn-hpko, however with more 
pronounced upregulation in MCVSyn-hpko (E). 
 
3.2. Assessing the effect of MCV-miR-M1 on cellular transcripts 
An early in silico study predicted several cellular transcripts as putative 
targets of MCV-miR-M1-5p, including AMBRA1, FOX2, MECP2, PIK3CD, 
PSME3 and RUNX1 (Lee et al. 2011). Therefore, in order to determine 
whether MCV-miR-M1 targets mRNA of the predicted genes, 293 cells were 
transfected with either pcDNA3.1 or pcDNA3.1/MCVmiR. Relative normalised 
expression of in silico predicted transcripts showed either no change 
(AMBRA1, MECP2, PSME3) or less than 1.2 fold upregulation (FOX2, 
RUNX1) in cells expressing MCV-miR-M1. Only PIK3CD transcript showed a 
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significant downregulation and this was nominal (~1.5-fold) (Figure 3.8). 
Given the inconsistency between in silico-predicted cellular targets of MCV-
miR-M1 and my qRT-PCR analysis of these cellular transcripts in cells 
expressing MCV-miR-M1 it is clear that an unbiased and global approach is 
required to identify if any cellular transcripts are modulated by MCV-miR-M1. 
This is described in detail in the chapter 4. 
 
Figure 3.8. Relative normalised expression of in silico-predicted targets of 
MCV-miR-M1-5p in the presence and absence of MCV-miR-M1 in 293 cells. 
Of the six predicted targets only PIK3CD shows a small but statistically 
significant downregulation (1.5 fold, p-value<0.01) in qRT-PCR analysis.  
 
3.3. Discussion  
Since the discovery of MCV and its causal link with the majority of MCC 
cases extensive research has been carried out to delineate various aspects 
of MCV life cycle and pathogenesis. The majority of research has focused on 
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two major early proteins LT and sT, however, far less is understood about 
how other MCV genome transcripts regulate infection and contribute to 
disease pathogenesis. In recent years, there has been mounting evidence for 
the important role of viral miRNAs in various aspects of virus-host interaction 
(Kincaid and Sullivan 2012). While the majority of these data have been 
obtained from herpesviruses (Kincaid and Sullivan 2012), several studies 
have provided insights into the key role of polyomavirus miRNAs in virus 
pathogenesis (Broekema and Imperiale 2013) and evasion of host immune 
response (Sullivan et al. 2005; Bauman et al. 2011; Chen et al. 2013; Theiss 
et al. 2015). Importantly, a recent study demonstrated that MCV miRNA is 
required for establishment of long-term infection in the host cell (Theiss et al. 
2015), however, a mechanistic explanation delineating how MCV miRNA 
contributes to the virus persistent infection and pathogenesis is still lacking. 
To facilitate how MCV-miR-M1 expression affects the levels of cellular 
transcripts, a range of tools were generated and tested for expression of 
MCV-miR-M1 including, MCV-miR-M1 mimics, pcDNA3.1/MCVmiR and Flp-
In™T-REx™293-MCVmiR inducible cell line (see sections 3.1.1.1 and 
3.1.1.2). With respect to higher expression (Figure 3.3) and having the 
advantage of assessing the specific effect of each strand of MCV-miR-M1 
individually it was decide to use MCV-miR-M1-5p and MCV-miR-M1-3p 
mimics in the follow-up experiments. Whilst there have been concerns over 
off-target effects of miRNA mimics it has been shown that this effect can be 
eliminated by chemical modification of passenger strand as demonstrated by 
Thomson and colleagues (Thomson et al. 2013).  
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In contrast to directly transfected miRNA mimics, the levels of mature MCV-
miR-M1 detected via stem-loop qRT-PCR in pcDNA3.1/MCVmiR-transfected 
cells and induced Flp-In™ T-REx™ 293-MCVmiR cells were ~2-fold and ~20-
fold lower, respectively (Figure 3.3). In Flp-In™ T-REx™ 293-MCVmiR cells 
one possible explanation for this could be inefficient processing of MCV-miR-
M1-5p and -3p from MCV-miR-M1. Several studies have demonstrated that 
flanking sequences at 5’ and 3’ ends of pre-miRNAs play a critical role in 
efficient expression of miRNAs (Chen et al. 2004; Zhou et al. 2005; Chang et 
al. 2006; Fukuda et al. 2006) and are a key factor in pri-miRNA transcript 
processing by Drosha (Zeng and Cullen 2005; Rumi et al. 2006). Therefore, it 
might have been beneficial to include a flanking region in MCV-miR-M1 
clones for generation of Flp-In™ T-REx™ 293-MCVmiR cells. Similar to Flp-
In™ T-REx™ 293-MCVmiR SCL, MCV-miR-M1 shows very low expression 
in MCV-positive MCC cell lines (Lee et al. 2011). Interestingly, in MCC where 
the MCV genome has undergone integration and truncation but retained the 
MCV-miR-M1 expression cassette only very low levels of miRNA expression 
are detected (Lee et al. 2011; Theiss et al. 2015). While the underlying 
mechanisms of low level MCV-miR-M1 expression from integrated MCV 
sequences is yet to be elucidated, a recent study demonstrated that 
transcription initiation sites upstream of MCV-miR-M1 locus are required for 
efficient MCV-miR-M1 expression (Theiss et al. 2015). Therefore, it is 
possible that inefficient expression of MCV-miR-M1 in induced Flp-In™ T-
REx™ 293-MCVmiR SCL is due to random insertion of MCV-miR-M1 
sequence into the genome of Flp-In™ T-REx™ 293 cells and lack of 
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upstream sequences required for efficient processing and biogenesis of 
mature MCV miRNA.  
qRT-PCR based miRNA expression analysis is unable to discriminate 
between RISC-bound and non-RISC-bound miRNA pools, therefore, miRNA 
reporter assays such as DLA are important complementary techniques in 
miRNA functional studies (Thomson et al. 2013; Thermo Fisher Scientific 
2014). DLA for concatemerised MCV LT response element (termed 
psiCHECK-2/wt-MCV-miR-concat) and its site mutated version (termed 
psiCHECK-2/mut-MCV-miR-concat) demonstrated that co-expression of 
MCV-miR-M1-5p and -3p mimics resulted in 50-fold and 20-fold 
downregulation, respectively (Figure 3.5). MCV-miR-M1 functionality was 
also assessed in induced and uninduced Flp-In™T-REx™293-MCV-LT SCL 
using MCV-miR-M1-5p and -3p mimics. qRT-PCR analysis revealed some 
basal expression of MCV LT in uninduced Flp-In™T-REx™293-MCV-LT, 
which can be attributed to the ‘leakiness’ of the T-Rex system (Campeau et 
al. 2009). In induced Flp-In™T-REx™293-MCV-LT a much smaller (but 
statistically significant, p-value<0.0001) downregulation of MCV LT 
expression was observed in the presence of MCV-miR-M1-5p and -3p 
mimics (36% and 46% downregulation, respectively, Figure 3.4 C). 
Regarding the discrepancy in the degree of MCV LT downregulation in 
induced Flp-In™T-REx™293-MCV-LT (less than 2-fold, Figure 3.4 C) and 
MCV LT DLA (more than 50-fold, Figure 3.5 B), I investigated MCV-miR-M1 
expression in Flp-In™T-REx™293-MCV-LT 24h post induction. Interestingly, 
whilst I could not detect any MCV-miR-M1 expression in uninduced cells, 
MCV-miR-M1-5p and -3p expression was confirmed in induced cells, with 
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MCV-miR-M1-3p demonstrating 12-fold higher expression relative to MCV-
miR-M1-5p (Figure 3.4 A). This observation suggests that MCV LT is 
downregulated by endogenous MCV-miR-M1 expressed from MCV LT locus, 
however, transfected MCV-miR-M1-5p and -3p mimics exert an extra level of 
downregulation which is manifested as a small decrease in MCV LT mRNA. 
Assuming equivalent expression levels of MCV-miR-M1-5p and -3p mimics in 
induced Flp-In™T-REx™293-MCV-LT the 10% further downregulation of 
MCV LT with MCV-miR-M1-3p can be explained by the higher levels of 
endogenous MCV-miR-M1-3p (see Figures 3.4 A & C). Furthermore, relative 
higher levels of MCV-miR-M1-3p in 24h post induction Flp-In™T-REx™293-
MCV-LT is consistent with relative higher expression of MCV-miR-M1-3p in 
MCVSyn at 24h p.t. (see section 3.1.2.5 and Figure 3.7 B).  
Recently, an article was published by Theiss et al. (Theiss et al. 2015), 
describing the generation of a synthetic MCV genome and corresponding 
mutant that lacks the MCV-miR-M1 transcript. This system enabled the study 
of MCV replication and infection that more closely resembled native 
conditions. Measuring the expression of MCV transcripts revealed increasing 
levels of MCV LT in MCVSyn-hpko-transfected cells over the 72h period 
whereas in MCVSyn-transfected cells a decreasing trend was observed 
(Figure 3.7 C). Similarly, MCV LT protein expression was upregulated in 
MCVSyn-hpko (see Figure 4.7). This trend is consistent with increasing 
levels of MCV-miR-M1 in MCVSyn and its lack in MCVSyn-hpko (Figure 3.7 
A). 
In addition to temporal expression of MCV-miR-M1 in MCVSyn, these data 
reproduced MCV LT functional data obtained from MCV-miR-M1-5p and -3p 
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mimics. Moreover, whilst both MCV-miR-M1-5p and -3p demonstrated a 
steady increase during 72h MCVSyn genome replication their relative and 
temporal expression varied significantly. Where MCV-miR-M1-3p expression 
relative to MCV-miR-M1-5p showed 5-fold upregulation at 24h p.t. this trend 
was reversed at 48h and 72h p.t. by respective 4-fold and 8-fold upregulation 
of MCV-miR-M1-5p relative to -3p (Figure 3.7 B).  
Although MCV-miR-M1 is expressed from late region of MCV genome a 
recent study has shown that low levels of MCV-miR-M1 pre-miRNA and 
mature MCV miRNA are expressed upon transcription initiation from MCV 
early region (Theiss et al. 2015). The authors describe an MCV early region 
intrinsic promoter upstream of the MCV-miR-M1 locus which can activate 
MCV-miR-M1 expression independent of MCV NCCR. My expression 
analysis of MCV-miR-M1 in MCVSyn revealed an initial higher expression of 
MCV-miR-M1-3p relative to -5p 24h p.t. However, with more efficient 
expression of MCV-miR-M1 following transcription initiation of the late region, 
relative higher levels of MCV-miR-M1-5p accumulate 48h and 72h p.t. 
Whether activation of this promoter region can lead to changes in the 
expression of MCV-miR-M1-3p relative to MCV-miR-M1-5p within the first 
24h p.t. is to be elucidated. If so, this can explain the MCV-miR-M1 temporal 
expression pattern where both MCV-miR-M1-5p and -3p demonstrate 
increasing levels during MCVSyn replication, but MCV-miR-M1-5p shows a 
more substantial temporal upregulation compared to MCV-miR-M1-3p 
(Figures 3.7 A & B). Nevertheless, an accurate explanation of distinct MCV-
miR-M1-5p and -3p expression patterns warrants further investigation within 
longer time periods of MCV genome replication.  
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In addition to MCV LT and MCV-miR-M1, I also investigated expression of 
MCV sT and MCV VP1 mRNAs in MCVSyn and MCVSyn-hpko. Whilst no 
direct correlation was observed between MCV-miR-M1 expression and MCV 
sT or MCV VP1 mRNA levels, as expected both transcripts showed a more 
significant increase in the absence of MCV-miR-M1 in MCVSyn-hpko due to 
LT upregulation and increased genome replication (Figures 3.7 D & E). 
These data are consistent with previous studies that suggest MCV miRNA 
can restrict MCV genome replication via direct targeting and downregulation 
of MCV LT (Theiss et al. 2015).  
Having established and functionally validated a miRNA mimic-based 
expression system for MCV-miR-M1, I revisited work by Lee et al. that 
postulated a number of potential cellular targets for MCV-miR-M1, based on 
seed-sequence (Lee et al. 2011). All but one of Lee et al.’s in silico-predicted 
targets showed no significant downregulation in the presence of 
pcDNA3.1/MCVmiR (Figure 3.8). One possible explanation for this is the 
MCV-miR-M1 seed-sequence used by Lee et al. in target algorithms as more 
recent miRNA-Seq fine mapping of mature MCV-miR-M1 describes a 
different seed sequence for MCV-miR-M1-5p (Theiss et al. 2015), suggesting 
that these targets were based on the incorrect seed matching and further 
strengthening the remit for an unbiased and global approach to identify true 
cellular MCV-miR-M1 targets. 
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4. MCV-miR-M1 cellular targets 
4.1. RNA sequencing (RNA-Seq) 
To date, there are no published studies investigating the cellular targets of 
MCV-miR-M1. Moreover, while studies exist detailing cellular targets for other 
polyomavirus miRNAs (Bauman et al. 2011), no one has investigated how 
human polyomavirus miRNAs affect the global transcriptional landscape. To 
address this question in MCV, it was decided to express MCV-miR-M1 in 293 
cells and to this end, several MCV-miR-M1 expression tools including 
pcDNA3.1/MCVmiR, Flp-In™T-REx™293-MCVmiR inducible cell line and 
commercially available MCV-miR-M1-5p and -3p mimics were assessed and 
validated, as described in chapter 3. Comparison of these MCV-miR-M1 
expression tools via stem loop qRT-PCR revealed highest expression levels 
of MCV-miR-M1 in MCV-miR-M1-5p and -3p mimic-transfected 293 cells 
(Figure 3.3). Importantly, this increased level corresponded with an active 
pool of miRNA, as evidenced by DLA experiments, demonstrating that of the 
three expression systems miRNA mimics were the most robust in terms of 
both expression and activity. Moreover, MCV-miR-M1-5p and -3p mimics 
provide the additional advantage of target specification for each strand of the 
MCV-miR-M1, an important consideration as previously demonstrated for the 
BK and JC polyomaviruses 3p miRNA (Bauman et al. 2011). For these 
reasons, to identify the effect of MCV-miR-M1 expression on the levels of 
cellular transcripts, RNA-Seq was carried out on total RNA extracted from 
293 cells transfected with MCV-miR-M1-5p and -3p mimics and control mimic 
in biological triplicates.  
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4.1.1. Assessment of MCV-miR-M1 expression in total RNA samples  
Prior to proceeding to the sequencing pipeline, it was crucial to confirm the 
expression of MCV-miR-M1-5p and -3p in the mimic-transfected 293 cells. 
Therefore, stem loop cDNA was generated from total RNA samples as 
described in section 2.15. As can be seen in Figure 4.1, expression of MCV-
miR-M1-5p and MCV-miR-M1-3p was confirmed via stem loop qRT-PCR in 
5p and 3p mimic transfected cells, but not in control mimic, NTC and NRT 
samples.   
 
Figure 4.1. Expression of MCV-miRNA-M1-5p and MCV-miR-M1-3p in MCV-
miR-M1 mimic- and control mimic-transfected 293 cells for RNA-Seq. NTC, 
no template control; NRT, no reverse transcriptase control. 
 
4.1.2. Quality control (QC) of RNA-Seq RNA samples 
To ensure that the total RNA samples were of a sufficient quality for library 
production and sequencing, QC of the samples was assessed using the 
Agilent 2100 Bioanalyzer system, as described in section 2.19.1. All RNA 
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samples passed the QC assay by RNA Integrity Number (RIN) with 8 of the 
samples scoring a RIN of 10 and the remaining sample a RIN of 9.8 (Figure 
4.2). RIN scores of 10 and 1 indicate an intact RNA and a completely 
degraded RNA, respectively (Schroeder et al. 2006) with a RIN score >8 
representing a sample of suitable quality for RNA-Seq (Gallego Romero et al. 
2014).  
 
Figure 4.2. RNA QC assay results are represented by RNA Integrity Number 
(RIN). All of the total RNA samples passed the QC assay by highest possible 
score of RIN=10 (for 5p1 RIN=9.80).  
 
4.1.3. Assessment of dscDNA samples  
To prepare RNA-Seq libraries for hybridisation onto the flow cell, each library 
undergoes three consequtive steps: adenylation, adapter ligation and PCR 
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amplification. Addition of a single ‘A’ nucleotide to the 3’ ends of each 
dscDNA provides an overhang for a ‘T’ nucleotide at the 3’ end of adapters 
and prevents the blunt ends of dscDNAs from ligating to one another.  
Adapters in turn act as primer for PCR enrichment of dscDNAs and as an 
adapter to hybridise to surface of the flow cell. Therefore, since all 
subsequent steps depend on formation of dscDNA, it was crucial to confirm 
the presence of dscDNAs prior to proceeding to adenylation, adapter ligation 
and PCR enrichment steps. To this end, following dscDNA clean-up samples 
were loaded and run on a High Sensitivity DNA 1000 Tape and the presence 
of dscDNAs was verified as  ~140-160bp products (Figure 4.3).   
 
              
 
Figure 4.3. Gel image of verified double-stranded cDNAs before adenylation 
and adapter ligation steps of sequencing. The dscDNAs are marked by small 
dark arrows corresponding to ~140-160bp sizes.  
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4.1.4. Quality control of RNA-Seq libraries  
After PCR enrichment, samples were loaded onto the flow cell for cluster 
generation and sequencing. Cluster generation includes denaturaion, 
hybridisation to flow cell surface, second strand generation and clonal 
amplification of second strand. The amplified strands are then sequenced. 
Consequently, the validity of sequencing results depends on the validity of 
final libraries and any primer dimer or non-specific PCR products can 
produce unreliable results. Therefore, validation of RNA-Seq libraries via 
quality control is a crucial step in the RNA sequencing workflow.  To this end, 
prior to pooling and loading the flow cell, the final libraries were loaded into a 
DNA 1000 chip as described in section 2.19.3.8 and analysed using an 
Agilent 2100 Bioanalyzer and 2100 expert software. The final libraries were 
verified as ~240-360bp products (Figure 4.4).   
 
Figure 4.4. Electropherogram summary of the final libraries. The final 
libraries are represented as short curves of ~240-350bp size between the 
two spike-shape lower (15bp) and upper markers (1500bp).  
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4.1.5. RNA-Seq and data analysis 
The TruSeq cDNA libraries described above were analysed via Illumina 
HiSeq2500 paired end 100bp run. To remove the least reliable data, often 
derived from overlapping clusters, raw data was filtered using the Illumina 
chastity filter and data analysed using TopHat (Institute of Genetic Medicine, 
Johns Hopkins University) which aligns RNA-Seq reads using the ultra-high-
throughput short read aligner Bowtie. These data were then analysed using 
‘edgeR’ (Bioconductor) which facilitates differential expression analysis of 
RNA-Seq profiles with biological replication via empirical Bayes estimation 
and exact tests based on the negative binomial distribution. Gene expression 
analysis revealed 69 and 110 transcripts with minimum 2-fold downregulation 
and statistical significance for MCV-miR-M1-5p and -3p, respectively (see 
Appendix). Gene ontology analysis carried out using The Database for 
Annotation, Visualization and Integrated Discovery (DAVID) highlighted 
various pathways downregulated by MCV-miR-M1, among which immune 
regulation, cell-cell signalling and regulation of cell proliferation pathways 
were of particular interest to this project (Figure 4.5 A & B).  
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Figure 4.5. Gene ontology (GO) of MCV-miR-M1-3p (A) and -5p (B) RNA-
Seq-identified targets base on - log2 of p-value. The bars represent - log2 p-
values of each GO. Cut off, p-value=0.05.  
4.2. Validation of RNA-Seq data 
4.2.1. qRT-PCR validation of RNA-Seq-identified targets of MCV-miR-M1 
Following gene expression analysis of the RNA-Seq data, transcripts with 
minimum 2-fold downregulation and statistical significance (p-value<0.05) 
were identified for MCV-miR-M1-5p and -3p. However, due to the large 
number of transcripts and time and budget limitations of the project it was 
necessary to prioritise targets for validation. With this view, targets of MCV-
miR-M1-5p and -3p were selected for further analysis based on a 
combination of their frequency in GO analysis and their identified role in 
relation to virus-host cell interaction as discussed in section 1.6.1, i.e. 
increasing host-cell longevity and evasion of host-cell immune response. 
Furthermore, although not identified via RNA-Seq, several other transcripts 
were considered for qRT-PCR validation due to existing evidence in the 
literature regarding their role in innate immunity and reported MCV T Ag 
locus-mediated downregulation, given the co-expression of MCV-miR-M1 
with LT (Shahzad et al. 2013).  
To validate RNA-Seq data, 293 cells were transfected with MCV-miR-M1-5p, 
MCV-miR-M1-3p or control miRNA mimics (see section 2.9).  Following stem 
loop qRT-PCR confirmation of MCV-miR-M1-5p and -3p expression in 
respective RNA samples, qRT-PCR of selected transcripts consistently and 
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universally corroborated all downregulated cellular targets identified via RNA-
Seq (Table 4.1 and Figure 4.6).  
As discussed in section 3.1.2.5, it was crucial to confirm miRNA mimics data 
in a system more akin to the replicative MCV. In this regard, 293 cells were 
transfected with MCVSyn and MCVSyn-hpko and expression of MCV-miR-
M1-5p and -3p was confirmed in MCVSyn. qRT-PCR validated RNA-Seq and 
MCV-miR-M1 mimics data in MCVSyn, suggesting that the observed 
changes in the expression of cellular transcripts are reproducible in the 
context of MCV replication. For a list of qRT-PCR validated targets refer to 
Table 4.1. 
Table 4.1. List of cellular transcripts tested for qRT-PCR validation of RNA-
Seq results using MCV-miR-M1 mimics and MCVSyn. Targets marked with 
asterisk (*) were not identified via RNA-Seq analysis. N/A, not applicable.  
Transcript name 
Downregulated by 
(RNA-Seq fold 
change) 
Validated by (MCV-miR-M1 
expression system) 
ADRA1D 5P (15 folds) MCV miR mimic MCVSyn 
CXCL8 3P (16 folds) MCV miR mimic MCVSyn 
IFI30 5P (5 folds) 3P (2.5 folds) MCV miR mimic MCVSyn 
IFIH1 3P (2.5 folds) MCV miR mimic MCVSyn 
MAPK10 3P (2 folds) MCV miR mimic MCVSyn 
RAET1G 
(ULBP5) 5P (2.3 folds) MCV miR mimic MCVSyn 
SELPLG 3P (32 folds) 5P (4.5 folds) MCV miR mimic MCVSyn 
SP100 5P (18 folds) MCV miR mimic MCVSyn 
CYB5R2 3P (32 folds) MCV miR mimic MCVSyn 
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KLLN 3P (2 folds) MCV miR mimic MCVSyn 
OSR1 3P (19 folds) MCV miR mimic MCVSyn 
TLR9* N/A MCV miR mimic MCVSyn 
C/EBPα* N/A MCV miR mimic MCVSyn 
C/EBPβ* N/A MCV miR mimic MCVSyn 
 
The validated targets can be generally classified as immune-related and 
tumour-related transcripts, however, regarding their appearance in various 
pathways some transcripts give rise to multifunctional proteins with distinct or 
associated roles in different pathways. These targets and their 
downregulation (p-value<0.05) in cells expressing MCV-miR-M1 are 
described in more detail below. 
4.2.1.1. Immune-related transcripts 
ADRA1D (alpha-1D adrenergic receptor) has been implicated in the 
activation of signalling pathways crucial to lymphocyte activation and 
migration (Tybulewicz and Henderson 2009; Kennedy et al. 2012) as well as 
inducing MAPK1/3 signalling through transactivation of epidermal growth 
factor (EGF) (Chen et al. 2006). ADRA1D was highlighted in several 
downregulated pathways such as, regulation of cell communication, cell-cell 
signalling and regulation of cell proliferation. qRT-PCR confirmed significant 
ADRA1D downregulation by more than 2-fold in the presence of MCVSyn 
and MCV-miR-M1-5p mimic (Figure 4.6 A).   
CXCL8 (C-X-C motif ligand 8), also known as interleukin 8 (IL-8) is a cytokine 
with chemoattractant activity for neutrophils and monocytes (Holmes et al. 
1991; Chuntharapai et al. 1994; Seely et al. 2002). Pathway analysis put 
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CXCL8 in most 3p-downregulated pathways including immune system 
process, organ development, defense response, cell motion, immune 
response and response to stress. qRT-PCR confirmed RNA-Seq data with 
both MCV-miR-M1-3p mimic and MCVSyn (Figure 4.6 B).  
IFI30 (interferon, gamma-inducible protein 30) or GILT (Gamma-interferon-
inducible lysosomal thiol reductase) plays an important role in MHC (Major 
Histocompatibility Complex) class I- and MHC class II-restricted antigen 
processing by facilitating degradation of endocytosed antigens via disulfide 
bond reduction (West and Cresswell 2013). Appearing in immune system 
process and regulation of cell proliferation pathways, IFI30 showed 5- and 
1.6-fold downregulation in MCV-miR-M1-5p mimic and MCVSyn qRT-PCR 
(Figure 4.6 C).  
IFIH1 (interferon induced with helicase C domain 1) or MDA5 (Melanoma 
Differentiation-Associated protein 5) is a pattern recognition receptor and 
plays an important role in innate antiviral response by inducing type I IFNs 
via mitochondrial antiviral-signalling protein (MAVS)  (Xu et al. 2005; Lei et al. 
2015). Similar to CXCL8, IFIH1 appeared in the majority of MCV-miR-M1-3p-
affected pathways including, immune system process, innate immune 
response, defense response, immune response and response to stress. 
qRT-PCR validation showed ~2-fold downregulation of IFIH1 by MCV-miR-
M1-3p mimic, whereas IFIH1 mRNA was absent even after 45 cycles in the 
presence of MCVSyn, resulting in three order of magnitude downregulation 
relative to MCVSyn-hpko (CT≈33) (Figure 4.6 D). 
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MAPK10 (Mitogen-activated protein kinase 10) or JNK3 (c-Jun N-terminal 
kinase 3) is a member of MAPK signalling pathway  and has been shown to 
stimulate TNF-α (Kanehisa et al. 2016e) and mediate CXCL8 secretion in 
response to DNA damage (Biton and Ashkenazi 2011). MAPK10 showed 3-
fold and ~1.5-fold downregulation with MCV-miR-M1-3p mimic and MCVSyn, 
respectively (Figure 4.6 E) in qRT-PCR and was highlighted in response to 
stress pathway.  
RAET1G (Retinoic acid early transcript 1G) or ULBP5 (UL16 binding protein 
5) is a cell surface ligand for NKG2D, an immunoreceptor found on various 
immune cells such as macrophages, CD8(+) alphabeta T-cells and 
gammadelta T-cells (Cosman et al. 2001; Raulet 2003; Obeidy and Sharland 
2009). ULBPs are related to MHC class I molecules and play an important 
role in antiviral immunity by stimulating cytokine and chemokine production in 
natural killer (NK) cells (Cosman et al. 2001). qRT-PCR confirmed RAET1G 
RNA-Seq results by 57-fold and 69-fold downregulation in MCV-miR-M1-5p 
mimic and MCVSyn, respectively (Figure 4.6 F).  
SELPLG (selectin P ligand) is expressed on neutrophils, monocytes and 
some T-cells (Kansas 1996) and is involved in recruitment of leukocytes to 
sites of inflammation and injury (Somers et al. 2000; Hubert et al. 2014). 
Selectin P mediates adhesion of neutrophils and monocytes to activated 
platelets and endothelium (Larsen et al. 1989; Geng et al. 1990) leading to 
the leukocyte tissue migration (Somers et al. 2000). SELPLG, by 32-fold and 
4.5-fold downregulation in 3p and 5p RNA-Seq targets, respectively, 
appeared in immune system process and cell motion GOs. qRT-PCR 
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validation showed more than 2-fold downregulation in the presence of MCV-
miR-M1-3p and -5p mimics and MCVSyn (Figure 4.6 G).  
SP100 (Speckled protein of 100 kDa), a component of promyelocytic 
leukaemia nuclear bodies (PML-NB), has been implicated in antiviral innate 
immunity via co-activation of interferon-stimulated gene (ISGs) and cytokines 
(Tavalai et al. 2011; Scherer and Stamminger 2016). In addition, a recent 
study suggests that SP100 can negatively regulate DNA replication in MCV 
(Neumann et al. 2016). SP100 was one of the top ten downregulated targets 
in the RNA-Seq dataset, exhibiting ~18-fold downregulation, qRT-PCR 
validation confirmed this and showed 11-fold and 5-fold downregulation in the 
presence of MCV-miR-M1-5p mimic and MCVSyn, respectively (Figure 4.6 
H). In pathway analysis, SP100 was highlighted in pathways such as, 
response to cytokine stimulus, response to chemical stimulus and immune 
system process.  
4.2.1.2. Tumour-related transcripts 
As discussed above, MCV-miR-M1 is expressed at very low levels in MCC, 
suggesting that the miRNA is unlikely to impact on the cancer phenotype. 
However, several transcripts associated with pathways to cancer were 
identified by RNA-Seq analysis and several of these were investigated 
further.  
CYB5R2 (cytochrome b5 reductase 2) is a member of cytochrome b-type 
NAD(P)H (Nicotinamide Adenine Dinucleotide Phosphate Hydrogen) 
oxidoreductases which have been implicated in a range of biological 
processes such as, biosynthesis of fats and oxidative burst (Zhu et al. 1999). 
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Oxidative or respiratory burst is a phenomenon in phagocytes during which 
elevated oxygen consumption is followed by oxygen reduction to superoxide 
(SO) and other reactive oxygen intermediates which are then used to destroy 
engulfed pathogens within phagolysosomes (Bose et al. 2014). In addition, 
CYB5R2 inactivation by promoter hypermethylation has been demonstrated 
in nasopharyngeal (Xiao et al. 2014) and prostate cancer (Devaney et al. 
2013). CYB5R2 exhibited a 32-fold downregulation in RNA-Seq datasets and 
was identified as the top 3p target, in terms of downregulation. qRT-PCR 
validation showed a significant  ~2-fold downregulation in cells expressing 
MCV-miR-M1-3p mimic and MCVSyn (Figure 4.6 I).  
KLLN (killin, p53-regulated DNA replication inhibitor) is a high-affinity DNA-
binding protein which negatively regulates DNA and RNA synthesis and has 
been demonstrated to be necessary and sufficient for P53-induced apoptosis 
(Cho and Liang 2008; Qiao et al. 2015). KLLN-mediated tumour suppression 
has been reported in breast and prostate cancers (Wang et al. 2013a; Wang 
et al. 2013b). KLLN RNA-Seq data was qRT-PCR-validated and showed 
more than 4-fold downregulation in the presence of MCV-miR-M1-3p mimic 
and MCVSyn (Figure 4.6 J). 
OSR1 (odd-skipped related 1) is a transcription factor and tumour suppressor 
gene the overexpression of which has been associated with cell cycle arrest 
and induction of apoptosis in gastric cancer cell lines, where its knockdown 
promotes cell growth in normal gastric cells (Otani et al. 2014). qRT-PCR 
confirmed OSR1 RNA-Seq results with more than 2-fold downregulation with 
MCV-miR-M1-3p mimic and MCVSyn (Figure 4.6 K).  
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4.2.1.3. Transcripts not identified via RNA-Seq (Miscellaneous 
transcripts) 
A recent study showed that MCV T Ag locus mediates downregulation of 
TLR9 promoter activity by downregulating C/EBPα and C/EBPβ and 
subsequent reduced binding to TLR9 promoter (Shahzad et al. 2013), 
however, the authors did not specify the mechanism by which C/EBPα and 
C/EBPβ are downregulated. Therefore, to address the possibility of miRNA-
mediated downregulation of their transcripts, TLR9, C/EBPα and C/EBPβ 
were also included in MCV-miR-M1 qRT-PCR assays.  
qRT-PCR analysis confirmed TLR9 downregulation in the presence of MCV-
miR-M1-5p and -3p mimics and MCVSyn (Figure 4.6 L), suggesting that 
TLR9 downregulation is MCV-miR-M1-dependent. C/EBPα was 
downregulated by more than 2-fold in the presence of MCV-miR-M1-5p and -
3p mimics while showing increased levels with MCVSyn (Figure 4.6 M). 
C/EBPβ was upregulated with both MCV-miR-M1 mimics and MCVSyn 
(Figure 4.6 N). Accordingly, whilst these data suggest a positive correlation 
between MCV-miR-M1 and C/EBPβ mRNA expression, C/EBPα expression 
presents a more complex association with MCV-miR-M1.  
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Figure 4.6. Panel i: Immune-related RNA-Seq-identified cellular transcripts. 
Panel ii: Tumour-related RNA-Seq-identified cellular transcripts. Panel iii: 
Miscellaneous transcripts downregulated by MCV T Ag locus (Shahzad et al. 
2013). Downregulation of these transcripts was qRT-PCR validated using 
cDNA of 293 cells transfected with MCV-miR-M1-5p, MCV-miR-M1-3p and a 
scramble miRNA mimic or with MCVSyn and MCVSyn-hpko. Expression of 
MCV-miR-M1 was confirmed via stem loop qRT-PCR. Due to higher relative 
expression of MCV-miR-M1, MCVSyn experiments were carried out using 
cDNAs of 72h time point. 5p and 3p, MCV-miR-M1-5p and -3p mimics; Ctrl, 
control (scramble) miRNA mimic; WT, MCVSyn; Mut, MCVSyn-hpko.  
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4.3. Investigating protein expression of MCV-miR-M1 targets 
Due to the limited consumables budget associated with the project, 
unfortunately it was not possible to investigate protein expression by western 
blot for all the qRT-PCR-validated transcripts. Therefore, it was decided to 
choose targets with the most functional relevance to MCV pathogenesis and 
life cycle, namely, CXCL8, SP100 and TLR9. As explained in section 4.2.1, 
CXCL8 is an important leukocyte chemoattractant whose downregulation 
may help MCV remain hidden from host immune surveillance. SP100 has 
also been implicated in cell antiviral response and a recent study has showed 
that SP100 expression is absent in a large proportion of cells with active 
MCV replication (Neumann et al. 2016), supporting existing data for the 
important role of SP100 in innate antiviral immunity. TLR9 was initially 
identified as a ligand for unmethylated CpG motif of bacterial DNA (Hemmi et 
al. 2000; Bauer et al. 2001) and has been implicated in immune recognition 
of dsDNA viruses such as herpesviruses (Krug et al. 2004), papillomaviruses 
(Hasan et al. 2007) and MCV (Shahzad et al. 2013). Moreover, SP100 and 
TLR9 have been linked to interferon and cytokine signalling pathways 
(Grotzinger et al. 1996; Krug et al. 2003; Lund et al. 2003; Krug et al. 2004; 
Scherer and Stamminger 2016). Given the role of MCV miRNA in virus 
persistence (Theiss et al. 2015), significant MCV-miR-M1-dependent 
downregulation of CXCL8 and SP100 in RNA-Seq analysis and MCV-driven 
downregulation of SP100 and TLR9, I embarked to investigate if MCV 
miRNA is undermining innate immune response by modulating protein 
expression of CXCL8, SP100 and TLR9.  Initially, it was important to confirm 
the effect of MCV-miR-M1 on the protein expression of MCV LT. To this end, 
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293 cells were mock-transfected or transfected with MCVSyn and MCVSyn-
hpko and western blotting was carried out for total protein of transfected cells 
using an MCV LT-specific antibody, CM2B4. Consistent with data for mRNA 
expression (Figure 3.7 C), MCV LT protein showed a steady and significant 
increase in MCVSyn-hpko  versus MCVSyn over 72h, with no expression in 
mock (Figure 4.7), confirming functionality of MCV-miR-M1 in our 293 system 
at protein expression level.  
 
Figure 4.7. Protein expression of MCV LT Ag in total protein of mock- and 
MCVSyn-transfected 293 cells. Densitometry analysis revealed more than 5-
fold and 22-fold increase in LT expression in MCVSyn-hpko versus MCVSyn 
at 48h and 72h time points, respectively. 
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Having confirmed that MCV-miR-M1 can negatively regulate its direct viral 
transcript at the level of protein expression, 293 cells were transfected with 
MCV-miR-M1-5p, -3p and control miRNA mimics to investigate whether 
MCV-miR-M1-5p and -3p can also downregulate protein expression of their 
identified cellular targets.  
Previous studies have shown that TLR9 is downregulated by a number of 
viruses and viral proteins including, hepatitis B virus (HBV) (Vincent et al. 
2011), human papillomavirus type 16 (HPV16) E6 and E7 proteins (Hasan et 
al. 2007), EBV latent membrane protein 1 (LMP1) (Fathallah et al. 2010) and 
BGLF5 (van Gent et al. 2011) as well as MCV T Ag locus (Shahzad et al. 
2013). This is not surprising given the important role TLR9 plays in innate 
immunity (Wagner 2002; Krug et al. 2004). In MCV, TLR9 expression is 
impaired by T Ag locus, however, it is not clear whether this effect is miRNA- 
mediated or T Ag-mediated or both. My initial investigation revealed that 
TLR9 mRNA is significantly downregulated by MCV-miR-M1-5p and -3p and 
in the presence of MCVSyn (Figure 4.6 L). Therefore, to investigate whether 
TLR9 protein expression is also reduced by MCV-miR-M1 expression, 
western blotting was carried out for total protein of MCV-miR-M1-5p, -3p and 
control miRNA mimic-transfected 293 cells. As seen in Figure 4.8 A, 
densitometry analysis of TLR9, normalised to GAPDH protein levels, 
demonstrated 1.7-fold decrease in the presence of MCV-miR-M1-3p mimic. 
To test whether TLR9 protein level is also downregulated following 
expression of MCV-miR-M1 in MCVSyn, 293 cells were mock-transfected or 
transfected with MCVSyn and MCVSyn-hpko and total protein was extracted 
72h p.t. The 72h time point was chosen due to higher levels of MCV-miR-M1 
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expression and larger degree of MCV LT downregulation at 72h compared to 
earlier time points (Figures 3.7 A & 4.7). Consistent with mimic data, TLR9 
protein expression demonstrated 2-fold increase in MCVSyn-hpko versus 
MCVSyn and mock at 72h p.t. (Figure 4.8 B), suggesting that reduced TLR9 
protein expression was MCV-miR-M1-dependent.   
 
 
Figure 4.8. Protein expression of TLR9 in total proteins of MCV-miR-M1-5p, -
3p and control mimic-transfected (A)  and mock-, MCVSyn- and MCVSyn-
hpko-transfected (B) 293 cells. Densitometry analysis revealed 1.7-fold 
downregulation of TLR9 with MCV-miR-M1-3p mimic and 2-fold upregulation 
in MCVSyn-hpko versus MCVSyn and mock at 72h p.t. (p-value<0.05). NS, 
no significance. Immunoblots are representative of three independent 
biological repeats.  
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SP100 is an IFN-stimulated gene (Grotzinger et al. 1996) whose alternative 
splicing gives rise to four isoforms including, SP100A (Szostecki et al. 1990), 
SP100B (Dent et al. 1996), SP100C (Seeler et al. 2001) and SP100-HMG 
(Guldner et al. 1999). Importantly, SP100B has been demonstrated to 
repress transcription of cellular and viral promoters (Wilcox et al. 2005) and 
preferentially bind to unmethylated CpG, hence targeting foreign DNA such 
as viral genomes (Isaac et al. 2006). SP100 has been implicated in immune 
response against dsDNA viruses such as HCMV (Kim et al. 2011; Tavalai et 
al. 2011; Wagenknecht et al. 2015), HSV-1 (Negorev et al. 2006; Negorev et 
al. 2009), HPV18 (Stepp et al. 2013) and MCV (Neumann et al. 2016). 
Further evidence for the important role of SP100 in host cell antiviral 
response comes from downregulation or loss of SP100 by several 
herpesvirus proteins including, HSV-1 ICP0 (Chelbi-Alix and de The 1999), 
VZV ORF61p (Kyratsous et al. 2009), HCMV IE1 (Tavalai and Stamminger 
2009) and Murine Gamma-Herpesvirus 68 (MHV-68) ORF75c (Tavalai and 
Stamminger 2009). A recent study has also shown that EBV BART1-miR-3p 
directly targets 3'UTR of SP100 in DLA (Skalsky et al. 2012), suggesting 
direct involvement of EBV miRNAs in modulation of host cell antiviral 
response, cell survival and proliferation. Importantly, SP100-mediated 
antiviral response against MCV gains support from a very recent study where 
authors showed an increase in MCV genome replication following SP100 
depletion in H1299 cells (Neumann et al. 2016). However, thus far there is no 
published data as to whether and how MCV counteracts SP100 by 
modulating its downregulation or depletion. To address this question, I 
demonstrated downregulation of SP100 mRNA via RNA-Seq and confirmed 
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this data via qRT-PCR with MCV-miR-M1-5p mimic and MCVSyn (Section 
4.2.1, Table 4.1 and Figure 4.6 H). To verify MCV-miR-M1-5p-dependent 
downregulation of SP100 at protein expression level, western blotting was 
carried out for total protein of MCV-miR-M1-5p, -3p and control mimic 
transfected-293 cells using SP100-specific antibody. Importantly, in Bauman 
et al.’s study of JCV and BKV miRNA-mediated downregulation of ULBP3 
(see section 1.6.1.2), the authors demonstrated that ULBP3 protein levels 
reduced despite no change in mRNA expression levels, suggesting that 
JCV/BKV miRNA achieves this by inhibition of translation and not repression 
of mRNA expression (Bauman et al. 2011). Therefore, MCV-miR-M1-3p 
mimic was also included in the experiment to see whether SP100 protein 
expression is affected by the 3p strand of MCV-miR-M1. As can be seen in 
Figure 4.9 A, SP100 protein expression was significantly downregulated by 
more than 2-fold in the presence of MCV-miR-M1-5p mimic and not -3p 
mimic. To confirm whether SP100 protein expression was also 
downregulated in the context of MCV replication, western blotting was 
repeated for SP100 72h p.t. using total protein isolated from mock-, 
MCVSyn- and MCVSyn-hpko-transfected 293 cells. Similar to MCV-miR-M1 
mimics experiment, SP100 protein expression demonstrated ~2-fold 
reduction at 72h p.t. in MCVSyn compared with MCVSyn-hpko and mock 
(Figure 4.9 B). Together, these data suggest that MCV drives downregulation 
of SP100 protein expression in an MCV-miR-M1-5p-dependent manner. 
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Figure 4.9. Protein expression of SP100 in total proteins of MCV-miR-M1-5p, 
-3p and control mimic-transfected (A)  and mock-, MCVSyn- and MCVSyn-
hpko-transfected (B) 293 cells. Densitometry analysis revealed more than 2-
fold downregulation of SP100 with MCV-miR-M1-5p mimic and in MCVSyn 
versus MCVSyn-hpko and mock at 72h p.t. (p-value<0.01). NS, no 
significance. Immunoblots are representative of three independent biological 
repeats. 
 
CXCL8 exhibited 16-fold downregulation in the MCV-miR-M1-3p RNA-Seq 
dataset and the highest frequency in immune-related pathways following GO 
analysis. Therefore, due to its key role in immune response and neutrophil 
activation and migration, I decided to investigate the impact of MCV-miR-M1 
on the secreted levels of CXCL8 protein. Secreted levels of CXCL8 were 
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determined via ELISA analysis of growth media (Baggiolini et al. 1989) 
derived from TNF-α-stimulated 293 cells transfected with either MCV-miR-
M1-3p or -5p mimic. As seen in Figure 4.10 A, growth media CXCL8 
concentrations showed more than 25% reduction in the presence of MCV-
miR-M1-3p mimic whereas secreted levels of CXCL8 protein remained 
unaltered in 293 cells transfected with the MCV-miR-M1-5p mimic. Next, to 
see if CXCL8 protein expression is also reduced in the presence of 
replicating MCVSyn, 293 cells were mock-transfected or transfected with 
MCVSyn and MCVSyn-hpko. Analysis via ELISA revealed that levels of 
secreted CXCL8 dropped by 70% in the growth media of MCVSyn-
transfected cells compared to MCVSyn-hpko 72h p.t. (Figure 4.10 A & B). As 
expected, no CXCL8 was detected in mock-transfected cells due to lack of 
stimulation. These data suggest that secreted CXCL8 protein is 
downregulated in a MCV-miR-M1-dependent manner. 
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Figure 4.10. Secreted CXCL8 levels in growth media of 293 cells stimulated 
with TNF-α and transfected with MCV-miR-M1 mimics or transfected with 
MCVSyn and MCVSyn-hpko. Growth media CXCL8 was downregulated by 
more than 70% (3-fold) and 25% in MCVSyn- versus MCVSyn-hpko- and 
MCV-miR-M1-3p versus control mimic-transfected cells, respectively (A). 
Relative expression of CXCL8 in growth media of MCVsyn- and MCVSyn-
hpko-transfected 293 cells increases by time. Downregulation of growth 
media CXCL8 in MCVSyn relative to MCVSyn-hpko is only detectable at 72h 
p.t. (B).  
 
4.4. Discussion 
Despite mounting evidence for the role of virus miRNAs in modulation of host 
cell transcripts (Kincaid and Sullivan 2012), thus far for most virus miRNAs 
there is a lack of global target identification. Recent studies have reported 
virus miRNA targetomes of KSHV and EBV in primary effusion lymphoma 
cell lines (Gottwein et al. 2011) and lymphoblastoid cell lines (Skalsky et al. 
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2012), respectively. In BKV and JCV, miRNA target identification has been 
limited to study of NKG2D ligands ULBP3, ULBP2 and MICA (Bauman et al. 
2011). In MCV, currently there is no published data regarding cellular targets 
of MCV-miR-M1 and Lee et al.’s in silico-predicted cellular targets of MCV-
miR-M1 (Lee et al. 2011) were based on incorrect MCV-miR-M1-5p seed 
sequence (Theiss et al. 2015). Therefore, there is an unmet need to identify 
potential targets of MCV-miR-M1 via an unbiased and global approach. It has 
been demonstrated that in the majority of cases (> 84%) miRNAs reduce the 
level of targeted mRNAs (Guo et al. 2010), suggesting mRNA expression 
level as a reliable indicator of miRNA impact. RNA-Seq has been used to 
measure differential transcriptomic changes induced by viruses such as 
KSHV (Viollet et al. 2015) or malignancies such as pancreatic cancer (Muller 
et al. 2015). In this project, using RNA-Seq in HEK293 cells I identified 
several hundred cellular transcripts with differential expression induced by 
MCV-miR-M1-5p and -3p mimics. To identify priority targets for downstream 
validation, GO analysis was carried out using DAVID software. A recent 
RNA-Seq-based comparative study of latent KSHV-infected cell line SLKK 
with non-infected SLK cell line has revealed differential expression of multiple 
pathways, among which are pathways associated with KSHV pathogenesis, 
such as regulation of the epithelial-to-mesenchymal transition pathway and 
CXCL8 signalling pathway (Viollet et al. 2015). Several studies have 
demonstrated that differential expression of pathways related to immune 
response are a common feature when investigating virus-host cell interaction 
(Juranic Lisnic et al. 2013; Rossetto et al. 2013; Mei et al. 2014; Wang et al. 
2014b; Park et al. 2015; Richards et al. 2015; Hu et al. 2016). For instance, 
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the KSHV polyadenylated nuclear RNA (PAN RNA) dysregulates pathways 
involved in regulation of immune response and inflammatory cytokine 
production (Rossetto et al. 2013). EBV-B95-8 miRNAs target a number of 
pathways including interleukin signalling and IFN-γ signalling pathways 
(Skalsky et al. 2012). Of particular interest to this project, a recent study has 
revealed that MCV T Ags induce upregulation of pathways associated with 
cell cycle, DNA replication and immune response (Richards et al. 2015). In 
the present project, GO analysis placed a number of hits in immune-related 
GO terms (Figure 4.5). Cross-referencing top hits with significant GOs 
associated with processes known to be important in polyomavirus infection 
and replication led to the identified list of targets in Chapter 4. Strikingly, 
consistent with proposed function of viral miRNAs in virus-host interaction, 
several pathways with relevance to virus pathogenesis were highlighted in 
my GO analysis including, immune response, regulation of cell proliferation 
and cellular processes and cell communication pathways. In addition, several 
other pathways were identified such as, female gamete generation, response 
to steroid hormone stimulus, regulation of blood pressure and several 
neurological pathways such as, regulation of synaptic transmission and 
synaptic plasticity, learning or memory, sleep and behaviour. It is possible 
that some of the identified transcripts within these GOs might encode for 
proteins with diverse but as yet unidentified functions, however, due to 
currently unknown relevance to MCV pathogenesis or life cycle these 
transcripts were not included in target validation experiments. It should be 
noted that the starting number of RNA-Seq-identified targets for qRT-PCR 
validation was larger than the number of validated transcripts in Table 4.1. 
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Failure to validate some of the selected targets was largely due to none or 
very low qRT-PCR amplification of the non-validated transcripts with cDNA of 
293 cells. In addition, in some cases target validation was not possible due to 
non-specific amplification of the transcripts, possibly as a result of alternate 
transcript variants. Importantly, at the end of my PhD project dermal 
fibroblasts were identified as the natural host of MCV (Liu et al. 2016) and it 
will be of interest and important to determine if key dysregulated cellular 
transcripts are also altered in response to MCV-miR-M1 expression in these 
cells.   
Following target selection, a two-tiered approach was taken to RNA-Seq 
target validation. MCV-miR-M1 responsive cellular targets were initially 
analysed and validated via qRT-PCR following transfection of 293 cells with 
either MCV-miR-M1-5p or -3p mimics. Functional analysis of MCV-miR-M1 
mimics demonstrated robust efficacy against their cognate target, MCV LT 
(Figure 3.5 B). However, it was important to establish if MCV-miR-M1 mimic-
modulated cellular targets were also significantly altered by virus-encoded 
MCV-miR-M1 expressed during virus replication.  To this end, the MCVSyn 
system was used to transfect 293 cells and expression of cellular targets was 
measured 72h p.t. due to higher expression and activity of MCV-miR-M1 at 
this time point (Figure 3.7 A & C). qRT-PCR analysis of the targets confirmed 
RNA-Seq and MCV-miR-M1 mimics data in all cases.  
miRNAs are post-transcriptional regulators of gene expression and 
predominantly downregulate protein expression of their targeted transcripts 
(Guo et al. 2010). A hallmark of virus-encoded miRNAs is downregulation of 
their cognate viral proteins. Such effect has been demonstrated for KSHV-
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miR-K12-9-5p suppression of KSHV RTA (Bellare and Ganem 2009), EBV-
miR-BART-20-5p suppression of EBV RTA and ZTA (Jung et al. 2014) and 
HCMV miR-UL112-1 downregulation of IE1, UL112/113 and UL120/121 
(Murphy et al. 2008). Polyomaviruses also express a miRNA which directly 
targets and downregulates protein expression of its cognate LT Ag (Sullivan 
et al. 2005; Seo et al. 2008). As discussed in section 1.6.1.3, it has been 
hypothesised that viruses use downregulation of their own proteins as a 
strategy to dampen lytic replication and avoid detection by the host immune 
system (Kincaid and Sullivan 2012). Therefore, LT Ag protein expression can 
be reliably used as a positive control in polyomavirus miRNA functional 
studies. With this view, 293 cells were transfected with MCVSyn system and 
expression of MCV LT was monitored for 72h at 24h intervals. Whilst MCV 
LT protein expression demonstrated 23-fold upregulation in MCVSyn-hpko-
transfected cells within 72h time period, its expression remained constant in 
MCVSyn (Figure 4.7) despite its steady mRNA downregulation during same 
time period (Figure 3.7 C). This may be due to relatively stable steady-state 
expression of MCV LT in MCVSyn (Selbach et al. 2008), suggesting that a 
more prolonged transcriptional repression is required for significant 
downregulation of MCV LT protein.  
In addition to their impact on the expression of viral proteins, there is 
mounting evidence for the key role of viral miRNAs in downregulation of 
proteins involved in host immune response. For instance, BKV and JCV 
identical miRNAs, BKV-miR-B1-3p and JCV-miR-J1-3p, directly target and 
downregulate immune ligand ULBP3 (Bauman et al. 2011). Although thus far 
there is no published data regarding cellular targets of MCV-miR-M1, a 
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recent study provided strong evidence for the involvement of MCV-miR-M1 in 
modulation of host immune response by showing in vitro that the miRNA-
deficient MCVSyn-hpko fails to establish long term persistent infection 
(Theiss et al. 2015). In addition, it has been shown that SP100 acts as a 
negative regulator of MCV genome replication and its expression is abolished 
in the majority of cells with active MCV replication, however, the authors did 
not provide a mechanistic explanation for this observation (Neumann et al. 
2016). Together, these observations suggest an association between MCV-
miR-M1 and the antiviral immune response. In my RNA-Seq analysis, among 
the top MCV-miR-M1 hits in terms of differential expression was the immune-
related transcript SP100 (>18-fold downregulation). Having confirmed mRNA 
downregulation of SP100 via MCV-miR-M1 mimic and MCVSyn systems, I 
investigated SP100 protein expression in the presence of MCV-miR-M1. 
Consistent with qRT-PCR data, western blotting confirmed downregulation of 
SP100 protein expression by MCV-miR-M1-5p mimic (Figure 4.9 A). In 
addition, it was crucial to determine whether endogenous expression of 
MCV-miR-M1 following MCV genome replication could also modulate SP100 
protein expression. To this end, western blotting confirmed that MCVSyn 
replication diminishes SP100 protein expression compared to MCVSyn-hpko- 
and mock-transfected cells (Figure 4.9 B).  
Importantly, Neumann et al.’s study about the relation of MCV replication and 
SP100 expression showed that while overexpression of sT or LT alone has 
no effect on SP100 expression, in cells with overexpressed early region 
where LT is expressed at substantially higher levels SP100 is significantly 
downregulated (Neumann et al. 2016). Therefore, Neumann et al.’s study 
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suggests that SP100 downregulation correlates with MCVSyn replication and 
level of LT expression, giving rise to the speculation that SP100 
downregulation is MCV LT-mediated. However, my data argues strongly 
against this since increased genome replication and LT expression in 
MCVSyn-hpko does not downregulate SP100 relative to MCVSyn- or mock-
transfected cells. Instead, I show SP100 downregulation independent of MCV 
LT and in the presence of MCV-miR-M1-5p mimic as well as in MCVSyn- 
versus MCVSyn-hpko- and mock-transfected cells (Figure 4.9). These data 
suggest a model where MCV-miR-M1 is expressed by MCV as a means to 
attenuate the host cell innate immune response via downregulation of 
SP100.  
In addition to its role in immune response, dispersal of SP100 from PML-NB 
by tumourigenic viruses such as KSHV and EBV (Tavalai and Stamminger 
2009) and its downregulation in MCV (Akhbari et al, in preparation) hint at a 
tumour suppressor role for SP100. This is supported by studies showing 
SP100 downregulation in laryngeal cancer (Li et al. 2010) and reduced 
proliferation and migration of glioma cells following SP100 overexpression 
(Held-Feindt et al. 2011). As described in section 4.2.1.2, this bifunctional 
immune-regulatory/tumour-suppressor characteristic is also relevant for other 
targets of MCV-miR-M1 including CYB5R2. Therefore, it is tempting to 
suggest that MCV modulates expression of transcripts which span the 
intersect of innate immunity and tumour suppression to establish a persistent 
infection necessary for MCV tumourigenesis. While my findings support this 
hypothesis whether this is the case requires further investigation.   
174 
 
SP100 is a cytokine-stimulating gene implicated in immune response against 
several dsDNA viruses such as HSV1, VZV, HCMV, EBV, KSHV, BKV and 
MCV (Tavalai and Stamminger 2009; Jiang et al. 2011; Tavalai et al. 2011; 
Wagenknecht et al. 2015; Neumann et al. 2016; Scherer and Stamminger 
2016) and is a permanent constituent of PML-NB, a nuclear protein complex 
involved in various activities including, transcription regulation, apoptosis and 
cell cycle, response to stress and hormone signalling and development 
(Negorev and Maul 2001). To date, no one has demonstrated a direct 
regulatory role for SP100 on CXCL8 or NF-κB-induced chemokine 
expression, however, there is evidence implicating SP100 in trans via 
activating transcription of chemokine-inducing genes or potentiating their 
effect. For instance, SP100 has been shown to directly interact with and 
stimulate transcription of the transcription factor ETS-1 (Wasylyk et al. 2002), 
which is a stimulator of several cytokines such as IL-2, IL-4, IL-5 and IFN-γ 
and the monocyte and neutrophil chemoattractant chemokine (C-C motif) 
ligand 2 (CCL2) (Reichel et al. 2009; Russell and Garrett-Sinha 2010). 
Interestingly, ETS-1 has also been shown to upregulate CXCL8 expression 
and secretion in neuroblastoma cells (Qiao et al. 2007). It is possible, 
therefore, that SP100 might mediate expression of CCL2, CXCL8 and other 
chemokines and cytokines via ETS-1.  
CXCL8 is a chemokine associated with various aspects of immune response 
such as, neutrophil activation, triggering neutrophil and IL-2-activated-NK 
cells chemotaxis (Sebok et al. 1993; DiVietro et al. 2001), mediating 
neutrophil endothelial arrest and binding via Lymphocyte function-associated 
antigen 1 (LFA1) and selectins (Lawrence and Springer 1991; Von Andrian et 
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al. 1992) and activating respiratory burst, rapid Ca++  release and 
degranulation of polymorphonuclear (PMN) cells (Lindley et al. 1988; Peveri 
et al. 1988; Carveth et al. 1989). Interestingly, several studies have emulated 
the CXCL8-mediated neutrophil recruitment in vivo by histological 
assessment of skin samples following intradermal injection of CXCL8 in 
human, rabbit and several other species (Colditz et al. 1990; Leonard et al. 
1991; Rot 1991). It has also been shown that whilst CXCL8 is the major 
human neutrophil chemoattractant, CXCL8-activated neutrophils can release 
gelatinase B which in turn potentiates CXCL8 by catalysing its N-terminal 
truncation (Van den Steen et al. 2000; Starckx et al. 2002), suggesting a 
positive-feedback loop between CXCL8 and neutrophils. Several viruses 
have been shown to reduce CXCL8 expression. HSV-1 protein kinase US3 
has been demonstrated to downregulate CXCL8 expression by inhibiting NF-
κB activation (Wang et al. 2014a). Adenovirus dl922-947 E1A protein also 
dampens CXCL8 and CCL2 production by displacing NF-κB p65 subunit from 
their promoter in anaplastic thyroid carcinoma (ATC) cell line 8505-c 
(Passaro et al. 2016). HCMV miR-UL112-3p has been shown to inhibit NF-κB 
activation via directly targeting TLR2, leading to downregulation of CXCL8, 
IL-6 and IL-1β (Landais et al. 2015). A recent study has also shown that MCV 
sT prevents nuclear translocation of NF-κB leading to downregulation of NF-
κB-stimulated genes including CXCL8, CXCL9 and CCL20 (Griffiths et al. 
2013). In my RNA-Seq investigation, CXCL8 was a top hit in MCV-miR-M1-
3p dataset by more than 16-fold downregulation. qRT-PCR confirmed CXCL8 
reduced expression in MCV-miR-M1-3p mimic-transfected 293 cells (Figure 
4.6 B). Having confirmed MCV-miR-M1-dependent downregulation of CXCL8 
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with MCV-miR-M1 mimic, CXCL8 mRNA expression using MCVSyn system 
also demonstrated significant CXCL8 downregulation 72h p.t. (Figure 4.6 B).  
Furthermore, to confirm whether downregulation of CXCL8 mRNA results in 
reduced protein expression secreted CXCL8 protein was measured in the 
growth media of MCV-miR-M1 mimic-transfected 293 cells. ELISA confirmed 
CXCL8 protein downregulation in MCV-miR-M1-3p mimic-transfected cells 
(Figure 4.10 A). Investigating growth media CXCL8 in MCVSyn-transfected 
cells corroborated MCV-miR-M1 mimic results at 72h p.t. (Figure 4.10 A & B). 
Whilst MCVSyn data confirm that CXCL8 is downregulated following MCV 
genome replication MCV-miR-M1 mimic data prove that this downregulation 
is MCV-miR-M1-dependent and independent of other MCV components, i.e. 
MCV LT proteins. Importantly, a recent study has shown that other 
components of MCV can modulate expression of cytokines. For instance, 
one study demonstrated downregulation of NF-κB-induced genes including 
CXCL8 using an expression vector and an inducible cell line expressing MCV 
sT (Griffiths et al. 2013). The authors showed that MCV sT interacts with 
IKKγ (NEMO), PP4C and PP2A Aβ in cytoplasmic puncta to prevent 
phosphorylation of IKKα and IKKβ and subsequent IkB degradation. This 
prevents NF-κB release and nuclear translocation which is required for 
transcription activation of NF-κB-inducible genes (Griffiths et al. 2013). Based 
on this model one would predict that we should see downregulation of 
CXCL8 in MCVSyn-hpko versus MCVSyn at 72h p.t., since at this time point 
MCV sT is upregulated in MCVSyn-hpko relative to MCVSyn (Figure 3.7 D). 
However, my findings show exactly the opposite where CXCL8 is 
downregulated at both mRNA and protein levels in MCVSyn versus 
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MCVSyn-hpko at 72h p.t. (Figures 4.6 B & 4.10). In addition, similar levels of 
secreted CXCL8 at 48h p.t. (Figure 4.10 B) do not correlate with higher levels 
of MCV sT transcripts in MCVSyn-hpko at this time point (Figure 3.7 D). 
Moreover, a recent study reported that MCV T Ags upregulate the expression 
of several inflammatory cytokines and chemokines including CXCL8 
(Richards et al. 2015). Interestingly, the authors also demonstrate that while 
tumour-derived MCV LT upregulates CXCL8 expression, tumour-derived 
MCV LT+sT enhances this effect by more than 2.5-fold and 15-fold at mRNA 
and protein levels, respectively (Richards et al. 2015). Therefore, if MCV T 
Ags stimulate CXCL8 expression we expect to see increased levels of 
CXCL8 in MCVSyn-hpko relative to MCVSyn. This is in perfect agreement 
with my data where CXCL8 mRNA and protein levels are upregulated in 
MCVSyn-hpko-transfected cells (Figures 4.6 B & 4.10). Importantly, given the 
significantly low expression of MCV-miR-M1 in MCV-positive MCCs (Lee et 
al. 2011; Theiss et al. 2015) and that Richards et al. used tumour-derived 
truncated LT stable cell lines, elevated levels of CXCL8 in their study might 
be attributed to the absence of sufficient amounts of MCV-miR-M1. It is also 
possible that these differences are due to experimental set-up, as MCV LT 
was excluded in Griffiths et al.’s experiments. Moreover, neither of the 
studies considered MCV-miR-M1 expression and cytokine and chemokine 
expression in the context of MCV infection/replication.  
TLR9 is an important PRR and unmethylated CpG ligand (Hemmi et al. 2000; 
Bauer et al. 2001) whose targeting and downregulation has been shown by 
EBV latent membrane protein 1 (LMP1) (Fathallah et al. 2010) and HPV16 
E6 and E7 oncoproteins (Hasan et al. 2007). In addition, a recent study 
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showed that MCV T Ag locus can mediate TLR9 downregulation by 
negatively regulating C/EBPα and C/EBPβ expression (Shahzad et al. 2013), 
however, the authors did not provide conclusive evidence as to how MCV T 
Ag achieves this. A recent study has investigated cellular targets of EBV-
B95-8 miRNAs in lymphoblastoid cell lines using Photoactivatable-
Ribonucleoside-Enhanced Crosslinking and Immunoprecipitation (PAR-CLIP) 
(Skalsky et al. 2012). PAR-CLIP is a technique used for determining binding 
sites of RBPs such as miRISC at a transcriptome-wide scale (Hafner et al. 
2010). Briefly, 4-thiouridine (4SU) is incorporated into cellular transcriptome 
to increase RNA-protein crosslinking efficiency via UV radiation (at 365nm). 
Cells are then lysed and RBPs are immunoprecipitated prior to protein 
removal by proteinase K. The remaining mRNAs are then reverse transcribed 
to cDNA and are subjected to deep sequencing to identify RBP-, i.e. miRISC-
bound mRNAs (Corden 2010; Hafner et al. 2010). Therefore, PAR-CLIP has 
the advantage of identifying miRNA-targeted mRNAs with high resolution. 
Nevertheless, Skalsky et al. report that PAR-CLIP failed to identify several 
EBV-B95-8 miRNA cellular targets (Skalsky et al. 2012), demonstrating that 
the technology is not infallible. Similarly, several studies have shown that 
biases inherent to RNA-Seq library preparation may result in 
underrepresentation of some transcripts (Hafner et al. 2011; Jayaprakash et 
al. 2011; Huang et al. 2013; Theiss et al. 2015). Therefore, given the 
importance of TLR9, C/EBPα and C/EBPβ in antiviral immune response and 
the possibility of remaining undetected by RNA-Seq these transcripts were 
included in MCV-miR-M1 functional analysis. Interestingly, initial qRT-PCR 
analysis of TLR9 expression revealed significant downregulation in MCV-
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miR-M1-3p and -5p mimic-transfected cells (Figure 4.6 L). Next, MCVSyn 
system was used to determine whether TLR9 expression is also impaired in 
the presence of MCV genome replication. qRT-PCR confirmed significant 
downregulation of TLR9 in the presence of MCVSyn 72h p.t. (Figure 4.6 L). 
Having confirmed MCV-miR-M1-dependent downregulation of TLR9 mRNA, 
western blotting was carried out to investigate changes at protein expression 
level. Whereas TLR9 protein expression remained unaltered with MCV-miR-
M1-5p mimic, a ~40% decrease was consistently detected in the presence of 
MCV-miR-M1-3p mimic (Figure 4.8 A). This is in agreement with qRT-PCR 
data where MCV-miR-M1-3p mimic demonstrated a greater impact on TLR9 
mRNA expression (>110-fold) compared to MCV-miR-M1-5p mimic (20-fold) 
(Figure 4.6 L). Furthermore, TLR9 protein expression was also probed in the 
MCVSyn system. Intriguingly, whilst TLR9 protein levels were increased in 
MCVSyn-hpko-transfected relative to MCVSyn- and mock-transfected cells, 
MCVSyn-transfected and mock-transfected cells showed similar levels of 
TLR9 protein expression (Figure 4.8 B). Thus, consistent with TLR9 
recognition of unmethylated CpG, it is possible that increased genome 
replication in MCVSyn-hpko-transfected cells induced TLR9 expression, 
whereas in MCVSyn-transfected cells a combination of MCV-miR-M1 effect 
and lower amounts of replicated genome prevented TLR9 expression above 
the basal level detected in mock-transfected cells.  
Given that the proposed model for TLR9 downregulation is that MCV T Ag 
locus mediates this via downregulation of C/EBPα and C/EBPβ expression 
(Shahzad et al. 2013), I also investigated the impact of MCV-miR-M1 on 
these transcripts. Data for C/EBPα was conflicting, with mimics 
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downregulating transcript levels and MCVSyn leading to increased 
expression in MCVSyn-transfected cells (Figure 4.6 M). For C/EBPβ, mRNA 
expression increased in MCV-miR-M1 mimics- and MCVSyn-transfected 
cells (Figure 4.6 N). These data show a negative correlation with TLR9 
expression (Figures 4.6 L & 4.8) and are in contrast with Shahzad et al.’s 
findings where the MCV T Ag locus mediates downregulation of TLR9 via 
downregulation of C/EBPβ and C/EBPα (Shahzad et al. 2013). Thus, further 
investigation is required to fully delineate the relationship between MCV-miR-
M1 and TLR9. 
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CHAPTER 5 
Functional Studies 
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5. Functional significance and direct targets of MCV-miR-M1 
In the previous chapter RNA-Seq analysis identified numerous cellular 
targets that display reduced expression in response to MCV-miR-M1. Several 
of these targets are key mediators of the host cell immune response and their 
presence in the RNA-Seq dataset was validated via qRT-PCR. Moreover, I 
demonstrated that several of these targets were reduced at the protein level 
in a MCV-miR-M1-dependent manner. In this chapter I describe experiments 
performed to determine if the observed effect on these targets is a result of 
direct activity of MCV-miR-M1 against the transcripts via DLA and whether 
the downregulation of host cell immune gene expression has a functional 
impact in terms of immune response.   
5.1. In silico investigation of MCV-miR-M1-5p and -3p target sites    
Having confirmed MCV-miR-M1-dependent downregulation of numerous 
cellular targets at the mRNA level and downregulation of several key 
immune-related genes (SP100, TLR9 and CXCL8) at both mRNA and protein 
levels, it was important to establish if these observed MCV-miR-M1-
dependent effects were due to direct targeting of the host-cell mRNA 
transcript or via a secondary mechanism. To address this, I performed in 
silico investigation using the RNAhybrid online tool (Rehmsmeier et al. 2004) 
to search for MCV-miR-M1 recognition sites in the 3'UTRs of downregulated 
transcripts. RNAhybrid scan revealed putative recognition sites in 3'UTRs of 
SP100, TLR9, CXCL8 and several other targets identified via RNA-Seq and 
validated by qRT-PCR (Figure 5.1).  
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Figure 5.1. In silico investigation of MCV-miR-M1 target sites in 3'UTR of 
RNA-Seq-identified transcripts using RNAhybrid online tool (G:U matches 
allowed). MCV-miR-M1-5p and -3p seed sequences are underlined. For each 
transcript, only the hit with suitable seed sequence match (5p or 3p) and 
lowest minimum free energy is shown. qRT-PCR-validated targets with no 
seed sequence match, including ADRA1D, IFI30 and IFIH1 are not presented 
here.  
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5.2. Validating MCV-miR-M1-5p and -3p target sites by DLA   
To determine if downregulation of qRT-PCR-validated transcripts was due to 
direct targeting of the in silico-identified sites by MCV-miR-M1, the 3'UTRs 
for each gene were PCR-amplified prior to cloning downstream of human 
Renilla luciferase (hRluc) in psiCHECK-2 plasmid (Figure 5.2). 
 
 
Figure 5.2. Map of psiCHECK-2 plasmid vector. To determine whether 
RNAhybrid scan-identified cellular 3'UTRs were bona fide targets of MCV-
miR-M1 (Figure 5.1), the 3'UTR sequences were PCR-amplified and inserted 
into XhoI/NotI, PmeI/NotI or  XhoI/PmeI sites of psiCHECK-2 downstream of 
hRluc gene.  
 
185 
 
The resulting psiCHECK-2 constructs were co-transfected with MCV-miR-
M1-5p mimic, -3p mimic or scramble mimic into 293 cells and cultured for 
24h prior to DLA. Analysis of relative luciferase activity consistently revealed 
a statistically significant reduction in luminescence in cells transfected with 
MCV-miR-M1 compared to scramble mimic for SP100 and MAPK10 (Figure 
5.3 A & C), whereas no significant reduction in luminescence was observed 
for CXCL8, KLLN, RAET1G and TLR9 across multiple independent 
experiments (Figure 5.3 E-H). To determine whether SP100 and MAPK10 
results were reproducible in a more virus-relevant context, 293 cells were co-
transfected with 3'UTR psiCHECK-2 constructs and MCVSyn or MCVSyn-
hpko. Similar to results obtained in mimic transfected cells, normalised 
luciferase signal reduced in MCVSyn for SP100 and MAPK10 when 
compared to MCVSyn-hpko that does not express MCV-miR-M1 (Figure 5.3 
B & D). Again, this effect was lost when MCVSyn was co-transfected with 
site-directed 3'UTR mutants lacking a seed-sequence match for MCV-miR-
M1 (Figure 5.3 A-D). Collectively, these results demonstrate that SP100 and 
MAPK10 3'UTRs are directly targeted by MCV-miR-M1, leading to 
downregulation of the activity of SP100 and MAPK10 genes.   
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Figure 5.3. Dual luciferase assay (DLA) of cellular 3'UTR targets of MCV-
miR-M1. Co-transfection of SP100 and MAPK10 3'UTR psiCHECK-2 
constructs with miRNA mimics and MCVSyn led to downregulation of relative 
luciferase activity in the presence of MCV-miR-M1 in WT but not Mut 
constructs (A-D). Relative luciferase activity remained unchanged for CXCL8, 
KLLN, RAET1G and TLR9 3'UTRs in the presence of MCV-miR-M1 mimics 
(E-H). 5p and 3p Mut, mutated 3'UTR seed sequence matches of MCV-miR-
M1-5p and -3p, respectively. NS, no statistical significance (p-value>0.05). 
 
5.3. Investigating functional consequences of MCV-miR-M1-dependent 
CXCL8 downregulation on neutrophil migration  
CXCL8 is a neutrophil chemoattractant and activator (Baggiolini et al. 1989; 
Modi et al. 1990; Harada et al. 1994) and therefore can modulate neutrophil 
migration. In order to establish if MCV-miR-M1-dependent downregulation of 
CXCL8 described in chapter 4 is significant in terms of attenuating neutrophil 
chemotaxis 293 cells were either transfected with MCVSyn or MCVSyn-hpko 
and cultured for 72h or stimulated with TNF-α prior to transfection with MCV-
miR-M1 mimics or scramble mimic control and cultured for 24h prior to 
growth media being used as a chemoattractant in transwell migration assays 
with neutrophils isolated from blood. As can be seen in Figure 5.4, neutrophil 
migration was significantly impaired in both MCVSyn and MCV-miR-M1-5p 
and -3p mimic transfected cells compared to control, suggesting that MCV-
miR-M1 negatively regulates neutrophil migration in vitro.  
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Figure 5.4. Transwell neutrophil migration assay. Neutrophils isolated from 
fresh blood were placed in upper chambers and growth media of MCVSyn- or 
miRNA mimic-transfected 293 cells were placed in lower chambers of a 
transwell plate. The plate was incubated for 2h at 37ºC with 5% CO2 prior to 
mixing the contents of lower chambers with CellTiter-Glo® 2.0 reagent 
(Promega). Luminescence of mixtures was recorded and chemotactic 
(migration) index was calculated by normalising the luminescence of 
MCVSyn (WT) to MCVSyn-hpko (Mut) and MCV-miR-M1 mimics to control 
mimic samples. Normalised luminescence showed 2-fold decrease in the 
presence of MCV-miR-M1 with statistical significance. 
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5.4. MCV-miR-M1-dependent downregulation of neutrophil migration is 
CXCL8-mediated 
CXCL8 exerts its chemical effects via high affinity binding to C-X-C motif 
chemokine receptor 1 (CXCR1) and CXCR2 (Holmes et al. 1991; Murphy 
and Tiffany 1991). CXCR1 and CXCR2 are expressed on PMN leukocytes, 
monocytes, some T-cells (Chuntharapai et al. 1994), epithelial and 
endothelial cells and fibroblasts (Russo et al. 2014). It has been shown that 
antagonist driven inhibition of CXCR2 is sufficient to block CXCL8-induced 
neutrophil migration in vitro and in vivo (White et al. 1998). Having 
established that downregulation of neutrophil migration is MCV-miR-M1-
dependent, it was crucial to determine if MCV-miR-M1 exerts this effect via 
CXCL8 downregulation. To this end, transwell migration assay was repeated 
in the presence and absence of the CXCR2 antagonist SB265610 (Bradley et 
al. 2009). As evidenced by Figure 5.5, blocking CXCR2 resulted in significant 
(p-value<0.05) downregulation of neutrophil migration towards growth media 
of both MCVSyn- and MCVSyn-hpko-transfected cells whereas no migration 
was observed towards DMEM (growth media used for 293 cell culture). This 
reduction was greater in MCVSyn-transfected cells where MCV-miR-M1 
induces CXCL8 downregulation. These data suggest that MCV-miR-M1 
mediates downregulation of neutrophil migration in a CXCL8-dependent 
manner.  
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Figure 5.5. Transwell neutrophil migration assay in the presence or absence 
of CXCR2 antagonist. Neutrophil migration assay was repeated plus or 
minus CXCR2 antagonist SB265610 for MCVSyn- and MCVSyn-hpko-
transfected 293 cells and cell growth media (DMEM) only. Addition of 
SB265610 to neutrophils resulted in ~20% and ~40% respective 
downregulation of neutrophil migration across transwell membrane towards 
growth media of MCVSyn-hpko- and MCVSyn-transfected 293 cells. No 
migration was detected towards DMEM. inh, SB265610; Media, DMEM; Mut, 
MCVSyn-hpko; WT, MCVSyn. 
 
5.5. Discussion 
miRNAs predominantly exert their effect by directing miRISC to the 3'UTR of 
target transcripts via seed sequence matching and supplementary binding 
(Lewis et al. 2003; Grimson et al. 2007). In this regard, various web-based 
tools have been devised to predict miRNA binding sites in the mRNAs of 
several species including, TargetScan (Agarwal et al. 2015), miRWalk 
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(Dweep and Gretz 2015) and RNAhybrid (Rehmsmeier et al. 2004). 
RNAhybrid has the advantage of predicting multiple putative target sites in 
any small to large RNA sequence by considering most favourable matches 
based on minimum free energy (mfe) and hence eliminating intramolecular 
hybridisations (Rehmsmeier et al. 2004). RNAhybrid has been widely used 
for predicting target binding of various miRNAs (Zhang et al. 2014; 
Khongnomnan et al. 2015; Yin et al. 2016) including the sequence match of 
BKV and JCV miRNA 3p strand in ULBP3 3'UTR (Bauman et al. 2011). 
Therefore, RNAhybrid was used to predict potential binding sites of MCV-
miR-M1 in the 3'UTR of validated targets. Having identified putative 
sequence matches for MCV-miR-M1 (Figure 5.1), 3'UTRs of predicted 
targets were PCR-amplified from cDNA of 293 cells and cloned into 
psiCHECK-2 plasmid to generate response elements (RE) for MCV-miR-M1 
(Figure 5.2).  
MCV-miR-M1 mimics proved highly efficient in DLA against their cognate 
MCV LT RE (Figure 3.5 B). Therefore, MCV-miR-M1-5p and -3p mimics were 
initially used to assess binding of MCV-miR-M1 to the putative targets. DLA 
data revealed reduced luminescence signal in response to MCV-miR-M1-5p 
mimic in SP100 and in response to MCV-miR-M1-5p and -3p mimics in 
MAPK10 3'UTR RE-transfected cells (Figure 5.3 A & C). Other tested 3'UTR 
REs, including CXCL8 and TLR9, did not demonstrate any significant 
changes in luminescence signal in response to MCV-miR-M1 mimics across 
multiple independent repeats (Figure 5.3 E-H). To determine if 
downregulation of SP100 and MAPK10 signal was due to MCV-miR-M1 
specific targeting of the respective REs, mutated REs were generated via 
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site-directed mutagenesis of seed match nucleotides. DLA of mutated REs 
for SP100 and MAPK10 showed a complete loss of reduction in 
luminescence signal in response to MCV-miR-M1 mimics (Figure 5.3 A & C). 
Having established binding of MCV-miR-M1 mimics to their RNAhybrid-
predicted target sites in SP100 and MAPK10 REs, it was desirable to 
reproduce these data using endogenous MCV-miR-M1. To this end, DLA 
was repeated by co-transfecting wild type and mutated SP100 and MAPK10 
REs with MCVSyn and MCVSyn-hpko and relative luminescence was 
measured 72h p.t. As shown in Figure 5.3 B & D, only in wild type SP100 and 
MAPK10 RE-transfected cells was luminescence signal downregulated in 
response to MCVSyn, confirming that MCV-miR-M1 directly targets SP100 
and MAPK10 3'UTRs to downregulate mRNA and protein expression. Direct 
targeting of SP100 3'UTR has also been shown by EBV-BART1-3p in EBV-
infected lymphoblastoid cell lines (Skalsky et al. 2012). SP100 data are of 
particular interest given that a negative correlation between MCV genome 
replication and SP100 expression has been shown by a recent study 
(Neumann et al. 2016). In this regard, whereas further analysis is required to 
determine the role of SP100 in regulating expression of cytokines and 
chemokines such as CXCL8, there is a possibility that MCV-miR-M1-5p 
downregulates neutrophil migration by directly targeting and downregulating 
SP100 expression.  
Intriguingly, MAPK10 has also been implicated in regulating the expression of 
inflammatory cytokines. For instance, MAPK10 is an inducer of TNF-α 
(Kanehisa et al. 2016c) and has been shown to mediate CXCL8 expression 
(Biton and Ashkenazi 2011). In addition, MAPK10 downregulation or loss has 
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been reported in several cancers including, nasopharyngeal carcinoma (Li 
and Luo 2017), brain tumours (Yoshida et al. 2001), lymphomas, gastric and 
breast carcinomas and hepatocellular carcinoma, suggesting a tumour 
suppressor role for MAPK10 (Ying et al. 2006). Moreover, whilst thus far 
there is no data regarding MAPK10 expression in MCs, its expression has 
been demonstrated in human epidermis (Sextius et al. 2015) and mice basal 
epidermis (April and Barsh 2006) where MCs reside (Lucarz and Brand 
2007). While I confirmed downregulation of MAPK10 in MCV-miR-M1-3p and 
-5p mimic-transfected cells via qRT-PCR (Figure 4.6 E), further studies are 
warranted for the impact of MCV-miR-M1 on MAPK10 protein expression and 
to determine whether MCV-miR-M1-3p mimic-dependent downregulation of 
CXCL8 is dictated via direct targeting of MAPK10.   
CXCL8 is a mediator of endothelial arrest, oxidative burst and degranulation 
in PMN leukocytes (Lindley et al. 1988; Peveri et al. 1988; Lawrence and 
Springer 1991). In addition, CXCL8 is a potent activator and chemoattractant 
of PMN, especially neutrophils (Baggiolini et al. 1989; Carveth et al. 1989; 
Detmers et al. 1990). As discussed in Chapter 4, MCV-miR-M1 induces 
downregulation of CXCL8 mRNA and protein expression. Having established 
the effect of MCV-miR-M1 on CXCL8 expression, it was also important to 
determine whether these changes are sufficient to have a functional impact. 
Given the integral role of CXCL8 in inducing neutrophil activation and 
migration in the skin (Colditz et al. 1990; Leonard et al. 1991; Rot 1991), 
Boyden chamber assays were employed to investigate the impact of MCV-
miR-M1-dependent CXCL8 downregulation on neutrophil migration. Initially, 
growth media of MCV-miR-M1 mimic-transfected cells revealed that 
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neutrophil migration is halved in the presence of MCV-miR-M1-5p and -3p 
mimics (Figure 5.4). Next, using 72h p.t. growth media of MCVSyn-
transfected cells I confirmed that replicating MCVSyn also hinders neutrophil 
transwell migration by up to 50% compared with the MCVSyn-hpko mutant 
(Figure 5.4). These data indicate that MCV-miR-M1 expression in the context 
of MCV genome replication has a measurable impact on CXCL8 secretion 
and that this impact is functionally important in terms of modulating neutrophil 
migration. Importantly, experiments with MCV-miR-M1 mimics demonstrate 
that this effect occurs independently of MCV T Ags. Moreover, when CXCL8 
stimulatory effect on neutrophils was blocked using the CXCR2 antagonist 
SB265610, neutrophil migration demonstrated a further downregulation 
compared to unblocked neutrophils. This effect was greater and more 
significant in MCVSyn-transfected cells where MCV-miR-M1 expression 
induced CXCL8 downregulation. Whilst CXCL8 does not exclusively bind to 
CXCR2 and CXCR2 is not specific to CXCL8 it has been shown that 
blockage of CXCR2 alone is sufficient to prevent CXCL8 chemotactic effect 
on neutrophils (White et al. 1998). Therefore, these observations strengthen 
the notion that MCV-miR-M1-dependent downregulation of neutrophil 
migration is mediated by CXCL8.  
Intriguingly, neutrophil migration was also significantly hindered by MCV-miR-
M1-5p mimic, which was somewhat surprising, as previous data 
demonstrated that CXCL8 mRNA and protein expression are only 
downregulated by MCV-miR-M1-3p mimic. This observation points at other 
contributing factors to neutrophil migration whose expression/function is 
modulated by MCV-miR-M1-5p. Interrogation of the RNA-Seq dataset 
195 
 
reveals two transcripts downregulated by MCV-miR-M1-5p mimic that have 
been associated with neutrophil activation and migration. Thrombopoietin 
(THPO) is an stimulator of megakaryocyte differentiation and platelet 
production (Kaushansky 2006). In mice, THPO triggers release of CXCR2 
ligands CXCL1 and CXCL3 (Kanehisa et al. 2016a) by megakaryocytes 
which can then mobilise neutrophils from bone marrow (Kohler et al. 2011). 
Prostaglandin-endoperoxide synthase 2 (PTGS2) or cyclooxygenase-2 
(COX-2) is an enzyme which plays an important role in inflammation by 
catalysing synthesis of prostaglandins (Hla and Neilson 1992). PTGS2 is 
induced by various factors such as TNF-α and NF-κB (Nakao et al. 2002), 
epidermal growth factor (EGF) and IL-1 (Hla and Neilson 1992). In PTGS2-
defficient mice CXCL2 expression was downregulated, resulting in reduced 
neutrophil recruitment to site of liver injury (Hamada et al. 2008). Moreover, 
inhibition of PTGS2 in vitro significantly reduced IL-1β, CXCL6 and CXCL8 
release from activated neutrophils (Kimura et al. 2003). THPO and PTGS2 
were downregulated in MCV-miR-M1-5p mimic dataset, however, attempts to 
validate THPO and PTGS2 RNA-Seq data using qRT-PCR were 
unsuccessful due to low and inconsistent expression of the transcripts. It 
should be noted that analysis of CXCL8 secretion by ELISA did reveal a 
downregulation in CXCL8 protein in response to transfection with the MCV-
miR-M1-5p mimic, however this was not significant. These data suggest that 
MCV-miR-M1-5p is able to indirectly modulate CXCL8 secretion presumably 
by targeting cellular transcripts that lead to changes in CXCL8 expression.  
An alternative explanation for the observed reduction in neutrophil migration 
as a consequence of MCV-miR-M1-5p expression relates to 5p-depednent 
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downregulation of SP100. The SP100-mediated antiviral response has been 
associated with its role as a transcriptional repressor and its preferential 
binding affinity for unmethylated CpG DNA (Wilcox et al. 2005; Isaac et al. 
2006). However, SP100 has also been shown to significantly increase IFN-β 
expression in a MAVS-dependent manner (Schmid et al. 2014). In addition, 
SP100 is induced by IRF7, a member of interferon regulatory factors (IRFs) 
which are involved in transcriptional regulation of IFNs and a number of other 
genes (Mamane et al. 1999; Barnes et al. 2004). An association between 
MAVS with IRFs and members of MAPK signalling pathway (Schmid et al. 
2014) and MAVS-dependent induction of CXCL8 via activation of NF-κB 
(Kawai et al. 2005) has been described. Therefore, it seems that SP100 is 
closely associated with immune-related pathways which utilise IFNs, NF-κB 
and chemokines such as RIG-I-like receptor signalling and MAPK signalling 
pathways (Kanehisa et al. 2016b; Kanehisa et al. 2016d). In this regard, it is 
possible that SP100 downregulation leads to downregulation of neutrophil-
stimulating cytokines and chemokines which manifestation is MCV-miR-M1-
5p-dependent reduction of neutrophil migration.  
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6. Discussion  
miRNAs act predominantly by repressing the expression of protein-coding 
transcripts (Guo et al. 2010) in a wide range of species, including mammals, 
plants, fungi and viruses (Sayed and Abdellatif 2011; Kincaid and Sullivan 
2012) where they play a key role in development and disease (Sayed and 
Abdellatif 2011; Wilczynska and Bushell 2015). Virus-encoded miRNAs are 
involved in various aspects of the virus life cycle, including regulation of 
genome replication, pathogenesis and evasion of the host cell immune 
response via modulation of both virus and host cell transcripts. KSHV-miR-
K12-9-5p prevents lytic replication by directly targeting and repressing KSHV 
RTA, a latent-to-lytic replication switch (Bellare and Ganem 2009). Such 
auto-regulatory effect has also been shown in BKV, JCV, SV40 and MCV 
where virus miRNA mediates LT Ag cleavage and hence negatively regulates 
genome replication (Sullivan et al. 2005; Seo et al. 2008; Lagatie et al. 2013). 
In accord with previous studies, my findings demonstrated that MCV-miR-M1 
gives rise to two mature miRNAs (Figure 3.7 A & B) which directly target and 
downregulate MCV LT expression (Figure 3.4 C, 3.5 B and 4.7).  
While a primary function of virus-encoded miRNAs is the auto-regulation of 
immunogenic virus-transcripts to limit host immune response, there is 
mounting evidence that virus-encoded miRNAs are also directly targeting key 
regulators of the host immune system. For example, EBV miR-BART2-5p 
and mir-BHRF1-3 directly target and downregulate MICB (NK ligand) and 
CXCL11 (T-cell chemoattractant), respectively (Xia et al. 2008; Nachmani et 
al. 2009). Moreover, these miRNAs also target innate immune-associated 
genes including PML-NB components SP100 and ZNF451 (Skalsky et al. 
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2012). BKV and JCV miRNA 3p strands repress host immune surveillance by 
directly targeting and downregulating ULBP3 (Bauman et al. 2011). In this 
project, RNA-Seq analysis of MCV-miR-M1 cellular targets uncovered a 
multitude of cellular transcripts modulated specifically by MCV-miR-M1-5p 
and -3p and GO analysis put most MCV-miR-M1-modulated targets in GO 
terms associated with immune response and regulation of various cellular 
processes.  
Virus miRNA-mediated downregulation of chemokines as a strategy for host 
immune evasion has been described by several studies in other viruses. 
EBV-miR-BHRF1-3 suppresses the T-cell chemoattractant CXCL11 (Xia et 
al. 2008), whereas HCMV-miR-UL148D downregulates CCL5 by directly 
targeting its 3'UTR (Kim et al. 2012). In addition, KSHV miRNAs have been 
shown to target CXCL8 signalling pathway in SLKK cell line (Viollet et al. 
2015) and KSHV-miR-K12-10a induces repression of CXCL8 and CCL2 by 
directly targeting TNF-like weak inducer of apoptosis receptor (TWEAKR) 
(Abend et al. 2010). Herein, I demonstrate that decreased levels of CXCL8 
are secreted during MCV replication in an MCV-miR-M1-dependent manner. 
Moreover, this decrease in CXCL8 has a significant impact on neutrophil 
chemotaxis, suggesting a possible molecular mechanism for the observed 
association between MCV-miR-M1 and persistent infection (Figure 4.6 B & 
4.10).   
Data presented in this PhD thesis contribute to the emerging hypothesis that 
viral miRNAs are significant players in virus-host cell interaction and 
modulation of cellular processes. More specifically, the findings presented 
provide compelling and novel evidence supporting a role for MCV-miR-M1 in 
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the direct modulation of host immune response genes and suggest a 
mechanism for the observed dependency of MCV-miR-M1 in the 
establishment of persistent infection (Theiss et al. 2015; Neumann et al. 
2016).  
Much remains to be done in terms of investigating the role of MCV-miR-M1-
modulated cellular transcripts and how these impact on MCV life cycle and 
pathogenesis. Initially, this can most easily be addressed via siRNA-
mediated depletion and overexpression studies followed by assessment of 
virus replication using the MCVSyn system. These studies could be followed 
up with CRISPR/Cas9-mediated mutation of MCV-miR-M1 seed-recognition 
sequences in direct cellular targets, an approach that would also enable long-
term infection studies to be carried out to assess the importance of MCV-
miR-M1-modulated cellular targets in this process. A particularly interesting 
area to interrogate is the association between chemokine-stimulating factors 
such as SP100 and MAPK10 with CXCL8, for instance, by measuring CXCL8 
expression following SP100 and MAPK10 knockdown and overexpression. 
Similar experiments could be used to investigate interplay between SP100 
and components of other important immune-regulatory pathways such as 
TLR signalling, RIG-I-like receptor signalling and MAPK signalling pathways. 
In addition, this project has produced a significant amount of data regarding 
the possible role of MCV-miR-M1 in virus replication and pathogenesis. 
Numerous cellular transcripts associated with cancer progression were 
dysregulated in response to MCV-miR-M1 expression including KLLN, 
CYB5R2 and OSR1. It will be of interest to determine if downregulation of 
these genes contributes to MCV tumourigenesis. Of note, several MCV-
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positive MCC cell lines including MKL1, MKL2, WaGa, PeTa, BroLi and MS-1 
were investigated for MCV-miR-M1 expression. While expression of MCV-
miR-M1 was very low in these cells (data not shown), inhibition of MCV-miR-
M1 using miRNA inhibitors resulted in inconsistent alterations in MCV LT 
expression (data not shown). The low expression levels of MCV-miR-M1 in 
these cell lines suggests that its functional importance in terms of cancer cell 
growth may be limited, however, a possible role for MCV-miR-M1 in 
transformation should not be disregarded. For instance, it will be of interest to 
determine if MCV-miR-M1 expression creates an environment in infected 
cells more conducive to LT truncation, MCV integration and inhibition of DNA 
damage response. This could be investigated by determining protein 
expression of these genes in the presence of MCV replication plus and minus 
MCV-miR-M1 inhibitors and by inducing DNA damage prior to measuring cell 
proliferation. In addition, expression of these tumour suppressor genes can 
be measured following transfection of MCV-miR-M1 inhibitors into MCV-
positive MCCs prior to investigating alterations in cell phenotypes and 
proliferation. These experiments will be an important step in determining 
whether inhibition of MCV-miR-M1 can be used as a therapeutic approach in 
MCC treatment.   
Finally, and of immediate importance are experiments to investigate the 
impact of MCV-miR-M1 inhibition on MCV replication and life cycle in dermal 
fibroblasts.   
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Appendix 1. RNA-Seq-identified cellular transcripts with >2-fold 
downregulation (p-value<0.05) in MCV-miR-M1-5p and MCV-miR-M1-3p 
mimic-transfected 293 cells.  
 
hgnc_symbol hgnc_name Fold decrease p-value
LOC101926969 uncharacterized LOC101926969 23.32318149 0.007815
LOC729040 uncharacterized LOC729040 21.17838367 0.019171
CCDC85A coiled-coil domain containing 85A 21.02701975 0.009823
SNAP25 synaptosomal-associated protein, 25kDa 18.43600523 0.017135
ARHGAP9 Rho GTPase activating protein 9 18.36259909 0.015628
MIR23B microRNA 23b 18.36259909 0.015628
CFAP99 cilia and flagella associated protein 99 18.36249688 0.015628
KIF25 kinesin family member 25 18.36085228 0.015883
SP100 SP100 nuclear antigen 18.33236489 0.023567
LOC645434 uncharacterized LOC645434 18.20123777 0.038921
MIR1289-1 microRNA 1289-1 18.11842676 0.037724
TIGIT T cell immunoreceptor with Ig and ITIM domains 16.15070759 0.038969
ADRA1D adrenoceptor alpha 1D 15.9225359 0.032946
LOC100128006 uncharacterized LOC100128006 15.92241069 0.03294
LOC440700 carbonic anhydrase XIV (CA14) pseudogene 15.88210699 0.031255
CCNI2 cyclin I family, member 2 7.29635443 0.012677
SCARNA14 small Cajal body-specific RNA 14 6.648865129 0.022084
H2BFM H2B histone family, member M 6.034934976 0.025776
PPIAP30 peptidylprolyl isomerase A (cyclophilin A) pseudogene 30 5.399180682 0.009798
DCX doublecortin 5.370853191 0.039963
SNORD9 small nucleolar RNA, C/D box 9 5.24963838 0.000995
LOC100126784 uncharacterized LOC100126784 5.236600348 0.001712
IFI30 interferon, gamma-inducible protein 30 4.893713881 0.000237
SELPLG selectin P ligand 4.561435997 0.049486
COX5BP6 cytochrome c oxidase subunit Vb pseudogene 6 4.470030356 0.004809
LOC101928809 uncharacterized LOC101928809 4.21176772 0.00829
LOC101927958 uncharacterized LOC101927958 4.180902341 0.03938
CYCSP52 cytochrome c, somatic pseudogene 52 4.169361804 0.042053
ZAN zonadhesin (gene/pseudogene) 4.157606234 0.043871
LOC101927354 uncharacterized LOC101927354 4.146856746 0.045739
OTOA otoancorin 3.985928911 0.024349
AOC1 amine oxidase, copper containing 1 3.845713397 0.048581
DENND2D DENN/MADD domain containing 2D 3.546480352 0.000513
IGF2 insulin-like growth factor 2 3.506608739 0.031384
IQSEC3 IQ motif and Sec7 domain 3 3.456262465 0.039912
LOC102724329 uncharacterized LOC102724329 3.452484679 0.04126
THPO thrombopoietin 3.452414669 0.038855
IL13RA2 interleukin 13 receptor, alpha 2 3.446991286 0.001034
LINC00102 long intergenic non-protein coding RNA 102 3.416540478 0.048763
MUC4 mucin 4, cell surface associated 3.324860584 0.046374
PARP9 poly (ADP-ribose) polymerase family, member 9 3.245221664 0.020743
ASIC4 acid sensing (proton gated) ion channel family member 4 3.242188227 0.043808
RGS9 regulator of G-protein signaling 9 3.125377015 0.011612
PMCH pro-melanin-concentrating hormone 3.083517354 0.001901
LOC101927040 uncharacterized LOC101927040 3.062271519 0.034925
PTPRD-AS1 PTPRD antisense RNA 1 2.743992076 0.014845
DSEL dermatan sulfate epimerase-like 2.739862866 0.028295
APOBEC3D apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3D 2.69685336 0.004953
TCTE1 t-complex-associated-testis-expressed 1 2.641885526 0.044148
ERBB4 erb-b2 receptor tyrosine kinase 4 2.631836973 0.045826
PTGS2 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) 2.617534968 0.022617
FAM131B family with sequence similarity 131, member B 2.610855965 0.007753
TKTL1 transketolase-like 1 2.5251386 0.010798
TSKS testis-specific serine kinase substrate 2.523453308 0.018217
GPR12 G protein-coupled receptor 12 2.508314979 0.038152
GNG3 guanine nucleotide binding protein (G protein), gamma 3 2.506780626 0.039491
TOLLIP-AS1 TOLLIP antisense RNA 1 (head to head) 2.411396587 0.045556
CLCNKB chloride channel, voltage-sensitive Kb 2.38227796 0.012892
LOC100335030 FGFR1 oncogene partner 2 pseudogene 2.367547325 0.022862
KCNA1 potassium channel, voltage gated shaker related subfamily A, member 1 2.366154092 0.015645
LOC100996348 uncharacterized LOC100996348 2.33963014 0.037625
RAET1G retinoic acid early transcript 1G 2.311296809 0.045665
BST2 bone marrow stromal cell antigen 2 2.255335835 0.015324
C6orf141 chromosome 6 open reading frame 141 2.15223303 0.03641
CRTAC1 cartilage acidic protein 1 2.102530982 0.037793
KLHL31 kelch-like family member 31 2.038972726 0.004805
ST7-OT4 ST7 overlapping transcript 4 2.037253381 0.001506
EGR1 early growth response 1 2.017910587 0.000125
HMGCLL1 3-hydroxymethyl-3-methylglutaryl-CoA lyase-like 1 2.012371342 0.023651
MCV-miR-M1-5p
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hgnc_symbol hgnc_name Fold decrease p-value
CYB5R2 cytochrome b5 reductase 2 31.86143921 0.000556
SELPLG selectin P ligand 31.71105286 0.003786
DMBT1 deleted in malignant brain tumors 1 27.24115832 0.007524
ARMC12 armadillo repeat containing 12 26.6735151 0.001954
LINC00403 long intergenic non-protein coding RNA 403 26.50008915 0.004961
ZNF20 zinc finger protein 20 24.08143507 0.004548
LMO3 LIM domain only 3 (rhombotin-like 2) 23.85258264 0.012588
LOC414300 uncharacterized LOC414300 22.88903319 0.018993
FAM198B family with sequence similarity 198, member B 22.88709241 0.018993
LOC729040 uncharacterized LOC729040 21.84209876 0.018993
LOC100130502 uncharacterized LOC100130502 21.7091442 0.009713
LOC101928386 uncharacterized LOC101928386 21.538836 0.007815
ZNF542P zinc finger protein 542, pseudogene 21.53872496 0.007815
LRAT lecithin retinol acyltransferase (phosphatidylcholine--retinol O-acyltransferase) 21.0819763 0.022565
DPP6 dipeptidyl-peptidase 6 20.5483961 0.031044
OSR1 odd-skipped related transciption factor 1 19.0460116 0.017199
ENAM enamelin 19.02696894 0.018658
MIR23B microRNA 23b 18.97154203 0.015628
MIR320D1 microRNA 320d-1 18.97154138 0.015628
SCN1A sodium channel, voltage gated, type I alpha subunit 18.96874175 0.015968
SLC26A3 solute carrier family 26 (anion exchanger), member 3 18.9461404 0.016328
LOC100507530 uncharacterized LOC100507530 16.47589039 0.048637
LOC102723716 uncharacterized LOC102723716 16.4699001 0.048541
CXCL8 chemokine (C-X-C motif) ligand 8 16.44218467 0.032909
CSTF3-AS1 CSTF3 antisense RNA 1 (head to head) 16.41003851 0.032218
MIR26A2 microRNA 26a-2 16.40414601 0.031255
CCDC27 coiled-coil domain containing 27 16.40406088 0.031255
ZNF311 zinc finger protein 311 16.40406088 0.031255
FLJ20712 uncharacterized FLJ20712 16.33340335 0.038877
DSCAS DSC1/DSC2 antisense RNA 16.31101585 0.034749
RXFP2 relaxin/insulin-like family peptide receptor 2 16.31088565 0.034754
MIR5685 microRNA 5685 16.20201659 0.040122
SLC26A5 solute carrier family 26 (anion exchanger), member 5 9.165206746 0.002607
MIR933 microRNA 933 8.450804043 0.006343
CTSS cathepsin S 7.749859678 0.006569
CYGB cytoglobin 7.068989285 0.012354
H2BFM H2B histone family, member M 6.423278063 0.025677
CDH8 cadherin 8, type 2 6.398904262 0.02313
MUC12 mucin 12, cell surface associated 5.910309589 0.003171
CPQ carboxypeptidase Q 5.707089381 0.039368
RNU6-45P RNA, U6 small nuclear 45, pseudogene 5.707084045 0.039363
LOC101927851 uncharacterized LOC101927851 5.704974568 0.039647
LINCR-0001 uncharacterized LINCR-0001 5.698306391 0.041469
IQSEC3 IQ motif and Sec7 domain 3 5.256871701 0.008324
CYBB cytochrome b-245, beta polypeptide 5.247259977 0.013657
RBP5 retinol binding protein 5, cellular 4.887843638 0.01657
ERN2 endoplasmic reticulum to nucleus signaling 2 4.835137803 0.028395
RPSAP52 ribosomal protein SA pseudogene 52 4.484569713 0.02634
LINC01160 long intergenic non-protein coding RNA 1160 4.479431099 0.02665
CCNI2 cyclin I family, member 2 4.469754662 0.024197
MIR4766 microRNA 4766 4.464987282 0.02389
TMEM92 transmembrane protein 92 4.075622314 0.000143
LILRB5 leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 5 4.063009314 0.042756
REXO1L1P REX1, RNA exonuclease 1 homolog (S. cerevisiae)-like 1, pseudogene 3.936316743 0.01141
APCDD1L adenomatosis polyposis coli down-regulated 1-like 3.922722889 0.005784
COL15A1 collagen, type XV, alpha 1 3.705708019 0.008746
LINC00926 long intergenic non-protein coding RNA 926 3.691664983 0.022672
PAX1 paired box 1 3.548778641 0.002739
OR7E14P olfactory receptor, family 7, subfamily E, member 14 pseudogene 3.548286131 0.002629
CGB7 chorionic gonadotropin, beta polypeptide 7 3.47791908 0.020251
LOC653786 otoancorin pseudogene 3.414433581 0.037531
C14orf105 chromosome 14 open reading frame 105 3.412437681 0.037596
PINLYP phospholipase A2 inhibitor and LY6/PLAUR domain containing 3.382202175 0.010351
LOC101929787 uncharacterized LOC101929787 3.266647597 0.020703
LOC339666 uncharacterized LOC339666 3.197382258 0.003862
YBX2 Y box binding protein 2 3.16609967 0.018975
GPR182 G protein-coupled receptor 182 3.00035932 0.028224
TREH trehalase (brush-border membrane glycoprotein) 2.974707187 0.010984
LOC101927972 uncharacterized LOC101927972 2.967128659 0.015942
MCV-miR-M1-3p
205 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
hgnc_symbol hgnc_name Fold decrease p-value
TRPV1 transient receptor potential cation channel, subfamily V, member 1 2.954869273 0.005262
LOC100133985 uncharacterized LOC100133985 2.83020859 0.028699
PNMT phenylethanolamine N-methyltransferase 2.829296605 0.045771
C2 complement component 2 2.809585563 0.007884
LOC440934 cancer/testis antigen 75 2.692652084 0.021323
LINC00412 long intergenic non-protein coding RNA 412 2.657661475 0.045444
ANGPTL2 angiopoietin-like 2 2.656437287 0.045354
CDH4 cadherin 4, type 1, R-cadherin (retinal) 2.642838482 0.005286
PTPRD-AS1 PTPRD antisense RNA 1 2.590733708 0.018567
SLC9C1 solute carrier family 9, subfamily C (Na+-transporting carboxylic acid decarboxylase), member 1 2.56482099 0.002062
LOC100126784 uncharacterized LOC100126784 2.561759581 0.031376
MAGI1-AS1 MAGI1 antisense RNA 1 2.558998412 0.031541
ETV4 ets variant 4 2.541666435 0.002687
IFI30 interferon, gamma-inducible protein 30 2.477344461 0.007329
IFIH1  interferon induced with helicase C domain 1 2.477258707 0.012839
C1orf168 chromosome 1 open reading frame 168 2.475154854 0.007119
LOC100996455 uncharacterized LOC100996455 2.46427354 0.038391
PIANP PILR alpha associated neural protein 2.45677274 0.006505
SOX10 SRY (sex determining region Y)-box 10 2.353775948 0.031266
CCDC176 coiled-coil domain containing 176 2.351070294 0.008777
PMCH pro-melanin-concentrating hormone 2.314931455 0.01336
FBXO24 F-box protein 24 2.312735458 0.012818
KCNT1 potassium channel, sodium activated subfamily T, member 1 2.280249665 0.02204
MAGEC2 melanoma antigen family C2 2.26838522 0.043498
LOC101928553 uncharacterized LOC101928553 2.225790014 0.038184
CEACAM1 carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) 2.218797953 0.013405
CPZ carboxypeptidase Z 2.21703077 0.046289
GPR3 G protein-coupled receptor 3 2.212743491 0.046141
GAS8-AS1 GAS8 antisense RNA 1 2.203207714 0.008793
RPAP2 RNA polymerase II associated protein 2 2.202231139 0.031013
PLAC8L1 PLAC8-like 1 2.194711747 0.014284
KLLN killin, p53-regulated DNA replication inhibitor 2.15711021 0.000993
TMPRSS5 transmembrane protease, serine 5 2.154639442 0.020967
MAPK10 mitogen-activated protein kinase 10 2.090909183 0.012
LOC101927768 uncharacterized LOC101927768 2.088550033 0.003877
TNFRSF10C tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain 2.080275672 0.006939
BCO2 beta-carotene oxygenase 2 2.079840908 0.026661
CADM2 cell adhesion molecule 2 2.051700096 0.017937
LOC101929234 uncharacterized LOC101929234 2.040439642 0.000158
MMP25-AS1 MMP25 antisense RNA 1 2.027249103 0.000723
GXYLT1P3 glucoside xylosyltransferase 1 pseudogene 3 2.000756595 0.048459
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